



Dr. Anthony W. Chow

Dr. Anthony W. Chow is Professor Emeritus of Medicine in the Division of Infectious Diseases at UBC, and former Director of the UBC MD/PhD Program. He is also the founding Director of the CIHR-UBC Strategic Training Program for Translational Research in Infectious Diseases, a multidisciplinary program funded by the Canadian Institutes of Health Research to develop and nurture the next generation of clinician-scientists conducting translational research in infectious diseases. He is a consultant physician in the Division of Infectious Diseases at the Vancouver Hospital Health Sciences Center. He received an MD from the University of Manitoba, and clinical training in Family Medicine and Internal Medicine in Calgary and Winnipeg, respectively. He then completed a clinical and research fellowship in Infectious Diseases at Harbor-UCLA, where he subsequently joined the Faculty and rose through the ranks to Associate Professor in 1977. In 1979, he became Professor and Head of the Division of Infectious Diseases at the University of British Columbia and Vancouver Hospital Health Sciences Center, a position he held until 1993. His main research interests include the role of anaerobic bacteria in health and disease, structure/function of staphylococcal superantigens, and the molecular pathogenesis of staphylococcal toxic shock syndrome. He has authored over 350 peer-reviewed papers and book chapters on various aspects of infectious disease clinical syndromes, diagnosis and treatment. He is co-recipient of several US patents on the use of the 60 kDa heat shock protein (HSP60) gene sequences as universal targets for infectious disease diagnosis and microbial species identification.

University of British Columbia
Curriculum Vitae for Faculty Members

Date: June 22, 2006
Initial: _____

1. SURNAME: Chow

FIRST NAME: Anthony
MIDDLE NAME(S): WC

2. DEPARTMENT/SCHOOL: Medicine (I. D.)

3. FACULTY: Medicine

JOINT APPOINTMENTS:

4. PRESENT RANK: Professor Emeritus of Infectious Disease

SINCE: Jan 1, 1979

5. POST-SECONDARY EDUCATION

(a)

University or Institution	Degree	Subject Area	Dates
Brandon College, University of Manitoba		Pre-Medicine	1961-1963
University of Manitoba	MD	Medicine	1967
University of Calgary		Rotating Internship	1967-1968
University of Manitoba		Internal Med Residency	1968-1970
University of California at Los Angeles		Infect. Dis. Fellowship	1970-1972

(b) Professional Qualifications

- 1 Rotating Intern, Calgary General Hospital, Calgary, Alberta, 1967-1968
- 2 Medical Council of Canada (LMCC) - 1968 (No. 27345)
- 3 Resident, Internal Medicine, Winnipeg General Hospital, Winnipeg, Manitoba, 1968-1970
- 4 National Board of Medical Examiners - 1970 (No. 96365)
- 5 Fellow, Infectious Diseases, Harbor-UCLA Medical Centre, UCLA, Torrance, California, 1970-1972
- 6 American Board of Internal Medicine - 1972 (No. 38312)
- 7 Fellow, Royal College of Physicians and Surgeons of Canada (FRCPC) - 1973 (No. 2655)
- 8 Infectious Disease, American Board of Internal Medicine - 1974 (No. 38312)
- 9 Fellow, American College of Physicians (FACP) - 1974

6. EMPLOYMENT RECORD

Prior

University, Company or Organization	Rank or title	Dates
University of California Los Angeles	Assistant Professor of Medicine	1972-1977
Harbor-UCLA Medical Center, Torrance, CA	Staff Physician, Div. of Infectious Diseases	1972-1978
Harbor-UCLA Medical Center, Torrance, CA	Associate Chief, Div of Infectious Diseases	1975-1978
University of California Los Angeles	Associate Professor of Medicine	1977-1978
University of British Columbia, Vancouver, BC	Head, Division of Infectious Diseases, UBC Department of Medicine	1979-1993
University of British Columbia, Vancouver, BC	Head, Division of Infectious Diseases, VGH Department of Medicine	1979-1993
University of British Columbia, Vancouver, BC	Director, GF Strong Infectious Disease Research Laboratories	1979-1993
University of British Columbia, Vancouver, BC	Vancouver Node Coordinator, Canadian Bacterial Disease Network	1990-1997
University of British Columbia, Vancouver, BC	Professor of Medicine, Department of Medicine	1979-2006
University of British Columbia, Vancouver, BC	Director, MD/PhD Program, Faculties of Medicine and Graduate Studies	1995-2006
University of British Columbia, Vancouver, BC	Coordinator, Division of Infectious Diseases, Experimental Medicine Graduate Program, Department of Medicine	1995-2006

Present

University, Company or Organization	Rank or title	Dates
University of British Columbia & Vancouver Hospital, BC	Professor Emeritus of Infectious Disease	2006-present
University of British Columbia, Vancouver, BC	Director, CIHR - UBC Strategic Training Program for Translational Research in Infectious Diseases, Faculties of Medicine and Science	2003-present

Date of granting tenure at UBC: 1/Jan/1979

7. LEAVES OF ABSENCE

University, Company Or Organization at which Leave was taken	Type of Leave	Dates
University of Victoria (Dr. Trevor Trust, Dept. of Biochemistry & Microbiology)	Sabbatical	January 1987 to April 1987
University of Calgary (Dr. William Costerton, Dept. of Biology)	Sabbatical	May 1987 to June 1987
Stanford University (Drs. Lucy Tompkins & Stanley Falkow, Dept. of Microbiology & Immunology)	Sabbatical	January 1994 to December 1994
University of California at San Diego (Dr. Joshua Fierer, Div. of Infectious Diseases)	Sabbatical	October 2002 to September 2003

8. AWARDS AND DISTINCTIONS

(a) Awards for Teaching (indicate name of award, awarding organizations, date)

1. Canadian Infectious Disease Society Award, for outstanding contributions to the acquisition of knowledge and teaching in infectious diseases, 1984
2. Don Whitlow Medical Grand Round Award, Department of Medicine, UBC and Vancouver Hospital, 2006

(b) Awards for Scholarship (indicate name of award, awarding organizations, date)

3. MRC Development Grant Awardee in Infectious Diseases, 1979-1983; Renewal Award, 1983-1988
4. Schering Fellowship Award, 1987, 1994
5. Canadian Bacterial Diseases Network, National Centers of Excellence Award, 1990- 1994
6. Vancouver General Hospital Academic Award for Scientific Achievement, 1992
7. Asan University School of Medicine Award of Recognition, Seoul, Korea, 1992
8. Elected to the Canadian Institute of Academic Medicine, 1993
9. Canadian Bacterial Diseases Network, National Centers of Excellence Awardee, Phase II Renewal Award, 1994-1998
10. UBC Faculty of Medicine Distinguished Medical Research Lecture Award, 1996
11. Chang Gung University Hospital Award of Recognition, Taipei, Taiwan, 1998
12. Canadian Bacterial Diseases Network, National Centers of Excellence Phase III Renewal Award, 1998-2005
13. Caritas Medical Centre Award of Recognition, Hong Kong, 2002
14. Dalhousie University Department of Medicine TJ Marrie Lecturer, Halifax, 2003
15. University of Victoria Cooperative Education Program Centennial Mentorship Award, Victoria, 2003
16. Asia - Men & Women of Achievement, 2003
17. Canadian Institutes of Health Research Strategic Training Program for Translational Research in Infectious Diseases (TRID) Award, 2003-2008

(c) Awards for Service (indicate name of award, awarding organizations, date)

18. International Courvoisier Leadership Award, 1993

19. Canadian Infectious Disease Society Janssen-Ortho Distinguished Service Award, 2004
(d) Other Awards
20. Who's Who in America, 1984 present
21. International Who's Who in Education, 1987
22. Who's Who in Science and Engineering, 1993-present
23. American Men and Women of Science, 1994-present
24. Who's Who in Pacific Asia, 1996-present

9. TEACHING

(a) Areas of special interest and accomplishments

- 1 Royal College Accreditation of Infectious Diseases Subspecialty Training: As a founding member of the Nucleus Committee of Subspecialty Training in Infectious Diseases, Royal College of Physicians & Surgeons of Canada, I helped to establish the curriculum content and evaluation process for the accreditation of Infectious Diseases Training Programs in Canada, and established one of the first such programs at UBC.
- 2 UBC MD/PhD Program: I chaired the Institutional Self Study subcommittee of the UBC MD/PhD Program during 1992, and was responsible for the implementation and restructuring of the revitalized UBC MD/PhD Program in 1994, serving as its first UBC Director. I have significantly improved the quality, morale, and reputation of this important graduate program, with integration of both clinical and basic sciences within the Faculties of Medicine and Graduate Studies. The Program was accredited by the CIHR in 1995, and has received competitive funding for CIHR MD/PhD studentships since its inception.
- 3 Strategic Training Program for Translational Research in Infectious Diseases (TRID): I assembled a multidisciplinary team from Infectious Diseases, Microbiology & Immunology, Medical Microbiology, and Health Care & Epidemiology and successfully competed for funding from CIHR to support a Strategic Training Program for Translational Research in Infectious Diseases in 2003 (1.8 million dollars over 6 years), and served as its founding Director. This innovative program is charged with the promotion of translational and transdisciplinary research within 5 thematic areas of Infectious Disease Research, targeting 5 categories of trainees (Undergraduate Coop and Summer Research Studentships, MD/PhD Studentships, Doctoral Studentships, Clinician Investigator Program Fellowships, and MD or PhD Postdoctoral Research Fellowships).
- 4 Pharmacy Resident Rotations In Infectious Diseases: I co-developed with Dr. Peter Jewesson this highly acclaimed clinical rotation for pharmacy residents to participate as a team member on the Infectious Diseases teaching and consultation service throughout the UBC-affiliated hospitals. This program has been highly sought after by pharmacy residents from hospitals throughout the lower mainland, interior B.C., and other provinces.
- 5 Clinical Skills: As chairman of the Curriculum Evaluation subcommittee in 1989, I assisted in revamping the undergraduate Clinical Skills I course for first year Medicine, resulting in much improved coordination and facilities for this important undergraduate curriculum.
- 6 Electronic Medical Literature Search: Successfully obtained funding and established the very first electronic literature search facility for medical residents in the Department of Medicine at the Vancouver Hospital in 1983.
- 7 Web-Based and Electronic Textbooks: I contributed key chapters to 4 highly successful, CD-ROM or Internet web-based electronic textbooks in General Medicine or Infectious Diseases: a) 5-Minute Clinical Consult (www.5mcc.com/); b) UpToDate (www.uptodate.com/); c) Best Practice of Medicine Infectious Diseases (merck.micromedex.com/); and d) ACP Medicine (www.acpmedicine.com). In addition, I co-developed and published an innovative computer program for the management of pneumonia (Light RB, Chow AW: Ralph Becker - computerized patient simulation of community-acquired pneumonia, Knowledge House, Halifax, 1991).

(b) Courses Taught at UBC:

Year	Session	Course Number	Scheduled	Class	Hours Taught
------	---------	---------------	-----------	-------	--------------

			Hours	Size	Lecture	Tutorials	Labs	Other
	Experimental Medicine	MEDI 501	2 h per session	40	2 h per yr			
	Experimental Medicine Labs	MEDI 502	20 wks per term	2-3			32 h/yr	
	Experimental Medicine, ID	MEDI 580	2 h per session	4-8	1 h/yr	1 h/yr		
	Experimental Medicine, ID	MEDI 580 Coordinator	2 h per session x 12	4-8				12 h/yr
	Inf Dis Fellows academic half-day		1 h per session	3-4	1 h per yr			
	Inf Dis Resident Rotations		4 h per session	2-3				240 h per yr
	Infectious Disease & Immunology Research Seminars		1 h every other wk	30-40	3 h/yr			
	Infectious Disease Academic Rounds, Coordinator		2 hr per session x 45 wk	20	3 h per yr			1/2 h per wk x 48 wk
	Med II Clinical Diagnosis - History	MEDI 425	4 h per session	4		12 h per yr		
	Med II Clinical Skills - Total Patient	MEDI 425	2 h per session	4		6 h per yr		
	Med II OSCE Exam	MEDI 425	4 h per session	60		4 h per yr		
	Med III Principles of Medicine	MEDI 450	2 h per session	120	2 h per yr			
	Med III Subspecialty - Infectious Diseases	MEDI 451	2 h per session	8-12		6 h per yr		
	Med III Therapeutics	PCTH 453	2 h per session	120		4 h per yr		
	Med IV Oral Exams	MEDI 475	4 h per session	4				4 h per yr
	Medicine IV Clerkships	MEDI 475	4 h per session	1-2				240 h per yr
	Microbiology Pathogenesis	MICB 507	2 h per session	8-10		6 h per yr		

	Orthopaedic Basic Science	ORPA 720	2 h per session	15-20	2 h per yr			
	Pharmacy Clinical Clerkships	PHAR 503	4 h per session	1-2				240 h per yr
2001-2004	Host Defense and Infection block lecture - "Toxin-mediated bacterial diseases"	FMED 401	1 h per session	160	1 h /yr			
2001-2004	Phase IV Oral Exam	Med III	2 h per session					
	Subspecialty Conference	MED IV ID	2 h per session	9-10		2 h /yr		

(c) Graduate Students supervised at UBC:

Student Name	Program Type	Year		Principal Supervisor	Co-Supervisors
		Start	Finish		
Rosten, Patricia	Microbiology, MSc	1984	1986	Chow AW	
Birnbaum, David	Interdisciplinary, PhD	1987	1992	Chow AW	Mathias R, Schulzer M, Noble M
See, Raymond	Experimental Pathology, PhD	1987	1992	Chow AW	
Chang, Alex	Experimental Medicine, MSc	1989	1992	Chow AW	
Li, Na	Microbiology, PhD (Incomplete)	1990	1995	Chow AW	
De Boer, Monica	Microbiology, PhD	1990	1996	Chow AW	
Bathe, Oliver, MD	Experimental Surgery, MSc	1993	1996	Phang PT	Chow AW
Drews, Steven	Experimental Pathology, MSc	1994	1998	Chow AW	
Lee, Soo Sen	Experimental Medicine, MSc	1995	1998	Chow AW	
Pang, Liwina	Experimental Medicine, MSc	1995	1999	Chow AW	
Hung, Ryan	Experimental Medicine, MD/PhD	1995	present	Chow AW	
Scott, Cameron	Experimental Medicine, PhD	1998	2003	Chow AW	
Leung, Ernest	Experimental Medicine, PhD	1999	2002	Chow AW	

Kalyan, Shirin	Experimental Medicine, PhD	1999	2005	Chow AW	
Stolte, Ellen	Microbiology & Immunology, Wageningen University, MSc	2002	2003	Savelkoul HFJ	Chow AW
Godin, Patrice	Experimental Medicine, MSc	2003	2005	Chow AW	
Li, Haowei	Experimental Medicine, PhD	2004	present	Chow AW	
Lam, Grace	Experimental Medicine, MSc	2004	present	Chow AW	

(d) Postdoctoral trainees and research associates supervised (* obtained Faculty positions):

1. Dr. Lee Lindquist, M.D., ID Fellow (1973-1974)
2. Dr. Jeffrey Galpin, M.D., ID Fellow (1973-1975) *
3. Dr. Larry Fisher, M.D., ID Fellow (1973-1975)
4. Dr. Arnold Bayer, M.D., ID Fellow (1974-1976) *
5. Dr. Phyllis Oill, M.D., ID Fellow (1974-1976) *
6. Dr. Stephan Targan, M.D., ID Fellow (1974-1976) *
7. Dr. Howard Pitchon, M.D., ID Fellow (1975-1977)
8. Dr. David Henderson, M.D., ID Fellow (1976-1978) *
9. Dr. Philip Raimondi, M.D., ID Fellow (1976-1978)
10. Dr. Jeremy Ota, M.D., Research Fellow (1977-1978)
11. Dr. Tania Sorrell, M.D., ID Fellow (1977-1979) *
12. Dr. David Tillman, M.D., ID Fellow (1977-1979) *
13. Dr. Chester Choi, M.D., ID Fellow (1978-1979) *
14. Dr. Norman Fujita, M.D., ID Fellow (1978-1979)
15. Dr. Marrie J. Gribble, M.D., ID Fellow (1979-1981) *
16. Dr. Peter Phillips, M.D., ID Fellow (1982-1983) *
17. Dr. David Burdge, M.D., ID Fellow (1982-1983; 1985-1986) *
18. Dr. David Megran, M.D., ID Fellow (1983-1986) *
19. Dr. Stephen Shafran, M.D., ID Fellow (1984-1986) *
20. Dr. Gary E. Garber, M.D., ID Fellow (1984-1987) *
21. Dr. Christina Williams, M.D., Gynaecology Resident (1985)
22. Dr. Amar Kureishi, M.D., ID Fellow (1985-1987) *
23. Dr. Diane Roscoe, M.D., ID Fellow (1985-1987) *

24. Dr. John L. Whiting, M.D., ID Fellow (1987-1988)
25. Dr. Jerry Vortel, M.D., ID Fellow (1987-1990)
26. Dr. Sali Alballa, M.D., ID Fellow (1988-1990) *
27. Dr. Elizabeth Behm, M.D., ID Fellow (1989-1990) *
28. Dr. Helen Oh, M.D., ID Fellow (1989-1990) *
29. Dr. David Patrick, M.D., ID Fellow (1989-1991) *
30. Dr. T.C. Yang, M.D., ID Fellow (1989-1991) *
31. Dr. Winnie Kum, Ph.D., Research Associate (1989-2005)
32. Dr. Dan Kertesz, M.D., ID Fellow (1990-1992)
33. Dr. Vivian T.P. Lee, M.D., ID Fellow (1990-1993)
34. Dr. David Forrest, M.D., ID Fellow (1991-1993) *
35. Dr. Greg Grant, M.D., ID Fellow (1991-1993) *
36. Dr. Warfeeq Mahmoud, M.D., ID Fellow (1991-1993) *
37. Dr. Blair Rudston-Brown, M.D., Vascular Surgery Resident (1992-1993)
38. Dr. Swee-Han Goh, Ph.D., Research Associate (1992-1994)
39. Dr. Oliver Bathe, M.D., Vascular Surgery Resident (1993-1994) *
40. Dr. Rani Azar, M.D., ID Fellow (1993-1995)
41. Dr. Robert Reynolds, M.D., ID Fellow (1994-1996) *
42. Dr. Frahad Al Rabiah, M.D., ID Fellow (1994-1996)
43. Dr. Adel Al Othman, M.D., ID Fellow (1995-1997)
44. Dr. Valerie Montessori, M.D., ID Fellow (1995-1997) *
45. Dr. Yasmin Arikan, M.D., ID Fellow (1996-1998)
46. Dr. Evalina Rubinchik, Ph.D., Postdoctoral Fellow (1997-1998)
47. Dr. Charles Shey-Chiang Su, M.D., Visiting Physician, McKay Memorial Hospital, Taipei, Taiwan (1997-1998) *
48. Dr. Satchan Takaya, M.D., ID Fellow (1997-1999) *
49. Dr. Rebecca Wong, Ph.D., Research Associate (1998-1999)
50. Dr. Natasha Press, M.D., ID Fellow (1998-2000) *
51. Dr. Kenneth Chuang, M.D., Visiting Physician, National Cheng Kung Univ., Tainan, Taiwan (1999-2000) *
52. Dr. David Greenberg, M.D., Pediatric ID Fellow (1999) *
53. Dr. Dwight Ferris, M.D., ID Fellow (1999-2001)
54. Dr. Abiye Iyo, Ph.D., Postdoctoral Fellow (1999-2002)
55. Dr. Rolando Descalzo, Ph.D., Research Associate (2000-2001)
56. Dr. Nigel Livesley, M.D., ID Fellow (2000-2002)
57. Dr. Lijuan Zhang, Ph.D., Research Associate (2001)

58. Dr. Lixin Zhou, Ph.D., Research Associate (2002)
59. Dr. Joe Chang-Pan Liu, M.D., Visiting Physician, McKay Memorial Hospital, Taipei, Taiwan (2001-2002) *
60. Dr. Abdul Sharkaway, M.D., ID Fellow (2001-2003) *
61. Dr. Kenny Chan, M.D., ID Fellow (2001-2003)
62. Dr. Lixin Zhou, PhD., Research Associate (2002)
63. Dr. Richard Lester, M.D., ID Fellow (2002-2003)
64. Dr. Sabine Ivison, Ph. D., Postdoctoral Fellow (2002-2005)
65. Dr. Jack Wu, M.D., ID Fellow (2003) *
66. Dr. Mark Hall, ID Fellow (2003-2005)
67. Dr. Bing Lam, Visiting Physician, Queen Elizabeth Hospital, Hong Kong (2005)
68. Dr. Stephen Reynolds, ID Fellow (2004-present)
69. Dr. Linda Hoag, Med Micro Resident (2004-present)
70. Dr. Julie Stone, Ob/Gyn ID Fellow (2004-2005)
71. Dr. Abeer Al Shkairi, ID Fellow (2004-present)
72. Dr. Ghassan Wali, ID Fellow (2004-present)

(e) Coop and summer research students supervised (*entered medical school; ** entered graduate studies):

1. Alison McInnes, University of British Columbia, Microbiology directed studies (1984) **
2. Linda Haug, University of British Columbia, summer student (1985) *
3. Steve Adilman, University of British Columbia summer student (1987) *
4. Kevin Laupland, University of Victoria, Coop student (1989-1991) *
5. Graham Wong, University of British Columbia summer student (1992) *
6. Julian Wood, University of Victoria, Coop student (1992-1994) **
7. Shiela Potter, University of Victoria, Coop student (1994) **
8. David Fenton, University of Victoria, Coop student (1995) *
9. John Addison, University of Victoria, Coop student (1995)
10. Andrew Lawe, University of Victoria, Coop student (1995) *
11. Isha Sharif, University of British Columbia, Coop student (1996)
12. Shanon McNeil, University of Victoria, Coop student (1996) **
13. Shanon Coffey, University of Victoria, Coop student (1997) **
14. Scott Cameron, Simon Fraser University, Coop student (1997) *
15. Carol Harty, University of Victoria, Coop student (1998) **
16. Julie Johnston, University of Victoria, Coop student (1998) **
17. Jason Wilson, University of Victoria, Coop student (1998) **
18. Craig Pigott, University of Victoria, Coop student (1999) **
19. Anita Thambaraji, University of Victoria Coop student (2001-2002) **
20. David Harris, University of Victoria Coop student (2001-2002) *

21. Lindsay Hawkins, University of Victoria Coop student (2001-2002) *
22. Robert Adams, Brunel University, Middlesex, UK; Univ. of Victoria International Exchange Coop student (2002) *
23. Marissa Blake, University of Victoria Coop student (2003)
24. Jenny Chuang, University of British Columbia undergraduate student (2003)
25. Michael Chuang, University of British Columbia undergraduate student (2003, 2004)
26. Andrew Purcell, University of British Columbia undergraduate student (2003)
27. Lori Sung, Simon Fraser University undergraduate student (2004)
28. Brian Yong, University of British Columbia undergraduate student (2004-2005) *
29. Susan Finlay, Simon Fraser University Coop student (2005)
30. Anna Burianova, University of Victoria Coop student (2005)
31. Jiyang Han, University of British Columbia Coop student (2005-2006)

(f) Other Continuing Education Activities

- 1 VGH Department of Medicine Grand Rounds: weekly; presenter 1-2 per year
- 2 Infectious Diseases Inter-city Rounds: weekly; presenter 6-8 per year
- 3 Infectious Diseases Journal Club: weekly
- 4 Infectious Diseases Academic Rounds Coordinator - Tuesday mornings year round
- 5 Orthopaedics Resident Lecture Series, 1-2 per year ex. "Current concepts in antibiotic pharmacology", 2001-2006
- 6 Cardiology Academic Half-day: 1 per year
- 7 Infectious Diseases Noon Rounds: monthly; presenter 2-3 per year
- 8 B.C. Society of Internal Medicine Infectious Disease Update: every other year
- 9 Royal College/American College of Physicians Bi-Annual Internal Medicine Review: Infectious Disease update
- 10 St. Pauls Hospital CME for Primary Physicians: Infectious Disease review, yearly
- 11 UBC Potable Course in Infectious Diseases: 1-2 per year
- 12 UBC MD/PhD` Student Research Forum: yearly
- 13 UBC Department of Medicine Resident Research Day: yearly
- 14 MEDI 580 Infectious Disease Lecture Series "Role of super antigens in disease", 2001-2005
- 15 Infectious Diseases subspecialty Noon Rounds - "Treatment of VRE and MRSA", July 9, 2001.
- 16 UBC Dept. of Medicine Lecture Series - Medicine in the 21st Century Conference
- 17 ID Fellow Academic Half Day lecture Series
- 18 ID Fellow Quarterly Evening Seminars
- 19 Infectious Disease Inter-City Academic Rounds: weekly; presenter 1-2 per year
- 20 Microbiology and Infectious Diseases Research Seminar Series
- 21 Infectious Diseases Research Seminars: bi-weekly; presenter 3-4 per year

10. SCHOLARLY AND PROFESSIONAL ACTIVITIES

(a) Areas of special interest and accomplishments

- 1 Molecular pathogenesis and clinical spectrum of staphylococcal toxic shock syndrome (TSS): These studies include the clinical spectrum and epidemiology of TSS; pathogenesis and animal models of TSS; clonality and genotyping of *S. aureus*- structure/function analysis and genetic regulation of TSS-associated staphylococcal toxins- mechanisms and signaling pathways of microbial superantigens. These studies have led to invitations as a key-note speaker and session chairman for several International Symposia on Toxic Shock Syndrome (1987 and 1997), Gordon Research Conference on Staphylococcal Diseases (1993), the International Congress of Chemotherapy Symposium on Staphylococcal Virulence (1995) and the Canadian Association of Medical Microbiology and Infectious Diseases Symposium on Staphylococcal Virulence (1996), and as a member of the site-visit team to review the US Army Medical Research Program on Toxins (2002).
- 2 Heat shock protein 60 kDa (hsp60) gene sequences in infectious disease diagnosis, microbial identification, phylogeny and pathogenesis: Two key observations from my laboratory led to the development of several patented diagnostic technologies: a) hsp60 genes from different organisms have both highly conserved as well as species-specific sequences; and b) universal hsp60 degenerate primers can amplify a 600-bp gene product from any microorganism of interest. These discoveries enabled us to develop novel approaches for the genotypic detection and accurate identification of fastidious and nonculturable pathogens, phylogenetic analysis of emerging pathogens, and the investigation of recombinant hsp60 peptides in the serodiagnosis and immunopathogenesis of infectious diseases.
- 3 Prospective, randomized clinical trials and in vitro susceptibility studies: This is an on-going effort to evaluate the efficacy, mechanisms of resistance, and safety of new antimicrobial and anti-cytokine agents, particularly for the treatment of febrile neutropenia in cancer patients, intraabdominal and pelvic infections, sinusitis and pneumonia, sepsis syndrome and septic shock, and prophylaxis for colo-rectal, biliary, and cardiovascular surgery. These studies have resulted in over 40 original publications, including the authorship of an FDA sponsored Infectious Disease Society of America Guideline for the Evaluation of New Anti-infective Agents for the Treatment of Respiratory Tract Infections in 1992, and the invitation by the FDA to serve as a consultant to the Anti-Infective Advisory Committee in 1994.
- 4 Role of anaerobic bacteria in health and disease: This has been a long-standing clinical and laboratory research interest to clarify and confirm the importance of obligate anaerobes in various infection-syndromes, including bacteremia, pelvic inflammatory disease, post-abortion and post-cesarean section infections, neonatal sepsis, intra-abdominal infections, orofacial and odontogenic infections, life-threatening infections of the head and neck, decubitus ulcers, and suppurative central nervous system infections. These studies have led to definitive reviews on odontogenic, central nervous system, and female genital tract infections.
- 5 Nosocomial infections, strategies for infection control, and rational use of antimicrobials: These studies focused on outbreak investigation and control of multiply resistant nosocomial infections; molecular epidemiological typing of *Staphylococcus aureus*, coagulase-negative staphylococci, and *Neisseria meningitidis*, mechanisms of resistance in gram-positive cocci; strategies for infection control measures, and for improving the cost-effective and rational use of antibiotics. These studies led to authorship of the Canadian Health and Welfare Guideline for Antimicrobial Utilization in Health Care Facilities in 1990, and the Canadian Guidelines for the Empirical Treatment of Community-Acquired Pneumonia in 2000.

(b)+(c) Research or equivalent grants/contracts (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC))

(b) Patents filed and received

1.	Goh SH, Chow AW , Hemmingsen S: HSP60 Genomic Locus and Primers for Species Identification. US Patent Serial #5,708,160; issued Jan 13, 1998
2.	Goh SH, Chow AW , Hemmingsen S: Universal Targets for Species Identification. US Patent Serial #5,989,821; issued Nov 23, 1999.
3.	Goh SH, Chow AW , Hemmingsen S: Universal Targets for Species Identification. International PCT National Phase entries: Australia (Patent No. 702237, issued June 3, 1999), Canada (No. 2,219,090), Japan (No. 08,532328), Europe (No. 96 91 8795.4), Korea (No. 97-707573), Norway (No. 97.4946), Russian Federation (No. 97119187).
4.	Kum WWS, Chow AW : Immunotherapeutic peptides (superantigenic and lethal domains of staphylococcal toxic shock syndrome toxin-1 localized by epitope mapping - therapeutic applications for superantigen-mediated autoimmune disorders), UBC Industrial Liaison Office, September 1992; US patent application docket No. PD-2744 SD, filed May 3, 1993; International Patent No. PCT/IB94/00140, filed May 3, 1994.

(c) Copyrights and Technology Disclosures:

1.	Light RB, Chow AW : Ralph Becker – computerized patient simulation series (community-acquired pneumonia), ver 1.9, Knowledge House, Halifax, 1991.
2.	Kum WWS and Chow AW : Purification of TSST-1 (large scale production of highly purified toxin; unique cytokine induction activity distinct from commercial sources), UBC Industrial Liaison Office, January 1992.
3.	Kum WWS and Chow AW : Panel of monoclonal antibodies to TSST-1 (including MAb with protective activity against rabbit TSS in vivo), UBC Industrial Liaison Office, January 1992.
4.	Goh SH, Byrne S and Chow AW : Molecular typing of <i>S. aureus</i> based on coagulase gene polymorphism (a novel and powerful epidemiological tool for outbreak investigation of both methicillin sensitive and resistant <i>S. aureus</i> infections), UBC Industrial Liaison Office, January 1992.
5.	Kertesz D, Byrne SK, Chow AW : Molecular typing of <i>Neisseria meningitidis</i> by PCR amplification and restriction endonuclease digestion of the porA gene (a novel and rapid epidemiological typing tool for outbreak investigation and control of meningococcal meningitis), UBC Industrial Liaison Office, March 1993.
6.	Chow AW , Kum WWS: Consensus sequence MHC class II binding epitopes of staphylococcal superantigen toxins (synthetic and recombinant superantigen peptides with potential application as cross-protective superantigen vaccines and MHC class II receptor inhibitors). UBC Industrial Liaison Office, July 1997.
7.	Smit J, Chow AW : Methods for producing a general purpose bacterial agglutination assay for serodiagnosis of infectious diseases (a novel and rapid diagnosis of infectious diseases by using patient sera to detect agglutinating antibodies to pathogen-specific recombinant HSP60 peptides expressed and displayed in the S-layer of <i>Caulobacter crescentus</i>). UBC Industrial Liaison Office, June 3, 1999.
8.	Kum WWS, Chow AW : Immunoregulatory superantigenic peptides (non-lethal staphylococcal toxic shock syndrome toxin-1 mutants which downregulate the Th1 immune response and may be used as immunosuppressive therapy for autoimmune inflammatory disorders), UBC Industrial Liaison Office, March 1, 2001.
9.	Chow AW , Nomellini J, Smit J: Method for obtaining recombinant peptides as species-specific bacterial antigens based on 60 kDa heat shock protein B-cell epitopes for the serologic diagnosis of infectious diseases, UBC Industrial Liaison Office, Jan 2002; patent application pending further review.

(d) Grants and contracts received

Granting Agency	Subject	COMP	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)
MRC	Pathogenesis of toxic shock syndrome	C	39,900	1978-1982	Chow AW	

Vancouver Foundation	Seroepidemiology of toxoplasmosis in BC	C	25,000	1979-1980	Chow AW	
Cynamid	Piperacillin vs gentamicin /carbenicillin in neutropenia	NC	30,000	1979-1981	Chow AW	
BC Health Care	Host defenses in pelvic inflammatory disease	C	20,000	1979-1982	Chow AW	
Glaxo	Ceftazidime vs anaerobes	NC	15,000	1980-1981	Chow AW	
Eli Lilly	Moxalactam vs anaerobes	NC	10,000	1980-1981	Chow AW	
Glaxo	Cefuroxime vs anaerobes	NC	10,000	1980-1981	Chow AW	
Vancouver Foundation	Immunoassay for Clostridium difficile toxin	C	30,000	1981-1982	Chow AW	
SKF	Ceftizoxime vs anaerobes	NC	15,000	1981-1982	Chow AW	
Burroughs Wellcome	Acyclovir for HSV infections	NC	4,500	1981-1982	Chow AW	
Merck Frosst	Imipenem vs anaerobes & Pseudomonas	NC	15,000	1981-1982	Chow AW	
NCI/Eli Lilly	Moxalactam vs azthreonam in neutropenia	NC	4,500	1981-1982	Chow AW	
SKF	Ceftizoxime in intraabdominal sepsis	NC	4,500	1981-1982	Chow AW	
Vancouver Foundation	ELISA for toxic shock toxin	C	35,500	1982-1983	Chow AW	
Ciba-Geigy	Cefotiam vs anaerobes	NC	12,000	1982-1983	Chow AW	
Merck Frosst	Intraocular & intrathecal thienamycin in rabbits	NC	15,375	1982-1983	Chow AW	
BC Health Care	Toxic shock toxins, purification	C	25,000	1982-1985	Chow AW	
MRC	Pathogenesis of toxic shock syndrome	C	64,000	1982-1987	Chow AW	
Bristol/Schering	Cefoperazone & SCH34343 vs anaerobes	NC	25,000	1983	Chow AW	
Squibb/NCI	Azthreonam & gut colonization	NC	16,500	1983-1985	Chow AW	
Abbott	Abbott quinolones vs anaerobes	NC	20,000	1984-1985	Chow AW	
Merck Frosst	Norfloxacin vs non-fermenting	NC	10,000	1984-1985	Chow AW	

	GNR			1985		
Vancouver Foundation	Seroepidemiology of toxic shock	C	36,000	1985-1986	Chow AW	
Miles	Ciprofloxacin vs anaerobes	NC	30,000	1985-1986	Chow AW	
Miles	Ciprofloxacin combinations vs GNR	NC	20,000	1985-1986	Chow AW	
Murex	Hepatitis B surface antigen detection	NC	15,000	1985-1986	Chow AW	
Eli Lilly	Daptomycin vs anaerobes	NC	15,000	1986	Chow AW	
BC Health Care	Vaginal antitoxic immunity	C	19,000	1986-1987	Chow AW	
Vancouver Foundation	TSS and Barrier contraception	C	25,000	1986-1987	Chow AW	
ICI Pharma	Cefotetan vs anaerobes	NC	20,000	1986-1987	Chow AW	
Roche	Ceftriaxone for vaginal hysterectomy	NC	25,000	1986-1987	Stiver HG	Chow AW
Health & Welfare	Contraceptives & urinary infections	C	48,000	1986-1990	Chow AW	Percival-Smith R
Playtex	Animal model of TSS	NC	24,000	1987	Chow AW	
Vancouver Foundation	Enterotoxins and nonmenstrual TSS	C	25,000	1987-1988	Chow AW	
Cyanamid	Gut flora, endotoxemia during neutropenia	NC	40,000	1987-1989	Chow AW	
MRC	Pathogenesis of toxic shock syndrome	C	65,500	1987-1990	Chow AW	
Merrell Dow	Teicoplan/vancomycin in febrile neutropenia	NC	33,000	1987-1990	Chow AW	
BC Health Care	Animal models of toxic shock	C	40,450	1989-1991	Chow AW	
Vancouver Foundation	Enterotoxins and nonmenstrual TSS	C	35,000	1990-1991	Chow AW	
MRC	Pathogenesis of toxic shock syndrome	C	83,000	1990-1993	Chow AW	
NSERC/MRC	Canadian Bacterial Diseases Network	C	110,000	1990-1993	Chow AW	
BC Health Care	Major equipment: labware washer	C	18,000	1991	Chow AW	
Roche	Betalactam-amino-glycoside combinations	NC	40,000	1991-1992	Chow AW	Lever-dierre M

Miles/Cutter	TNF monoclonal in sepsis syndrome	NC	33,500	1991-1993	Chow AW	
Smith-Kline	Biliary & colorectal surgical prophylaxis	NC	23,750	1991-1993	Jewesson PJ	Chow AW
BC Health Care	Major equipment: FPLC system	C	47,800	1992	Chow AW	
Merck Frosst	Imipenem/cefoxitin in intraabdominal sepsis	NC	36,000	1992-1993	Chow AW	
BC Health Care	Cervicovaginal toxic shock vaccine	C	40,000	1992-1994	Chow AW	
Vancouver Foundation	Streptococcal exotoxin antibodies	C	30,000	1992-1994	Chow AW	Fairley J
Nordic Merell-Dow	Teicoplanin prophylaxis in open heart surgery	NC	76,473	1992-1994	Chow AW	Stiver HG
NSERC/MRC	Heat shock protein genes, CBDN	C	10,000	1993-1994	Chow AW	Goh SH
Nordic Merell-Dow	S. aureus molecular typing in open heart surgery	NC	36,000	1993-1994	Chow AW	
MRC	Pathogenesis of toxic shock syndrome	C	83,000	1993-1996	Chow AW	
Parke-Davis	Clinifloxacin/imipenem & intraabdominal sepsis	NC	48,000	1994-1997	Chow AW	Stiver HG
Bayer	TNF monoclonal for human septic shock	N	60,000	1994-1997	Chow AW	Tweed-dale MG
NSERC/MRC	Canadian Bacterial Diseases Network	C	102,000	1994-1998	Chow AW	
Parke-Davis	Clinifloxacin vs imipenem in febrile neutropenia	NC	54,375	1995-1996	Chow AW	Nantel S, Stiver G
Micrologix	Recombinant cationic antimicrobial peptides	NC	76,175	1995-1998	Chow AW	
MRC	Pathogenesis of toxic shock syndrome	C	78,844	1996-2001	Chow AW	
Bayer	Cost-effectiveness analysis for septic shock	NC	14,212	1997	Chow AW	Wright C
Vancouver Foundation	Genotype diagnosis for infectious diarrhea	C	39,850	1997 - 1998	Chow AW	
BC Health Care	Speciation and phylogeny of staphylococci	C	42,000	1997-1998	Chow AW	
NSERC/MRC	Canadian Bacterial Diseases Network	C	91,300	1998-2002	Chow AW	
NCE-Canadian	HSP60 genes as universal targets for species identification		106,930	1998-2005	Chow AW	

Bacterial Diseases Network	and infection diagnosis			2005		
Eli-Lilly	LY333328 vs vancomycin in gram-positive infections	NC	15,000	1999	Chow AW	Stiver HG
CIHR	MD/PhD studentship award to Ryan Humg, MD/PhD student		19,030/yr	1999-2004	Chow AW	
Bayer	Etiologic diagnosis of community acquired pneumonia by hsp60 dot blot analysis	NC	50,000	2000-2001	Chow AW	Marrie T, Low D
CIHR/Rx&D	Etiologic diagnosis of community acquired pneumonia by hsp60 dot blot analysis	C	25,000	2000-2001	Chow AW	Marrie T, Low D
Can Infect Dis Society	Vancomycin hetero-resistance in Staphylococcus haemolyticus	C	45,000	2000-2001	Chow AW	
CIHR/Bayer Rx&D Industry Partnership	Etiologic diagnosis of community acquired pneumonia by HSP60 dot blot analysis		75,000	2000-2001	Chow AW	
CIHR	Doctoral Research Award to Scott Cameron, PhD student, Experimental Medicine, 3 yrs		19,030/yr	2000-2003	Chow AW	
CIHR	Doctoral Research Award to Earnest Leung, PhD student, Experimental Medicine		19,030/yr	2000-2003	Chow AW	
CIHR	Transdisciplinary Training Grant in Infection, Immunity and Communicable Disease Epidemiology Initiative (2001)		5,000	2001	Chow AW	
CIHR	Training grant infrastructure support	C	5,000	2001	Chow AW	
Can Blood Service/CIHR	Detection of bacterial contaminants in platelet concentrates by hsp60 DNA	C	87,839	2001-2003	Chow AW	Doyle P
CIHR	Doctoral Research Award to Shirin Kalyn, PhD student, Experimental Medicine		19,030/yr	2001-2004	Chow AW	
CIHR	Pathogenesis of staphylococcal toxic shock syndrome	C	98,278	2001-2006	Chow AW	
CIHR	Training grant infrastructure support	C	5,000	2002	Chow AW	
CIHR	Multi-User Equipment Maintenance Grant	C	198,000	2002	Hmama Z	Av-Gay, Chow, Duronio, Mui, Nandan, Reiner, Steiner

NCE/CBDN	Serodiagnosis of infectious diseases	C	98,019	2002-2005	Chow AW	
Michael Smith Foundation	Immunity & Infection Research Centre Infrastructure Award	C	150,000	2003-2007	McMaster R	Av-Gay, Brunham, Chow, Chung, Duronio, Hmama, Mui, Reiner, et al
Vancouver Coastal Health	Training Program for Translational Research in Infectious Diseases	NC	20,000	2003-2008	Chow AW	
CIHR	Strategic Training Program for Translational Research in Infectious Diseases	C	310,500	2003-2009	Chow AW	Hancock, Brunham, Schechter
Vancouver Coastal Health	Pilot Project Award, Hsp60 in staphylococcal pathogenesis	NC	10,000	2004	Chow AW	

(e) Salary Support Awards

Granting Agency	Trainee	Award	COMP	\$ Per Year	Year	Principal Investigator
UBC	Linda Haug	Summer research studentship	C	\$5,000	1985	Chow AW
UBC	Steve Adilman	Summer research studentship	C	\$5,000	1987	Chow AW
UBC	Graham Wong	Summer research studentship	C	\$5,000	1992	Chow AW
NHRDP	David Birnbaum	Doctoral research fellowship	C	\$15,000	1988-1991	Chow AW
CIHR	Raymond See	Doctoral research fellowship	C	\$15,000	1990-1992	Chow AW
LCDC	Dan Kertesz	Research fellowship	C	\$44,000	1991-1992	Chow AW
NSERC	Monica DeBoer	Graduate studentship	C	\$15,000	1991-1993	Chow AW
CIDS	Vivian Lee	Research fellowship	C	\$44,000	1992-1993	Chow AW
CIHR	Ryan Hung	MD/PhD Studentship	C	\$21,000	1997-2004	Chow AW
CIHR	Scott Cameron	Doctoral research fellowship	C	\$21,000	1999-2003	Chow AW
CIHR	Earnest Leung	Doctoral research fellowship	C	\$21,000	1999-2002	Chow AW

MSFHR	Shirin Kalyan	Junior studentship	C	\$15,000	1999-2002	Chow AW
MSFHR	Shirin Kalyan	Senior studentship	C	\$21,000	2002-2005	Chow AW
CIHR/TRID	Haowei Li	Doctoral research fellowship	C	\$10,000	2004-2006	Chow AW
UBC	Jenny Chuang	Summer research studentship	C	\$5,000	2003	Chow AW
MSFHR	Grace Lam	Junior studentship	C	\$15,000	2004-2006	Chow AW
CIHR/TRID	Lori Sung	Coop studentship	C	\$10,504	2004-2005	Chow AW
CIHR/TRID	Susan Finlay	Coop studentship	C	\$5,252	2005	Chow AW
CIHR/TRID	Anna Burianova	Coop studentship	C	\$5,252	2005	Chow AW
CIHR/TRID	Ziyang Han	Coop studentship	C	\$10,504	2005-2006	Chow AW

(f) Visiting Professorship (indicate university/organization and dates)

1. Northwestern University 1980
2. University of Autonoma de Guadalajara, Mexico 1980
3. University of Kansas 1980
4. Nara Medical College, Japan 1982
5. University of Calgary 1982
6. University of California at Los Angeles 1982
7. University of Toronto 1982
8. University of Alberta 1983
9. University of Colorado 1983
10. University of Manitoba 1983
11. University of California at Los Angeles 1984
12. University of California at San Francisco 1984
13. University of Wisconsin 1984
14. University of Washington 1985
15. University of Alberta 1986
16. University of California at Los Angeles 1986
17. University of Chicago 1986
18. University of Hawaii 1986

19.	University of Oregon	1986
20.	University of California at Irvine	1987
21.	University of California at San Francisco	1987
22.	University of Ottawa	1987
23.	University of Victoria	1987
24.	Capital Medical College, Beijing	1988
25.	University of Calgary	1989
26.	Capital Medical College, Beijing	1990
27.	Dalhousie University	1990
28.	Memorial University	1990
29.	University of Hong Kong	1990
30.	University of Toronto	1991
31.	Asan University Medical Center, Seoul, South Korea	1992
32.	National University of Seoul, South Korea	1992
33.	Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	1993
34.	National University of Singapore, Singapore	1993
35.	University of California at Los Angeles	1993
36.	University of Hong Kong	1993
37.	Stanford University	1994
38.	University of Alberta	1994
39.	University of California at San Francisco	1994
40.	Catholic University of Louvain, Brussels	1995
41.	Free University of Belgium, Brussels (1995)	1995
42.	University Hospital of Antwerp, Belgium	1995
43.	University Hospital of Gent, Belgium	1995
44.	University Hospital of Leuven, Belgium)	1995
45.	University Hospital of Liege, Belgium	1995
46.	University of Saskatchewan & VIDO	1996
47.	National University of Singapore, Singapore	1997
48.	University of Calgary	1997
49.	University of Hong Kong	1997
50.	University of Ottawa	1997
51.	Chang Gung University & Memorial Hospital, Teipei, Taiwan	1998

52.	McKay Memorial Hospital, Taipei, Taiwan	1998
53.	Laval University	1999
54.	University of Toronto	2000
55.	Chi Mei Foundation Hospital, Tainan, Taiwan	2001
56.	Industrial Technology Research Institute, Hsinchu, Taiwan	2001
57.	Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan	2001
58.	McKay Memorial Hospital, Taipei, Taiwan	2001
59.	Caritas Medical Centre, Hong Kong	2002
60.	Dalhousie University	2003
61.	University of California at San Diego	2003
62.	University of Manitoba	2003
63.	University of Toronto	2003
64.	University of Hong Kong	2004
65.	University of Toronto	2004
66.	University of Calgary	2006

(g) Invited Lectures

1. University of Calgary Harry Brody Memorial Lecture, Recent advances in pelvic inflammatory disease, Calgary, 1982
2. Canadian Infectious Disease Society Lecture, New insights in the pathogenesis of staphylococcal toxic shock syndrome, Toronto, 1984
3. Canadian Association of Medical Microbiology and Infectious Diseases Lecture, Virulence mechanisms in mixed anaerobic infections, Edmonton, 1987
4. First Annual Mount Sinai Hospital Department of Otorhinolaryngology Lecture, Life-threatening Infections of the Head and Neck, Toronto, 1991
5. LCDC Consensus Conference on Bloodborne Pathogens in the Health Care Setting, Current Canadian Infection Control Guidelines: What they are and how are they practised, Ottawa, 1991
6. Pacific Interurban Clinical Club Lecture, Microbial Superantigens - their implications in Clinical Medicine, Vancouver, 1992
7. 24th Congress of the International Society of Haematology, Teicoplanin versus vancomycin in the empiric treatment of febrile neutropenic patients, London, England, 1992
8. Canadian Society of Microbiology, Microbial superantigens and their clinical implications, University of Calgary, Alberta, 1992
9. FDA Anti-Infective Advisory Committee Open Meeting, Evaluation of new anti-infective agents for the treatment of respiratory tract infections, Bethesda, 1992
10. Gordon Research Conference on Staphylococcal Diseases, Pathophysiology and animal models of toxic shock syndrome, Andover, NH, 1993
11. Chinese Association of Hospital Infection Control, Strategies for improving antimicrobial utilization in health care facilities, infection control principles and practice in the 90s, Han-Zhou, China, 1993
12. National University of Singapore, Opportunistic infections in AIDS, Principles of antibiotic use, Pathophysiology and treatment of septic shock, Singapore, 1993

13. Spanish Society of Haematology-Oncology, Empiric Antibiotic therapy for febrile neutropenia, Rome, 1993
14. Centre Hospitalier Universitaire Vaudois Infectious Disease Rounds, Empiric antibiotic regimens for presumed infections in immunocompromised patients, Lausanne, Switzerland, 1993
15. Marion-Merrell-Dow Symposium on Gram-positive infections, Glycopeptides and nephrotoxicity, Prague, 1993
16. Stanford University Microbiology and Immunology Seminar Series, Role of superantigens in the staphylococcal toxic shock syndrome, Stanford, 1994
17. Marion-Merrell-Dow Symposium, Pharmaco-economics of gram-positive infections, Edinburgh, 1994
18. Pharmaceutical Forum, BC Ministry of Science, Infectious disease research program in British Columbia, Vancouver, 1994
19. 19th International Congress of Chemotherapy Symposium Speaker, Regulation of staphylococcal toxins and virulence factors, Montreal, 1995
20. Free University of Belgium, Microbial superantigens: implications for the clinician, Brussels, 1995
21. Catholic University of Louvain, Nephrotoxicity of Glycopeptides and other antimicrobial agents, Brussels, 1995
22. UBC Faculty of Medicine Distinguished Medical Research Lecture, Pathogenesis of toxic shock syndrome: a bedside to bench adventure, Vancouver, 1996
23. Bristol-Meyers-Squibb Symposium Lecture, "Evolving concepts in the management of respiratory tract infections," New Orleans, 1996
24. National Pharma Physician and Public Education Program in Travel Medicine, "Traveller's diarrhea: etiology, prevention and treatment," Vancouver, 1996
25. Plenary Symposium speaker, Canadian Association for Clinical Microbiology and Infectious Diseases Annual Meeting, "Old Pathogens - new guises and different vices," Hamilton, 1996
26. Royal Society International Symposium on Toxic Shock Syndrome Plenary Speaker, "Recombinant superantigen peptide vaccines", London, England, 1997
27. University of Hong Kong Microbiology & Immunology Research Seminar, "Pathogenesis of staphylococcal toxic shock syndrome," Hong Kong, 1997
28. Singapore Society of Pathology and Academic Medicine, "Infection prevention in the immunocompromised host," Singapore, 1997
29. International College of Surgeons Combined Scientific Meeting, "Current infection control issues in acute care" and "Guidelines for antibiotic prophylaxis in surgery - Symposium on Surgical Infections," Singapore, 1997
30. National University of Singapore Hoechst Marion Roussel Lecture, "Glycopeptide nephrotoxicity and dosing revisited," Singapore, 1997
31. University of Ottawa, Ottawa General Hospital Department of Medicine Grand Rounds, "Microbial Superantigens - Role for the Clinician," Ottawa, 1997
32. University of Ottawa, Division of Infectious Diseases Research Seminar, "Speciation and molecular phylogeny of staphylococci based on HSP60 gene sequences," Ottawa, 1997
33. National Research Council of Canada Seminar Series, "Immunogenicity and Functional Characterization of Recombinant Staphylococcal Toxic Shock Syndrome Toxin-1 Superantigen Peptides," Ottawa, 1997
34. Chang Gung University Memorial Hospital Grand Rounds, "Molecular tools for epidemiologic typing and speciation of staphylococci," Taiwan, 1998
35. Taiwan Society of Infectious Diseases Lecture, "Overview and clinical implications of gram-positive infections," Taipei, 1998
36. McKay Memorial Hospital Medical Grand Rounds, "Empiric Treatment of Nosocomial infections," Taipei, 1998
37. International Congress of Antimicrobial Agents and Chemotherapy Symposium speaker, "Empiric antibiotic treatment for febrile patients with neutropenia," San Diego, 1998
38. Wyeth-Ayerst Symposium Organizer and Speaker, "Antibiotic stewardship and resistance," Whistler, BC, 1998
39. Laval University Department of Microbiology and Infectious Diseases Grant Rounds, "Heat shock gene

sequences for infectious disease diagnosis," St Foy, Quebec City, 1999

40. Laval University Department of Microbiology and Infectious Diseases Grand Rounds, "Heat shock proteins - role in infection, immunity, and autoimmunity," St. Foy, Quebec City, 1999
41. Abbott Western Conference in Infectious Diseases speaker, "Glycopeptide resistance in coagulase negative staphylococci," Whistler, BC, 1999
42. Parke-Davis Symposium Chair and Speaker, "Empirical antimicrobial therapy," San Francisco, 1999
43. Upjohn Pharmacia Symposium Chair and speaker, "Microbiology and in vitro activity of clinafloxacin," Toronto, 1999
44. University of Toronto Department of Microbiology and Infectious Diseases Grand Rounds, "Coagulase-negative staphylococci - the real superbug," Toronto, 2000
45. University of Toronto Department of Microbiology and Infectious Diseases Research Seminar, "Kinetics of surface marker expression and cytokine secretion in human peripheral blood mononuclear cells following toxic shock syndrome toxin-1 superantigen stimulation," Toronto, 2000
46. University of British Columbia Golden Jubilee lecture in Infectious Diseases, "The superbugs, what can we do to prevent their scourges?," Vancouver, 2000
47. Bayer Western Regional Symposium speaker, "Evolving concepts in the development of treatment guidelines for community-acquired pneumonia," Vancouver, 2000
48. Anormed Biotech Lecture, "Antibiotic resistance in the new millennium," Langley, BC, 2000
49. SmithKlineBeechem Western Canadian Anti-Infective Conference speaker, "Appropriate use of antibiotics," Vancouver, BC, 2000
50. Canadian Bacterial Disease Network Annual Scientific Meeting Plenary speaker, "Applications of heat shock protein 60 kDa (HSP60) technology for infectious disease diagnosis and microbial identification", Canmore, AB 7 May 2000
51. Pharmacia Upjohn Linezolid Symposium speaker, "Glycopeptide resistance in staphylococci", Stockholm, 28 May 2000
52. Taiwan Society of Infectious Diseases HIV/AIDS Symposium, "Update on prophylaxis and treatment of HIV-related opportunistic infections", Kaohsiung, Taiwan, March 2001.
53. Kaohsiung Veterans General Hospital Department of Medicine Grand Rounds, "Mechanism of glycopeptide resistance in coagulase-negative staphylococci", Kaohsiung, Taiwan, March 2001.
54. Chi Mei Foundation Hospital Department of Medicine Grand Rounds. "Heat shock protein 60 kDa gene sequences as universal targets for infectious disease diagnosis". Tainin, Taiwan, March 2001.
55. MacKay Memorial Hospital Department of Medicine and Grand Rounds, "Coagulase-negative staphylococci - the real superbug", Taipei, Taiwan, March 2001.
56. Industrial Technology Research Institute Research Seminar, "HSP60 gene sequences as universal targets for infectious disease diagnosis", Hsinchu, Taiwan, March 2001.
57. UBC Departments of Medicine, Annual Course, Advances in Internal Medicine: Medicine in the 21st Century, "MRSA and VRE", Vancouver BC, June 2001.
58. Fort St. John Medical Society lecture, "Empirical treatment of sepsis", Fort St. John, BC, September 2001.
59. Vancouver International Oribal Symposium, "Future and emerging treatments for microbial infections," Vancouver, British Columbia, March 2002.
60. University of Manitoba Medical College Foundation, Class of 1967 Symposium, "Infectious diseases in the new millennium," Winnipeg Manitoba, Aug 10, 2002.
61. Caritas Medical Centre Open Lecture, "Management of septic shock- current concepts," Hong Kong, November 16, 2002.
62. Caritas Medical Centre Lecture Series, "Intra-abdominal infections," Hong Kong, November 14, 2002.
63. Caritas Medical Centre Lecture Series, "Musculoskeletal," Hong Kong, November 14, 2002.

64. Caritas Medical Centre Lecture Series, "Microbiology for the clinician," Hong Kong, November 15, 2002.
65. Caritas Medical Centre Lecture Series, "Infections in the immunocompromised host," Hong Kong, November 15, 2002.
66. UCSD Biomedical and Clinical Research Center Seminar, "HSP60 genes as universal targets for infectious disease diagnosis", San Diego, Feb 12, 2003
67. San Diego Microbiology Group Research Seminar, "HSP60 genes as universal targets for infectious disease diagnosis", San Diego, April 16, 2003
68. TJ Marrie Lecture in Infectious Diseases, Dalhousie University, "Molecular diagnosis of infectious diseases in the post-genome era - still a pipe dream?", Halifax, May 27, 2003
69. Dalhousie Division of Infectious Diseases Research Day Keynote Presentation, "Death and Suppression by the Staphylococcal superantigen TSST-1", Halifax, May 27, 2003
70. UCSD Division of Infectious Diseases Research Seminar, "Death and Suppression by the Staphylococcal superantigen TSST-1", San Diego, June 5, 2003
71. University of Toronto Department of Medical Microbiology, Infectious Diseases and Medical Microbiology Fellows' Retreat keynote lecture, "Staphylococcal Toxic Shock Syndrome Toxin-1", Toronto, Aug 18, 2003
72. University of Toronto Department of Medical Microbiology, Infectious Diseases and Medical Microbiology Fellows' Retreat keynote lecture, "Life-threatening head and neck infections", Toronto, Aug 17, 2004
73. University of Hong Kong Infectious Disease Program, "Life-threatening head and neck infections", Hong Kong, November 13, 2004
74. University of Hong Kong Infectious Disease Program, "Necrotizing skin and soft tissue infections", Hong Kong, November 13, 2004
75. University of Hong Kong Infectious Disease Program, "Bacterial toxin-mediated infectious diseases", Hong Kong, November 13, 2004
76. University of Hong Kong Infectious Disease Program, "Superantigens: their role in disease", Hong Kong, November 14, 2004
77. BC Centre for Disease Control Seminar, "The challenges of staphylococcal infections", Vancouver, Mar 18, 2005
78. Pfizer MRSA Preceptorship Workshop, "Overview of staphylococcal infections", Vancouver, November 2, 2005
79. Wyeth Regional Anti-infective Symposium, "Current concepts in the management of septic shock", Vancouver, November 4, 2005
80. Western and BC Society of Anaesthesiology Combined Annual Meeting Medical Intelligence Lecture, "Life-threatening head and neck infections – what the anaesthesiologist needs to know", Seattle, December 4, 2005
81. University of Calgary Departments of Medicine, Microbiology and Infectious Diseases Research Seminar, "Controlling staphylococcal infections – prospects and challenges in 2006", Calgary, January 9, 2006
82. Wyeth Intraabdominal Surgical Infections Symposium, "IDSA surgical intra-abdominal infection guidelines with a Canadian perspective", Toronto, February 25, 2006

(h) Conference Participation (Organizer, Keynote Speaker, etc.)

1. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): Session Chair, 1976 (Chicago); 1982 (Miami Beach); 1985 (Minneapolis)
2. Chairman, Canadian Public Health Association Annual Meeting, Vancouver, 1984
3. Session Chair, International Symposium on Toxic Shock Syndrome, Atlanta, 1987
4. Session Chair, American College of Physicians/UBC Internal Medicine Review, Vancouver, 1988, 1990, and 1992
5. Chairman, CSCI/Royal College/CIDS Symposium, Bacterial Toxins, Edmonton, 1989
6. Chairman, National Consensus Workshop on Universal Precautions and Prevention of viral hepatitis and AIDS, LCDC, Ottawa, 1991

7. Chairman, BC Society of Internal Medicine Symposium, Infectious Disease Update, Vancouver, 1992
8. Session Chair, BC Pharmaceutical Forum, Vancouver, 1994
9. Symposium Co-Chairman, 19th International Congress of Chemotherapy, Montreal, 1995
10. 19th International Congress of Chemotherapy Scientific Program Committee, Infectious Diseases Section, Montreal, 1995
11. Session Chair, Western Association of Clinical Research, Carmel, 1996, 1998
12. Chairman, Bristol-Myers-Squibb Symposium, Evolving concepts in the management of respiratory tract infections, New Orleans, 1996
13. Chairman, Bristol-Myers-Squibb and CBDN Symposium, "Therapeutic choices and strategies for overcoming antibiotic resistance", Vancouver, 1997
14. Chairman, Wyeth-Ayerst Symposium, "Antibiotic Stewardship Program", Whistler, 1998
15. Chairman, Park-Davis Symposium, "Empiric antimicrobial therapy", San Francisco, 1999
16. Moderator, First Annual CSCI Western Regional meeting, Vancouver, 1999
17. Organizer, UBC MD/PhD Student Research Forum, Vancouver, 2000
18. Organizer, UBC MD/PhD Student Research Forum, Vancouver, 2001
19. Organizer, UBC MD/PhD Student Research Forum, Vancouver, 2002
20. Organizer, 1st Thematic TRID Research Day Symposium, "Deciphering global host-microbe interactions", Vancouver, June 4, 2004
21. Organizer, 2nd Thematic TRID Research Day Symposium, "Application of basic and clinical research to epidemiological problems", Vancouver, December 1, 2004
22. Organizer, UBC MD/PhD Student Research Forum, Vancouver, 2004
23. Organizer, UBC MD/PhD Student Research Forum, Vancouver, 2005
24. Organizer, 3rd Thematic TRID Research Day Symposium, "Emerging and re-emerging infectious diseases", Vancouver, May 25, 2005
25. Organizer, 4th Thematic TRID Research Day Symposium, "Innate immunity and immunomodulation in Infectious Diseases", Vancouver, December 12, 2005

11. SERVICE TO THE UNIVERSITY

(a) Thesis Dissertation Committees:

1. Lucy Mutharia, PhD, Department of Microbiology, UBC, 1983
2. Thalia Nicas, PhD, Department of Microbiology, UBC, 1984
3. Lori Graham, PhD, Department of Biology, University of Calgary, 1986
4. Patricia Rosten, MSc, Department of Microbiology and Immunology, UBC, 1986
5. Nadarajah Ganeshkumar, PhD, Department of Microbiology, UBC, 1988
6. Alex Chang, MSc, Experimental Medicine Graduate Program, UBC, 1992
7. David Birbaum, PhD, Interdisciplinary Studies, UBC, 1992
8. Raymond See, PhD, Department of Pathology, UBC, 1992
9. Xiao Wen Liao, PhD, Department of Microbiology and Immunology, UBC, 1996
10. Oliver Bathe, M.D., MSc, Department of Experimental Surgery, 1996
11. Min Jiang, PhD, Department of Microbiology, University of Saskatchewan, 1996
12. Monica DeBoer, PhD, Department of Microbiology and Immunology, UBC, 1996
13. Dan Wilson, PhD, Department of Microbiology and Immunology, UBC, 1997
14. Patrick Tang, MD/PhD, Department of Microbiology and Immunology, UBC, 1998

15. Steven Yip, MD/PhD, Department of Microbiology and Immunology, UBC, 1998
16. Carol Friedrich, MSc, Department of Microbiology and Immunology, UBC, 1998
17. Wai Keung Leung, PhD, Department of Oral Biology, UBC, 1998
18. Monisha Gough, MSc, Department of Microbiology and Immunology, UBC, 1998
19. Soo Sen Lee, MSc, Experimental Medicine Graduate Program, UBC, 1998
20. Steven Drews, MSc, Department of Experimental Pathology, UBC, 1998
21. Liwina Pang, MSc, Experimental Medicine Graduate Program, UBC, 1999
22. Khani Hanjini, PhD, Experimental Medicine Graduate Program, UBC, 2000
23. Earnest Leung, Comprehensive Examinations, Experimental Medicine, December 12, 2001
24. Shirin Kalyan, Comprehensive Examination, Experimental Medicine, September 26, 2001
25. Catherine Health, PhD, Department of Health Care & Epidemiology, UBC, 2002
26. Liangxuan Zhang, PhD, Department of Oral Biological & Medical Sciences, UBC, 2002.
27. Dr. Woo Chiu Yat Patrick, Doctor of Medicine thesis dissertation, University of Hong Kong, Faculty of Medicine, External Examiner, 2002
28. Ryan Hung, MD/PhD, Experimental Medicine Graduate Program, UBC, 2004
29. Scott Cameron, PhD, Experimental Medicine Graduate Program, UBC, 2004
30. **Evette Haddad, PhD candidate, Comprehensive examination, Genetics Graduate Program, UBC, 2005**
31. **Patrice Godin, MSc, Experimental Medicine Graduate Program, UBC, 2005**
32. **Haowei Li, PhD Comprehensive examination, Experimental Medicine Graduate Program, UBC, 2005**
33. **Audrey Steenbeek, PhD defense chair, Department of Healthcare & Epidemiology, UBC, 2005**
34. **Paula Braitstein, PhD defense, Department of Healthcare & Epidemiology, UBC, 2005**
35. **Grace Lam, MSc Comprehensive examination, Experimental Medicine Graduate Program, UBC, 2005**
36. **Ainsley Sutherland, PhD candidate, Comprehensive examination, Experimental Medicine, UBC, 2006**
37. **Jimmy Lee, MD/PhD Internal thesis defense, Department of Pathology & Laboratory Medicine, UBC, 2006**

(b) UBC Faculty & Departmental Committees:

- 1 President's Advisory Committee for Search of Dean of Medicine, 1989
- 2 President's Advisory Committee for Search of Head of Medicine, 1989
- 3 President's Review Committee of the Office of Research Services, 1993
- 4 President's Advisory Committee for Search of Head of Microbiology, 1990
- 5 Faculty of Medicine Executive Committee, 1986-1989
- 6 Faculty of Medicine Nominations Committee, 1988-1989
- 7 Faculty of Medicine Curriculum Evaluation Committee, 1988-1990
- 8 Faculty of Medicine Review of Medical Microbiology, 1989
- 9 Chairman, Curriculum Evaluation of Clinical Skills I, Faculty of Medicine, 1989
- 10 Faculty of Medicine Internal Review Committee for the Clinician Investigator Program, 1998
- 11 Faculty of Medicine Graduate Education Committee, 1998-present
- 12 Faculty of Medicine LMCC Accreditation Committee, 1991-1992
- 13 Vancouver Node Coordinator, Canadian Bacterial Diseases Network National Centres of Excellence, 1990-1997
- 14 Chairman, MD/PhD Program Subcommittee, Institutional Self Study, Faculty of Medicine, 1992
- 15 Chairman, Faculty of Medicine MD/PhD Program Implementation Committee, 1994

- 16 Director, UBC MD/PhD Program, Faculties of Medicine and Graduate Studies, 1995-present
- 17 Department of Medicine Medical Advisory Committee, 1979-1993
- 18 Department of Medicine Appointments, Promotions & Tenure Committee, 1995-1998
- 19 Department of Medicine Cardiology Review, 1999
- 20 Department of Medicine Experimental Medicine Program (Coordinator for Infectious Diseases), 1995-2002
- 21 Faculty of Medicine Search Committee for Associate Dean of Admissions, 2002
- 22 President's Advisory Committee, selection of a new Dean for the Faculty of Pharmaceutical Sciences, 2002
- 23 Faculty of Science Search Committee for Department Head, Microbiology & Immunology, 2002
- 24 Faculty of Medicine Search Committee for the selection of Associate Vice President Medicine, University of Northern British Columbia and UBC, 2002
- 25 Faculty of Medicine Review Committee for the UBC Clinician Investigator Program, 2004

12. SERVICE TO THE HOSPITAL

- 1 VGH and UBCH Foundation Special Opportunities Research Fund Selection Committee
- 2 Hospital Infection Control Committee, VGH, 1979-1984; 1993
- 3 Hospital Infection Control Committee, CCABC Hospital, 1979-1987
- 4 Hyperbaric Committee, VGH, 1979
- 5 Therapeutics Committee, VGH, 1979-1985
- 6 Antibiotic Utilization Committee, VGH; Chairman 1984-1987; member 1984-present
- 7 AIDS Committee Chairman, VGH, 1986-1990
- 8 Search Committee for Hospital Head of Gastroenterology, VGH, 1986
- 9 Search Committee for Hospital Head of Medicine, VGH, 1987
- 10 Department of Medicine Research Committee, VGH, 1992-1994
- 11 Animal Care Committee, VHHSC, 1995-1997
- 12 Ambulatory Clinics Accreditation Committee, 1995-1996
- 13 Munroe Clinical Tailoring Committee, 1996- 2001
- 14 Vancouver Hospital Foundation, Board Member, 1999- 2002
- 15 Vancouver Coastal Health Research Institute, Scholarship Adjudication Committee, 2003
- 16 Vancouver Coastal Health Research Institute "In It for Life New Investigator Awards" Review Committee, 2005

13. SERVICE TO THE COMMUNITY

(a) Membership on scholarly societies, including offices held and dates

i. International:

1. American Society for Microbiology, member, 1972-present
2. American Federation for Clinical Research, member, 1972-present
3. American College of Physicians, Fellow, 1974-present
4. Infectious Disease Society of America; Fellow, 1976-present
5. American Institute of Biological Sciences, member, 1979-present
6. New York Academy of Sciences, member, 1982-present
7. Society for Experimental Biology and Medicine, member, 1982-present
8. Western Association of Physicians, member, 1983-present

9. American Venereal Disease Association, member, 1985-present
- 10 Food and Drug Administration/Infectious Disease Society of America Advisory Committee on New Drug Submissions; Chairman, Respiratory Tract Infections Subcommittee, Washington DC, 1988-92
- 11 Western Society for Clinical Investigation, Councilor, 1992-95
- 12 USA Federal Drug Administration, Anti-infective Advisory Committee, Washington DC, 1994
- 13 Infectious Disease Society of America, Antibiotic Use and Clinical Trials Committee, 1994-1997
- 14 American Institute of Biological Sciences Peer Review Committee for the U.S. Army Medical and Material Command Therapeutics Research Program, Nov 2001
- 15 External site review of the University of Idaho campus in Moscow application to the NIH Extramural Research Facilities Improvement Program, Jan 2002
- 16 International Scientific Program Committee, First International Conference on Community Acquired Pneumonia, Nov 2002
- 17 Infectious Disease Society of America (IDSA) Intra-abdominal Infections Antimicrobial Treatment Guideline Committee, 2001-2003
- 18 University of Hong Kong Postgraduate Degree Program in Infectious Diseases, External Board Member, 2002-present

ii. National:

- 1 Canadian Infectious Diseases Society, member, 1979-present; Councilor, 1995-1998
- 2 Canadian Association of Clinical Microbiology and Infectious Diseases, member, 1980-present
- 3 Health and Welfare Canada Bureau of Infection Control, Steering Committee member, 1980-1993
- 4 Health and Welfare Canada Bureau of Infection Control Working Group on Infection Control Guidelines, 1987, 1992-1993
- 5 Royal College of Physicians of Canada Subspecialty Committee for Infectious Diseases, Corresponding member, 1982-1990; Nucleus member, 1990-1995
- 7 Canadian Society of Microbiology, member, 1985-present
- 8 Canadian Public Health Association, member, 1986
- 9 Canadian Society for Clinical Investigation, Councilor, 1986-1989
- 11 Health and Welfare Canada Bureau of Infection Control Working Group on Antimicrobial Utilization for Health Care Facilities, Chair 1988-1990
- 12 Canadian Institute of Academic Medicine, 1993-present
- 16 College of Reviewers, Canada Research Chairs Program, 2002-present
- 17 Expert Advisory Board on Anti-infective Therapies, Office of Science Policy Bureau, Therapeutic Products, Health Canada, 2002-present
- 18 Review Committee, Department of Medical Microbiology Graduate Programs, University of Manitoba, Mar 2003

iii. Provincial:

1. College of Physicians and Surgeons of Manitoba, member, 1973-present
2. British Columbia Medical Association, member, 1979-present
3. College of Physicians and Surgeons of British Columbia, member, 1979-present
4. British Columbia Health Officers' Council Committee for Communicable Diseases, 1981
5. British Columbia Health Care Research Foundation Scientific Advisory Committee, 1981-1985
6. British Columbia Provincial Medical Advisory Committee on AIDS, 1987

7. British Columbia Provincial Bone Marrow Transplantation Committee, 1988
8. British Columbia Ministry of Health Review Panel on Microbiological Research and Public Health Protection, 1988
9. British Columbia Society of Internal Medicine, member, 1988-present
10. British Columbia Society of Internal Medicine, 1988-present
11. British Columbia Ministry of Health Advisory Committee for Strategic Planning of Applied Research and Knowledge (SPARK), 1992-1993
12. British Columbia Provincial Advisory Committee for Therapeutic Guidelines in AIDS, 1992-1993
13. British Columbia Ministry of Health Medical Task Force for IVIG Utilization Management, 2001-present

(b) Journal editorial boards and ad hoc reviewer

i. Editorial Boards”

1. The University of Manitoba Medical Journal, Editor in Chief, 1966-1967
2. Infectious Disease Alert, 1981-1994
3. Antimicrobial Agents and Chemotherapy, 1983-1994
4. Diagnostic Microbiology and Infectious Disease, 1983-1994
5. Contemporary Infectious Disease, 1987-1989
6. Case Reports – Infectious Diseases, 1986-1991
7. Clinical Investigative Medicine, Publications Committee, 1987-1989
8. Anaerobe, 1994-present
8. Canadian Journal of Diagnosis, 1987-present
9. Focus: Infectious Disease Canada, 1988-1991
10. The Medicine Group Editorial Advisory Board (Infectious Diseases), 1989-present
11. Canadian Journal of Infectious Diseases, Publications Committee, 1993-1997
12. In Sight Editorial Board, Science Magazine, Academic Press, 1999
13. Journal of Microbiology, Immunology and Infection, Lippincott Williams & Wilkins, 2002 - present

ii. Ad hoc reviewer for selected journals:

American Journal of Medicine
 American Journal of Obstetrics and Gynecology
 Annals of Internal Medicine
 Antimicrobial Agents and Chemotherapy
 Archives of Internal Medicine
 Canadian Infectious Disease Journal
 Canadian Journal of Microbiology
 Canadian Medical Association Journal
 Cellular Immunology
 Chest
 Clinical and Investigative Medicine
 Clinical and Investigative Medicine
 Clinical Immunology
 Clinical Infectious Diseases
 Diagnostic Microbiology and Infectious Diseases

Drugs
Infection and Immunity
Journal of Clinical Microbiology
Journal of Infectious Disease
Journal of Pediatrics
Journal of Virological Methods
New England Journal of Medicine
Obstetrics and Gynecology
Pediatric Infectious Diseases
Pediatrics
Reviews of Infectious Diseases
Sexually Transmitted Diseases
The Medical Letter
Western Journal of Medicine

(c) Granting Agency Review Committees and Ad Hoc Reviews:

1. Alberta Heritage Foundation
2. American Heart Association
3. B.C. Children's Hospital Research Institute Investigatorship Review Committee
4. B.C. Health Care Research Foundation
5. Canadian Bacterial Diseases Network Science and Budget Committee, 1990-1997
6. Canadian Cystic Fibrosis Foundation
7. Canadian Heart Foundation
8. Canadian Infectious Disease Society Grants and Awards Committee Chair, 1995-1998
9. Canadian Institutes of Health Research IAI Pilot Project Program Grant Review Committee, 2002-2006
10. Canadian Kidney Foundation
11. External Reviewer, University of Idaho Infrastructure Application to the National Institutes of Health Extramural Research Facilities Improvement Program, USA, Jan 2002
12. External Reviewer, US Army Medical Research Institute of Infectious Diseases Therapeutics Program, Toxins Panel, American Institute of Biological Sciences, USA, Jan 2002
13. Health and Welfare Canada Microbiology and Infectious Diseases Grants Committee, 1987
14. Hong Kong Research Grant Council, 2002
15. Medical Research Council of Canada Microbiology and Infectious Diseases Grants Committee, 1983
16. MRC Microbiology and Infectious Diseases Grants Committee, 1996-1999
17. Michael Smith Foundation for Health Research, Clinical Research Evaluation Committee, 2001-2002
18. NIAID Scientific Review Panel, "Impact of Microbial Interactions on Infectious Diseases", 2002
19. National Science and Engineering Research Council of Canada
20. New Zealand Health Research Council, Jan 2004
21. Ontario Health Care Research Foundation
22. Saskatchewan Health Care Research Foundation
23. Singapore Ministry of Health, 1997
24. USA National Institutes of Health, Allergy and Infectious Diseases (NIAID), Bacteriology and Mycology Study Section (P14), Bethesda, MD, 1997-1999

Section (BM-1), Bethesda, MD, 1987-1991

25. USA National Institutes of Health, Allergy and Infectious Diseases (NIAID) Grant Review Committee, "Impact of Microbial Interactions on Infectious Diseases", Nov 2002
26. US Veterans Administration, Washington, D.C.
27. Vancouver Hospital Young Investigator Program, Chair for Infectious Diseases, 2001-2002
28. Vancouver Coastal Health Research Institute, "In It for Life New Investigator Program", 2003-2005

14. CLINICAL & SCIENTIFIC ADVISORY BOARDS OR CONSULTANTSHIPS (indicate organization and dates)

1. Abbott Laboratories Scientific Advisory Board on Anti-infectives, 1997
2. AnorMed Biotech Inc., Consultant for novel anti-infectives, 1999
3. Astra Zeneca Scientific Advisory Board for anti-infectives, 2000-2004
4. Aventis-Pasteur Anti-Infective Scientific Advisory Board for ketoloid antibiotics, 2000-2005
5. Bayer Western Regional Scientific Advisory Board on Anti-infectives, 1997-present
6. Clinical Advisors Advisory Board, New York, 2005
7. Daichii Scientific Advisory Board on New Fluoroquinolones, 1998
8. Genex Biotech Korea, Consultant for antimicrobial peptides, 1999
9. Genome Prairie Project Science and Management Advisory Committee, 2003-2005
10. Hoechst Marion Roussel Scientific Advisory Board for Teicoplanin, 1997
11. Hycult Biotech Inc., Netherlands, 2000-present
12. Iminex Pharmaceuticals Inc, Scientific Advisory Board, 2003-present
13. MEDACORP Consultancies, Boston, 2005-present
14. Merck Sharp and Dome Scientific Advisory Board on Anti-infectives, 1998
15. Micrologix Biotech Inc, Scientific & Medical Advisory Board, 1993-2004
16. Migenix Clinical Advisory Board, Vancouver, 2004-present
17. Parke-Davis Scientific Advisory Board on Anti-infectives, 1998-2000
18. Pfizer Scientific Advisory Board on Anti-infectives, 1997, 2004, 2005
19. Protein Engineering Network of Centres of Excellence, Scientific Advisory Board, 1996-2003
20. Schering Scientific Advisory Board on Anti-infectives, 1997
21. Smith-Klein Beecham Pharma Primary CARE Network Western Region Advisory Board, 2000-2004
22. Upjohn-Pharmacia Scientific Advisory Board for Linezolid, 1999-2002
23. Wyeth Anti-Infective Scientific Advisory Board, 2004-2006
24. Xenon Genetics Inc, Consultant in Infectious Diseases, 2002

**University of British Columbia
Publications Record**

Date: Feb 12, 2006

Initial: _____

FIRST NAME: Anthony

MIDDLE NAME(S): W

1. SURNAME: Chow

1. REFEREED PUBLICATIONS

(a) Journals

1. Winters R, Chow AW, Hecht R, Hewitt W: Combined use of gentamicin and carbenicillin. *Ann Intern Med* 75:925-927, 1971.
2. Keys T, Hecht R, Chow AW: Endocervical Neisseria meningitidis with meningococemia. *New Engl J Med* 285:505- 506, 1971
3. Chow AW, Forester J, Hryniuk W: Cytosine arabinoside therapy for Herpes virus infections. *Antimicrob Ag Chemother* 1970, pp 214- 217, 1971
4. Chow A, Hecht R, Winters R: Gentamicin and carbenicillin penetration into the septic joint. *New Engl J Med* 285:178-179, 1971
5. Chow AW, Guze LB: More on antibiotic susceptibility of Bacteroides. *Ann Intern Med* 75:810, 1971
6. Fiala M, Chow A, Guze LB: Susceptibility of herpes viruses to cytosine arabinoside: Standardization of susceptibility test procedure and relative resistance of Herpes simplex type II strains. *Antimicrob Ag Chemother* 1:354- 357, 1972
7. Hryniuk W, Forester J, Shojania M, Chow A: Cytarabine for herpes virus infections. *JAMA* 219:715- 718, 1972
8. Goldin RH, Chow AW, Edwards J, Louie JS, Guze LB: Sternoarticular septic arthritis in heroin users. *New Engl J Med* 289:616- 618, 1973
9. Chow AW, Ronald A, Fiala M, Hryniuk W, Weil ML, St. Geme Jr J, Guze LB: Cytosine arabinoside therapy for Herpes simplex encephalitis - clinical experience with six patients. *Antimicrob Ag Chemother* 3:412-417, 1973
10. Chow AW, Bushkell LL, Yoshikawa TT, Guze LB: Haemophilus parainfluenzae epiglottitis with meningitis and bacteremia in an adult. A case report. *Amer J Med Sci* 267:365- 368, 1974
11. Yoshikawa TT, Miyamoto S, Chow AW, Guze LB: In vitro resistance of Neisseria gonorrhoeae to metronidazole. *Antimicrob Ag Chemother* 6:327-329, 1974
12. Galpin JE, Chow AW, Yoshikawa TT, Guze LB: "Pseudoanaphylactic" reactions from inadvertent infusion of procaine penicillin G. *Ann Intern Med* 81:358- 359, 1974
13. Chow AW, Leake RD, Yamauchi T, Anthony BF, Guze LB: The significance of anaerobes in neonatal bacteremia - analysis of 23 cases and review of the literature. *Pediatrics* 54:736-745, 1974
14. Yoshikawa TT, Chow AW, Guze LB: Bacteroidaceae bacteremia with disseminated intravascular coagulation. *Amer J Med* 56:725- 728, 1974
15. Chow AW, Montgomerie JZ, Guze LB: Parenteral clindamycin therapy for severe anaerobic infections. *Arch Intern Med* 134:78-82, 1974.
16. Fiala M, Chow AW, Miyasaki K, Guze LB: Susceptibility of herpes viruses to three nucleoside analogues and their combinations, and the enhancement of antiviral effect in acid pH of medium. *J Infect Dis* 129:82-85, 1974
17. Yoshikawa T, Chow AW, Montgomerie JZ, Guze LB: Paratracheal abscess - an unusual complication of transtracheal aspiration. *Chest* 65:105-106, 1974

18. Chow AW, Guze LB: Bacteroidaceae bacteremia: Clinical experience with 112 patients. *Medicine (Balt.)* 53:93-126, 1974
19. Chow AW, Patten V, Guze LB: Rapid screening of Veillonella by ultraviolet fluorescence. *J Clin Microbiol* 2:546-548, 1975
20. Chow AW: Genital infection with type II Herpes simplex virus - a common venereal disease. *Postgrad Med* 58:66-70, 1975
21. Boston Interhospital Virus Study Group and the NIAID sponsored Cooperative Antiviral Clinical Study (Chow AW, participant): Failure of high dose 5-iodo-2'-deoxyuridine in the therapy of herpes simplex virus encephalitis - evidence of unacceptable toxicity. *New Engl J Med* 292:599-603, 1975
22. Bayer AS, Nelson SC, Galpin JE, Chow AW, Guze LB: Necrotizing pneumonia and empyema due to Clostridium perfringens - report of a case and review of the literature. *Amer J Med* 59:851-856, 1975
23. Chow AW, Marshall Jr, Guze LB: Anaerobic infections of the female genital tract - prospects and perspectives. *Obstet Gynec Survey* 30:477-494, 1975
24. Galpin JE, Chow AW, Yoshikawa TT, Guze LB: Meningococcal pneumonia - a case report. *Amer J Med Sci* 269:247-250, 1975
25. Finegold SM, Bartlett JG, Chow AW, Flora DJ, Gorbach SL, Harder EJ, Tally FP: Management of anaerobic infections. *Ann Intern Med* 83:375- 390, 1975
26. Chow AW, Patten V, Guze LB: Comparative susceptibility of anaerobic bacteria to minocycline, doxycycline and tetracycline. *Antimicrob Ag Chemother* 7:46-49, 1975
27. Chow AW, Malkasian KL, Marshall JR, Guze LB: Acute pelvic inflammatory disease and clinical response to parenteral doxycycline. *Antimicrob Ag Chemother* 7:133 138, 1975
28. Chow AW, Malkasian KL, Marshall JR, Guze LB: The bacteriology of acute pelvic inflammatory disease - value of cul-de-sac cultures and relative importance of gonococci and other aerobic or anaerobic bacteria. *Amer J Obstet Gynecol* 122:876-879, 1975
29. Fisher LS, Chow AW, Yo AW, Yoshikawa TT, Guze LB: Cephalothin and cephaloridine therapy for bacterial meningitis an evaluatio - an evaluation. *Ann Intern Med* 82:689-693, 1975
30. Chow AW, Culver B, Yoshikawa TT, Guze LB: Primary meningococcal pericarditis presenting with tamponade. *Chest* 67:611- 613, 1975
31. Chow AW, Patten V, Guze LB: Susceptibility of anaerobic bacteria to metronidazole-relative resistance of non spore forming gram-positive bacilli. *J Infect Dis* 131:182-185, 1975
32. Chow AW, Alexander E, Montgomerie JZ, Guze LB: Non meningitic listerial brain abscess - successful treatment of non-meningitic listerial brain abscess without operation. *West J Med* 122:167-171, 1975
33. Yoshikawa TT, Chow AW, Guze LB: The role of anaerobic bacteria in subdural empyema. Report of four cases and review of 327 cases from the English literature. *Amer J Med* 58:99- 104, 1975
34. Whitley RJ, Ch'ien LT, Dolin R, Galasso GJ, Alford CA Jr, and the Collaborative Study Group (Chow AW, participant): Adenine arabinoside therapy of herpes zoster in the immunosuppressed - NIAID Collaborative Antiviral Study. *J Med* 294:1193-1199, 1976
35. Dysart NK Jr, Griswold WR, Schanberger JE, Goscienski PJ, Chow AW: Meningitis due to Bacteroides fragilis in a newborn infant. *J Ped* 89:509-510, 1976
36. Montgomerie JZ, Pickett MJ, Yoshimori RN, Chow AW, Guze LB: Susceptibility of Acinetobacter calcoaceticus var. anitratus (Herellea vaginicola) to minocycline. *Antimicrob Ag Chemother* 10:102-105, 1976
37. Chow AW, Ota JK, Guze LB: Clindamycin plus gentamicin as expectant therapy for presumed mixed infections. *Can Med Assoc J* 115:1225-1229, 1976
38. Targan SR, Chow AW, Guze LB: Spontaneous peritonitis of cirrhosis due to Campylobacter fetus. *Gastroenterology* 71:311- 313, 1976
39. Bayer AS, Chow AW, Anthony BF, Guze LB: Serious adult infections due to group B streptococci - clinical and serotypic characterization. *Amer J Med* 61:498-503, 1976

40. Galpin JE, Chow AW, Bayer AS, Guze LB: Sepsis associated with decubitus ulcers. *Amer J Med* 61:346- 350, 1976
41. Chow AW, Cunningham PJ, Guze LB: Survival of anaerobic and aerobic bacteria in a nonsupportive gassed transport system. *J Clin Microbiol* 3:128-132, 1976
42. Chow AW, Soll BA, Targan SR, Guze LB: Hyperamylasemia associated with gonococcal salpingitis and perihepatitis - a case report. *Obstet Gynecol* 48 (suppl):29S-30S, 1976
43. Fisher LS, Chow AW, Lindquist L, Guze LB: Failure of metronidazole in amebic liver abscess. *Amer J Med Sci* 271:65-68, 1976 (A42)
44. Chow AW, Ota JK, Guze Lb: Initiele therapie met clindamycine en gentamicine bij mogelijke menginfecties. *Med Mag & TGO/JDR (Amsterdam)* 2:31- 41, 1977
45. Okada DM, Chow AW, Bruce VT: Neonatal scalp abscess and fetal monitoring: factors associated with infection. *Amer J Obstet Gynecol* 129:185-189, 1977
46. Okada DM, Chow AW: Neonatal scalp abscess following intrapartum fetal monitoring: prospective comparison of two spiral electrodes. *Amer J Obstet Gynecol* 127:875-878, 1977
47. Bayer AS, Chow AW, Guze LB: *Listeria monocytogenes* endocarditis: Report of a case and review of the literature. *Amer J Med Sci* 273:319-323, 1977
48. Whitley RJ, Soong SJ, Dolin R, Galasso GJ, Ch'ien LT, Alford CA, and the Collaborative Study Group (Chow AW, participant): Adenine arabinoside therapy of Herpes simplex encephalitis - NIAID Collaborative Antiviral Group. *New Engl J Med* 297:289-294, 1977
49. Henderson DK, Chow AW, Guze LB: Comparative susceptibility of anaerobic bacteria to ticarcillin, cefoxitin, metronidazole, and related antimicrobial agents. *Antimicrob Ag Chemother* 11:679-682, 1977
50. Bayer AS, Chow AW, Louie JS, Nies KM, Guze LB: Gram negative bacillary septic arthritis: clinical, radiographic, therapeutic and prognostic features. *Semin Arthritis Rheum* 7:123-132, 1977
51. Bayer AS, Chow AW, Louie JS, Guze LB: Sternoarticular pyoarthrosis due to gram-negative bacilli. *Arch Intern Med* 137:1036-1040, 1977
52. Goodman SJ, Cahan L, Chow AW: Subgaleal abscess - a preventable complication of scalp trauma. *West J Med* 127:169-172, 1977
53. Klein EJ, Fisher LS, Chow AW, Guze LB: Therapeutic regimens for anorectal gonococcal infections in the male. *Arch Intern Med* 137:1234-1235, 1977
54. Klein EJ, Fisher LS, Chow AW, Guze LB: Anorectal gonococcal infection. *Ann Intern Med* 86:340-346, 1977
55. Barry RE, Chow AW, Billesdon J: Role of intestinal microflora in colonic pseudoobstruction complicating jejunioileal bypass. *GUT* 18:356-359, 1977
56. Roser SM, Chow A, Brady FA: Necrotizing fasciitis. *J Oral Surg* 35:730-732, 1977
57. Chow AW, Marshall Jr, Guze LB: A double blind comparison of clindamycin with penicillin plus chloramphenicol in treatment of septic abortion. *J Infect Dis* 135(suppl):S35-S39, 1977 (A56)
58. Chow AW, Galpin JE, Guze LB: Clindamycin for treatment of sepsis caused by decubitus ulcers. *J Infect Dis* 135(suppl):S65-S68, 1977
59. Targan SR, Chow AW, Guze LB: Role of anaerobic bacteria in spontaneous peritonitis of cirrhosis - report of two cases and review of the literature. *Amer J Med* 62:397-403, 1977
60. Targan SR, Chow AW, Guze LB: *Campylobacter fetus* associated with lung abscess and empyema. *Chest* 71:105-108, 1977
61. Bayer AS, Chow AW, Concepcion N, Guze LB: Susceptibility of 40 Lactobacilli to six antimicrobial agents with broad gram-positive anaerobic spectra. *Antimicrob Ag Chemother* 14:720-722, 1978
62. Chow AW, Bednorz D: Comparative in vitro activity of newer cephalosporins against anaerobic bacteria. *Antimicrob Ag Chemother* 14:668-671, 1978
63. Oill PA, Chow AW, Flood TP, Guze LB: Acute *Hemophilus influenzae* type B vertebral osteomyelitis: a case report and review of the literature. *Clin Orthoped Rel Res* 136:253-256, 1978

64. Chow AW, Paten V, Bednorz D: Susceptibility of *Campylobacter fetus* to 22 antimicrobial agents. *Antimicrob Ag Chemother* 13:416-418, 1978
65. Bayer AS, Chow AW, Betts D, Guze LB: Lactobacilemia - report of nine cases. Important clinical and therapeutic considerations. *Amer J Med* 64:808-813, 1978
66. Yoshikawa TT, Shibata SA, Chow AW, Guze LB: Outbreak of multiple drug resistant *Proteus mirabilis* originating in a surgical intensive care unit: in vitro susceptibility pattern. *Antimicrob Ag Chemother* 13:177-179, 1978
67. Oill PA, Chow AW, Roberto RR, Guze LB: An intercity outbreak of adult meningococcal meningitis. *West J Med* 128:189-194, 1978
68. Chow AW, Roser SM, Brady FA: Orofacial odontogenic infections. *Ann Intern Med* 88:392-402, 1978
69. Oill PA, Chow AW, Guze LB: Adult bacteremic *Haemophilus parainfluenzae* infections - seven case reports and literature review. *Arch Intern Med* 139:985-988, 1979
70. Whitley RJ, Alford CA, and the NIAID Collaborative Antiviral Study Group (Chow AW, participant): Encephalitis and adenine arabinoside - An indictment without fact. *Hasting Cent Rep* 9(8):444-446, 1979
71. Bayer AS, Chow AW, Concepcion NF, Guze LB: Comparative in vitro activity of five cephalosporins against the lactobacilli. *Antimicrob Ag Chemother* 16:112-113, 1979
72. Morgan D, Young RF, Chow AW, Mehringer CM, Itabashi H: Recurrent intracerebral blastomycotic granuloma - diagnosis and management. *Neurosurg* 4:319-324, 1979
73. Chow AW, Taylor PR, Yoshikawa TT, Guze LB: A nosocomial outbreak of multiply resistant *Proteus mirabilis* infections - Role of intestinal colonization as a major reservoir. *J Infect Dis* 139:621-627, 1979
74. Chow AW, Patten V, Marshall JR: The bacteriology of acute pelvic inflammatory disease suboptimal survival of *Neisseria gonorrhoeae* in a nonbuffered transport system. *Amer J Obstet Gynecol* 133:363-365, 1979
75. Chow AW, Carlson C, Sorrell TC: Host defences in acute pelvic inflammatory disease. I. Bacterial clearance in murine uterus and oviduct. *Amer J Obstet Gynecol* 138:1003-1005, 1980
76. Bayer AS, Chow AW, Morrison JD, Guze LB: Bactericidal synergy between penicillin or ampicillin and aminoglycosides against antibiotic tolerant lactobacilli. *Antimicrob Ag Chemother* 17:359-363, 1980
77. Drulak MW, Chow AW: Comparative in vitro activity of ceftizoxime, cefoperazone and cefoxitin against anaerobic bacteria. *Antimicrob Ag Chemother* 20:683-685, 1981
78. Sorrell TC, Marshall JR, Yoshimori R, Chow AW: Antimicrobial therapy of postpartum endomyometritis. II. Prospective, randomized trial of mezlocillin versus ampicillin. *Amer J Obstet Gynecol* 141:246-251, 1981
79. Sorrell TC, Marshall JR, Chow AW: Antimicrobial therapy of postpartum endomyometritis. I. Comparative susceptibility of mezlocillin and other antibiotics to genital anaerobic bacteria. *Amer J Obstet Gynecol* 141:242-245, 1981
80. Gribble MJ, Salit IE, Isaac Renton J, Chow AW: *Campylobacter* infections in pregnancy - case report and literature review. *Amer J Obstet Gynecol* 140:423-427, 1981 (80)
81. Bayer AS, Chow AW, Ishida K, Morrison JO, Guze LB: Therapy of experimental infective endocarditis due to antibiotic tolerant *Lactobacillus plantarum*. *Chemotherapy* 27:444-451, 1981
82. Strassburg MA, Imagawa DT, Fannin SL, Turner JA, Chow AW, Murray RA, Cherry JD: Rubella outbreak among hospital employees. *Obstet Gynecol* 57:283-288, 1981
83. Whitley RJ, Soong SJ, Dolin R, Betts R, Linnomann C Jr, Alford CA Jr, and the NIAID Collaborative Antiviral Study Group (Chow AW, participant): Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. *New Engl J Med* 807:971-975, 1982
84. Prober CG, Kirk LE, Keeney RE and the Collaborative Study Group (Chow AW, participant): Acyclovir therapy of chicken-pox in immunosuppressed children: a collaborative study. *J Ped* 101:622-625, 1982
85. Harris GS, Chow AW: Management of infective endophthalmitis by pars plana vitrectomy. *Can J Ophthalmol* 17:194-198, 1982.
86. Polisky R, Chow AW: Quinacrine madness. *BC Med J* 24:217-218, 1982
87. Chow AW, Gribble MJ, Bartlett KH: Hemolytic activity of toxic shock syndrome associated *Staphylococcus aureus*. *J Infect Dis* 146:22-26, 1982

J Infect Dis 146:98, 1982

88. Dornan KJ, Thompson DM, Conn AR, Wittmann BK, Stiver HG, Chow AW: Toxic shock syndrome in the postoperative patient. *Surg Gynec Obstet* 154:65-68, 1982
89. Percival Smith R, Bartlett KH, Chow AW: Vaginal colonization of *Escherichia coli* and its relation to contraceptive methods. *Contraception* 27:497- 504, 1983 (90)
90. Balfour HH, Bean B, Laskin OL, et al, and the Burroughs Wellcome Collaborative Acyclovir Study Group (Chow AW, participant): Acyclovir halts progression of herpes zoster in immunocompromised patients. *New Engl J Med* 308:1448-1453, 1983
91. Gribble MJ, Chow AW, Naiman SC, Smith JA, Bowie WR, Sacks SL, Grossman L, Buskard N, Grove GH, Plenderleith IH: Piperacillin monotherapy versus carboxypenicillin aminoglycoside combination regimens in the empirical treatment of serious bacterial infections. A prospective randomized trial. *Antimicrob Ag Chemother* 24:388-393, 1983
92. Isaac Renton JL, Lee A, Chan R, Chow AW, Sacks S: Drug resistance in three cases of malaria. *Can Med Assoc J* 129:454-457, 1983
93. Jewesson PJ, Ho R, Jang Q, Watts G, Chow AW: Auditing antibiotic use in a teaching hospital - focus on cefoxitin. *Can Med Assoc J* 128:1075-1078, 1983
94. Sorrell TC, Baker PA, Chow AW: Host defences in the upper genital tract of the female - studies in a murine system. *Aust J Exp Bio Med Sci* 61:287-299, 1983
95. Kwan WC, Lam SC, Chow AW, Lepawsky M, Glanzberg MM: Empyema caused by *Clostridium perfringens*. *Can Med Assoc J* 128:1420-1422, 1983
96. Smith JA, Isaac Renton J, Jellett JF, Chow AW, Ngui Yen J: Inhibitory and lethal activity of rosaramicin, erythromycin and clindamycin against *Campylobacter* subsp *jejuni* and *intestinalis*. *Amer J Vet Res* 44:1605-1606, 1983
97. Chow AW, Finlay KR, Stiver HG, Carlson CL: Intrathecal penetration of N formimidoyl thienamycin in normal rabbits - potentiation by co administration of renal dipeptidase enzyme inhibitor. *Antimicrob Ag Chemother* 23:634-636, 1983
98. Finlay KR, Carlson CL, Chow AW: Ocular penetration of N formimidoyl thienamycin (MK 787) and potentiation by dipeptidase inhibitor (MK 791). *Invest Ophthalmol Vis Sci* 24:1147-1149, 1983
99. Chow AW, Gribble MJ, Bartlett KH: Characterization of the hemolytic activity of *Staphylococcus aureus* associated with toxic shock syndrome. *J Clin Microbiol* 17:524-528, 1983
100. Megran D, Carlson C, Chow A: In vitro activity of imipenem against anaerobic bacteria. *Eur J Clin Microbiol* 3:488-489, 1984
101. Chow AW, Wittmann BK, Bartlett KH, Scheifele DW: Variant postpartum toxic shock syndrome with probable intrapartum transmission to the neonate. *Am J Obstet Gynecol* 148:1074-1079, 1984
102. Chow AW, Bartlett KH, Goldring AM: Quantitative vaginal microflora in women convalescent from toxic shock syndrome and in healthy controls. *Infect Immun* 44:650-652, 1984
103. Chow AW, Bartlett KH, Percival Smith R, Morrison BJ: Vaginal colonization with *Staphylococcus aureus*, positive for toxic-shock marker protein, and *Escherichia coli* in healthy women. *J Infect Dis* 150:80-84, 1984
104. Chow AW, Wong CK, Macfarlane AMG, Bartlett KH: Toxic shock syndrome clinical and laboratory findings in 30 patients. *Can Med Assoc J* 130:425-430, 1984
105. Megran DW, Scheifele DW, Chow AW: Odontogenic infections. *Ped Inf Dis* 3:257-265, 1984 (B47)
106. Shafran SD, Wong J, Chow AW: In vitro activity of SCH 34343 and cefbuperazone against anaerobic bacteria. *Antimicrob Ag Chemother* 27:749-752, 1985
107. Garber GE, Chow AW: Multiple co existing sexually transmitted diseases in a bisexual man. *Sex Transm Dis* 11:161-162, 1985
108. Jewesson PJ, Bachand RL, Bell GA, Ensom RJ, Chow AW: Quality use of parenteral metronidazole therapy in a teaching hospital. *Can Med Assoc J* 132:785-789, 1985

109. Feld R, Louie TJ, Mandell L, Bow EJ, Robson HG, Chow A, Belch A, Miedzinski L, Rachlis A, Pater J, Wilan A: A multicentre comparative trial of tobramycin and ticarcillin vs moxalactam and ticarcillin in febrile neutropenic patients. *Arch Intern Med* 145:1083-1088, 1985
110. Burdge DR, Chow AW, Sacks SL: Neurotoxic effects during vidarabine therapy for herpes zoster. *Can Med Assoc J* 132:392-395, 1985
111. Chow AW, Jewesson PJ: Pharmacokinetics and safety of antimicrobial agents during pregnancy. *Rev Infect Dis* 7:287-313, 1985
112. Shafran SD, Chow AW: A syndromic approach to common parasitic diseases. *Can Med Assoc J* 133:743-752, 1985
113. Chow AW, Cheng N, Bartlett KH: In vitro susceptibility of *Clostridium difficile* to new b- lactam and quinolone antibiotics. *Antimicrob Ag Chemother* 28:842-844, 1985
114. Haldane DJM, Bauman DS, Chow AW, Doyle P, Garber G, Ngui Yen J, Smith JA: False negative latex agglutination test in cryptococcal meningitis a case report. *Ann Neurol* 19:412-413, 1986
115. Chow AW, Percival-Smith R, Bartlett KH, Goldring AM, Morrison BJ: Vaginal colonization with *Escherichia coli* in healthy women. Determination of relative risks by quantitative culture and multivariate statistical analysis. *Am J Obstet Gynecol* 154:120-126, 1986
116. Burdge DR, Bowie WR, Chow AW: *Gardnerella vaginalis* associated balanoposthitis. *Sex Transm Dis* 13:159-162, 1986
117. Koo KB, Bachand RL, Chow AW: Vancomycin induced neutropenia. *Drug Intell Clin Pharm* 20:780-782, 1986
118. Stiver HG, Bartlett KH, Chow AW: Comparison of the susceptibility of gentamicin resistant and sensitive *Acinetobacter calcoaceticus* to 15 alternative antibiotics. *Antimicrob Ag Chemother* 30:624-625, 1986
119. Williams CM, Okada DM, Marshall JR, Chow AW: Clinical and microbiologic risk evaluation for postcesarean section endometritis by multivariate discriminant analysis. *Am J Obstet Gynecol* 156:967-974, 1987
120. Rosten PM, Bartlett KH, Chow AW: Detection and quantitation of toxic shock syndrome toxin 1 in vitro and in vivo by a noncompetitive enzyme linked immunosorbent assay. *J Clin Microbiol* 25:327-332, 1987
121. Bachand RL, Jewesson PJ, Chow AW: Implementation of a reserved antimicrobial drug program. *Can J Hosp Pharm* 40:167-170, 1987
122. Whiting JL, Chow AW: Life threatening infections of the mouth and throat. *J Crit Illness* 2:36-58, 1987
123. Chow AW, Jewesson PJ: Use and safety of antimicrobial agents during pregnancy. *West J Med* 146:761-764, 1987
124. Whiting JL, Cheng N, Chow AW: Interactions of ciprofloxacin with clindamycin, metronidazole, cefoxitin, cefotaxime and mezlocillin against gram positive and gram negative anaerobic bacteria. *Antimicrob Ag Chemother* 31:1379-1382, 1987
125. Phillips P, Rippon JW, Stein L, Black WA, Chow AW: Fungal sinusitis caused by *Chrysosporium pruinosum*. *Otolaryngology Head Neck Surg* 96:577-579, 1987
126. Rosten PM, Bartlett KH, Chow AW: Serologic responses to toxic shock syndrome (TSS) toxin 1 in menstrual and nonmenstrual TSS. *Clin Invest Med*, 11:187-192, 1988
127. Chow AW, Wong J, Bartlett KH: Synergistic interactions of ciprofloxacin and extended spectrum betalactams or aminoglycosides against multiply drug resistant *Pseudomonas maltophilia*. *Antimicrob Agents Chemother* 32:782-784, 1988
128. Chow AW, Cheng N: In vitro activities of Daptomycin (LY146032) and paldimycin (U 70138F) against anaerobic gram positive bacteria. *Antimicrob Agents Chemother* 32:788-790, 1988
129. Zaremba CD, Bachand RL, Chow AW, Jewesson PJ: Drug usage review of cefamandole at a teaching hospital. *Can J Hosp Pharm* 41:195-214, 1988
130. Chow AW, Wong J, Bartlett KH: Synergistic interactions of ciprofloxacin and extended spectrum beta lactams or aminoglycosides against *Acinetobacter calcoaceticus* ss. *anitratu*s. *Diagn Microbiol Infect Dis* 9:213-217, 1988
131. Hunter T, Chow AW: *Peptostreptococcus magnus* septic arthritis. A report and review of the English literature. *J Clin Microbiol* 15:100-107, 1986

Rheumatol 15:136-137, 1988

132. Reesor C, Chow AW, Kureishi A, Jewesson PJ: Kinetics of intraventricular vancomycin in infections of cerebrospinal fluid shunts. *J Infect Dis* 158:1142-1143, 1988
133. Whiting JL, Rosten PM, Chow AW: Demonstration by western blot (immunoblot) of seroconversions to toxic shock syndrome (TSS) toxin 1 and enterotoxin A, B, or C during infection with TSS and non TSS associated *Staphylococcus aureus*. *Infect Immun* 57:231-234, 1989
134. Sadhu K, Domingue PAG, Chow AW, Nelligan J, Cheng N, Costerton JW: *Gardnerella vaginalis* has a gram positive cell wall ultrastructure and lacks classical cell wall lipopolysaccharide. *J Med Microbiol* 29:229-235, 1989
135. Sadhu K, Domingue PAG, Chow AW, Nelligan J, Bartlett K, Costerton JW: A morphological study of the in situ tissue associated autochthonous microflora of the human vagina. *Microb Ecol Health Dis* 2:99-106, 1989
136. See RH, Adilman S, Bartlett KH, Chow AW: Colony immunoblot assay for the detection of staphylococcal toxic shock syndrome toxin 1 (TSST 1) with anti TSST 1 F(ab')₂ fragments. *J Clin Microbiol* 27:2050-2053, 1989
137. Whitley RJ, Cobbs CG, Alford CA, Soong SJ, Hirsch MS, Connor JD, Corey L, Hanley DF, Levin M, Powell DA, and the NIAID Collaborative Antiviral Study Group (Chow AW, participant): Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. *JAMA* 262:234-239, 1989 (B72)
138. Chow AW, Wong J, Bartlett KH, Shafran SD, Stiver HG: Cross resistance of *Pseudomonas aeruginosa* to ciprofloxacin, extended spectrum beta lactams, and aminoglycosides and susceptibility to antibiotic combinations. *Antimicrob Ag Chemother* 33:1368-1372, 1989
139. Reid G, McGroarty JA, Domingue PAG, Chow AW, Bruce AW, Eisen A, Costerton JW: Coaggregation of urogenital bacteria in vitro and in vivo. *Curr Microbiol* 20:47-52, 1990
140. See RH, Krystal G, Chow AW: Binding competition of Toxic shock toxin 1 and other staphylococcal exoproteins to receptors on human peripheral blood mononuclear cells. *Infect Immun* 58:2392-2396, 1990
141. Musser JM, Schlievert PM, Chow AW, Ewan P, Kreiswirth BN, Rosdahl VT, Naidu AS, Witte W, Selander RK: A single clone of *Staphylococcus aureus* causes the majority of cases of toxic shock syndrome. *Proc Natl Acad Sci USA* 87:225-229, 1990
142. Kureishi A, Jewesson PJ, Bartlett KH, Cole CD, Chow AW: Application of a modified bioassay for monitoring serum teicoplanin and vancomycin in febrile neutropenic patients. *Antimicrob Ag Chemother* 34:1642-1647, 1990
143. Birnbaum D, Schulzer M, Mathias RG, Kelly M, Chow AW: Adoption of guidelines for universal precautions and body substance isolation in Canadian acute care hospitals. *Infect Control Hosp Epidemiol* 11:465-472, 1990
144. Birnbaum D, Schulzer M, Mathias RG, Kelly M, Chow AW: New infection control strategies in acute care. *Dimensions* May:26-29, 1990
145. Birnbaum D, Schulzer M, Mathias RG, Kelly M, Chow AW: Needlestick injury do preventive measures works? *Dimensions* Nov:29-32, 1990
146. Chow AW, Elder R, Jewesson P, Lavoie L, Mandell L, Nicolle L, Rotstein O, Schlech W, Carroll M, Casault Sequin J, Health and Welfare Canada: Guidelines for antimicrobial utilization in health care facilities. *Can J Infect Dis* 1:64-70, 1990 (B76)
147. Kureishi A, Jewesson PJ, Morrell R, Cole CD, Reece DE, Phillips GL, Smith JA, Chow AW: Double blind comparison of teicoplanin vs vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin. Effect of cyclosporin A associated nephrotoxicity. *Antimicrob Ag Chemother* 35:2246-2252, 1991
148. Domingue PAG, Sadhu K, Costerton JW, Bartlett K, Chow AW: The human vagina normal flora considered as an in situ tissue associated adherent biofilm. *Genitourinary Med* 67:226-231, 1991
149. Soong SJ, Watson NE, Caddell GR, Alford Jr CA, Whitley J, NIAID collaborative Antiviral Study Group (Chow AW, participant): Use of brain biopsy for diagnostic evaluation of patients with suspected Herpes simplex encephalitis a statistical model and its clinical implications. *J Infect Dis* 163:17-22, 1991
150. Birnbaum D, Kelly M, Chow AW: Epidemiologic typing systems for coagulase negative staphylococci. *Infect Control Hosp Epidemiol* 12:319-326, 1991 (B86)
151. Dow GCK, Chow AW: *Legionella* associated lung abscess critical pathogen or minor isolate? *Can J Infect Dis* 3:315-318, 1992

152. See RH, Krystal G, Chow AW: Receptors for toxic shock syndrome toxin 1 and staphylococcal enterotoxin A on human blood monocytes. *Can J Microbiol* 38:937-944, 1992
153. See RH, Kum WWS, Chang AH, Goh SH, Chow AW: Induction of TNF and IL 1 by purified staphylococcal toxic shock syndrome toxin 1 requires the presence of both monocytes and T lymphocytes. *Infect Immun* 60:2612-2618, 1992
154. Goh SH, Byrne SK, Zhang JL, Chow AW: Molecular typing of *Staphylococcus aureus* on the basis of coagulase gene polymorphisms. *J Clin Microbiol* 30:1642-1645, 1992
155. See RH, Chow AW: Staphylococcal toxic shock syndrome toxin-1 induced tumor necrosis factor alpha and interleukin-1 beta secretion by human peripheral blood monocytes and T lymphocytes is differentially suppressed by protein kinase inhibitors. *Infect Immun* 60:3456-3459, 1992
156. Bow EJ, Pater JL, Louie TJ, Feld R, Mandell L, Robson HG, Chow AW, Belch A, Miedzinski L, Paul N, Elliott CR, Willan AR: Reduction in clinical response to empiric antimicrobial therapy of febrile granulocytopenic patients receiving TMP/SMX infection prophylaxis. *Can J Infect Dis* 3:235-239, 1992
157. Lee VTP, Chang AH, Chow AW: Detection of staphylococcal enterotoxin B among toxic shock syndrome (TSS)- and non-TSS-associated *Staphylococcus aureus* isolates. *J Infect Dis* 166:911-915, 1992
158. See RH, Chow AW: Role of the lymphocyte adhesion molecule, LFA-1, in toxic shock syndrome toxin-1 induced TNF α and IL-1 β secretion by human monocytes. *Infect Immun* 60:4957-4960, 1992
159. Kertesz D, Chow AW: Infected pressure and diabetic ulcers. *Clin Geriatric Med* 8:835-852, 1992 (B90)
160. Chow AW: Life-threatening infections of the head and neck. State of the Art Clinical Article. *Clin Infect Dis* 14:991-1004, 1992 (B91)
161. Chow AW, Hall CB, Klein JO, Kammer R, Meyer RD, Remington JS: FDA/IDSA guidelines for the evaluation of new anti infective agents for the treatment of respiratory tract infections. *Clin Infect Dis* 15 (suppl 1):S62-88, 1992
162. Kain KC, Schulzer M, Chow AW: Clinical spectrum of nonmenstrual toxic shock syndrome (TSS). Comparison with menstrual TSS by multivariate discriminant analyses. *Clin Infect Dis* 16:100-106, 1993
163. Sett SS, Hudon MP, Jamieson WR, Chow AW: Prosthetic valve endocarditis - experience with porcine bioprostheses. *J Thorac Cardiovasc Surg* 105:428-434, 1993
164. Kum WWS, Laupland KB, See RH, Chow AW: Improved purification and biologic activities of staphylococcal toxic shock syndrome toxin 1. *J Clin Microbiol* 31:2654-2660, 1993
165. Kertesz DA, Byrne SK, Chow AW: Characterization of *Neisseria meningitidis* by polymerase chain reaction and restriction endonuclease digestion of the *porA* gene. *J Clin Microbiol* 31:2594-2598, 1993
166. Kureishi A, Jewesson PJ, Rubinger M, Cole CD, Reece DE, Phillips GL, Smith JA, Chow AW: Das nephrotoxische potential von teicoplanin im vergleich zu vancomycin bei der empirischen behandlung von febrilen neutropenischen patienten. *FAC Fortschritte der antimikrobiellen u. antineoplastischen Chemotherapie Band 11-5:677-88*, 1993 (B94)
167. Grant GA, Chow AW: Otitis media and externa. *Curr Opin Infect Dis* 6:644-50, 1993 (B96)
168. Laverdiere M, Gallimore B, Restieri C, Poonia K, Chow AW: In vitro synergism of ceftriaxone combined with aminoglycosides against *Pseudomonas aeruginosa*. *Diagn Microbiol Infect Dis* 19:39-46, 1994
169. De Boer M, Chow AW: Toxic shock syndrome toxin-1 producing *Staphylococcus aureus* isolates contain the staphylococcal enterotoxin B genetic element but do not express staphylococcal enterotoxin B. *J Infect Dis* 170:818-827, 1994
170. Birnbaum D, Herwaldt L, Low DE, Noble M, Pfaller M, Sherertz R, Chow AW: Efficacy of microbial identification system for epidemiologic typing of coagulase-negative staphylococci. *J Clin Microbiol* 32:2113-2119, 1994
171. Ng J, Ng LK, Chow AW, Dillon JA: Identification of five *Peptostreptococcus* species isolated predominantly from the female genital tract by using the rapid ID32A system. *J Clin Microbiol* 32:1302-1307, 1994
172. Chow AW, Azar RM: Glycopeptides and nephrotoxicity. *Intensive Care Med* 20:S23-S29, 1994
173. Goh SW, Wood J, Hemmingsen S, Chow AW: Analysis of cloned HSP60 and HSP10 genes from *Staphylococcus epidermidis* and *Staphylococcus aureus*. *GenBank Database*, accession No. U13618, 1995

174. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Pnnnington JE, Wherry JC, and TNF-a MAb Sepsis Study Group (Chow AW, participant): Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter Clinical Trial. *JAMA* 273:934-941, 1995
175. Lakeman FD, Whitley RJ, and the National Institute of Allergy and Infectious Diseases collaborative Antiviral Study Group (Chow AW, participant): Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. *J Infect Dis* 171:857-863, 1995
176. Jewesson PJ, Stiver G, Wai A, Frighetto L, Nickoloff D, Smith J, Schwartz L, Sleigh K, Danforth D, Scudamore C, Chow AW: Double-blind comparison of cefazolin (CFZ) and ceftizoxime (CTZ) for prophylaxis against infections following elective biliary tract surgery. *Antimicrob Ag Chemother* 40:70-74, 1996 (B.C. Branch Canadian Society of Hospital Pharmacists Publication Award)
177. Goh SH, Potter S, Wood JO, Hemmingsen SM, Reynolds RP, Chow AW: HSP60 gene sequences as universal targets for microbial species identification - studies with coagulase-negative staphylococci. *J Clin Microbiol* 34:818-23, 1996
178. Kum WWS, Wood JAO, Chow AW: A mutation at glycine residue 31 of toxic shock syndrome toxin-1 defines a functional site critical for major histocompatibility complex class II binding and superantigenic activity. *J Infect Dis* 174:1261-70, 1996
179. Bathe OF, Rudston-Brown B, Chow AW, Phang PT: Gut is not a source of cytokines in a porcine model of septic shock. *Surgery*, 120:522-533, 1996
180. Christou NV, Turgeon P, Wassef R, Rotstein O, Bohnen J, Potvin M and the Canadian Intraabdominal Infection study Group (Chow AW, participant): Management of intra-abdominal infections - the case for intra-operative cultures and comprehensive broad spectrum antibiotic coverage. *Arch Surg* 131:1193-1201, 1996
181. Hung RWY, Chow AW: Apoptosis - molecular mechanisms, regulation, and role in pathogenesis. *Can J Infect Dis*, 1997
182. Jewesson PJ, Chow AW, Wai A, Frighetto L, Nickoloff D, Smith J, Schwartz L, Sleigh K, Danforth D, Pezim M, Stoller J, Stiver G: A double-blind, randomized study of three antimicrobial regimens in the prevention of infections after elective colorectal surgery. *Diagn Microbiol Infect Dis* 29:155-165, 1997
183. Chow AW: Odontogenic infections in the elderly. *Infect Dis Clin Prac* 6:587-596, 1997
184. Bathe OF, Chow AW, Phang PT: Splanchnic origin of cytokines in a porcine model of mesenteric ischemia-reperfusion. *Ann Surg* 123:79-88, 1998
185. Bathe OF, Rudston-Brown B, Chow AW, Phang PT: The liver as a focus of ischemia and cytokine production in a porcine model of endotoxemia. *J Surg Res* 123:79-88, 1998
186. Bathe OF, Rudston-Brown B, Chow AW, Phang PT: Liver as a focus of impaired oxygenation and cytokine production in a porcine model of endotoxemia. *Crit Care Med* 26:1698-1706, 1998
187. Chow AW, Rubinchik R: Recombinant expression and immunogenicity of class II MHC-binding receptors of staphylococcal TSST-1. *Toxic Shock Syndrome*. Arbutnott J, Furman (eds.). International Congress and Symposium Series 229. Royal Society of Medicine Press, London, UK, 1998:85-88
188. Kwok AYC, Su SC, Reynolds RP, Bay SJ, Av-Gay Y, Dovichi NJ, Chow AW: Species identification and phylogenetic relationships based on partial HSP60 gene sequences within the genus *Staphylococcus*. *Int J Sys Bacteriol*, 49:1181-1192, 1999
189. DeBoer ML, Kum WWS, Chow AW: *Staphylococcus aureus* isogenic mutant, deficient in toxic shock syndrome toxin-1 but not staphylococcal enterotoxin A production, exhibits attenuated virulence in a tampon-associated vaginal infection model of toxic shock syndrome. *Can J Microbiol*, 45:250-256, 1999
190. Verdrengh M, Kum W, Chow A, Tarkowski A: The effect of site-specific monoclonal antibodies directed to toxic shock syndrome toxin-1 in experimental *Staphylococcus aureus* arthritis. *Clin Exp Immunol* 118:268-270, 1999
191. De Boer ML, Kum WWS, Pang LTY, Chow AW: Co-production of staphylococcal enterotoxin A with toxic shock syndrome toxin-1 (TSST-1) enhances TSST-1 mediated mortality in a D-galactosamine sensitized mouse model of lethal shock, *Mol Pathog* 27:61-70, 1999

192. Epstein JB, Chow AW: Oral Complications associated with immunosuppression and cancer therapies, *Infect Dis Clin N Am* 13:901-923, 1999
193. DeBoer ML, Kum WWS, Chow AW: Interaction of toxic shock syndrome toxin-1 and staphylococcal enterotoxin A on T cell proliferation and TNF α secretion in human peripheral blood mononuclear cells. *Can J Infect Dis* 10:403-409, 1999
194. Rolston KVI, Chow AW, Bodey GP: Prospective, double-blind, randomized trial of teicoplanin versus vancomycin for the therapy of vascular access-associated bacteremia caused by gram-positive pathogens. *J Infect Chemother* 5:208-212, 1999
195. Pang LTY, Kum WWS, Chow AW: Inhibition of staphylococcal enterotoxin B-induced lymphocyte proliferation and TNF secretion by MAb5, an anti-TSST-1 monoclonal antibody. *Infect Immun* 68:3261-3268, 2000
196. Kum WWS, Laupland KB, Chow AW: Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality. *Can J Microbiol* 46:171-179, 2000
197. Rubinchik E, Chow AW: Recombinant expression and neutralizing activity of an MHC class II binding epitope of toxic shock syndrome toxin-1. *Vaccine* 18:2312-2320, 2000
198. Pang LTY, Kum WWS, Chow AW: Inhibition of staphylococcal enterotoxin B-induced lymphocyte proliferation and tumor necrosis factor alpha secretion by MAb5, an anti-toxic shock syndrome toxin 1 monoclonal antibody. *Infect Immun* 68:3261-3268, 2000
199. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH and the Canadian Community-Acquired Pneumonia Working Group. Canadian Guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. *Clin Infect Dis* 31:383-421, 2000
200. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH: Summary of Canadian guidelines for the initial management of community-acquired pneumonia. An evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. *Can Respir J* 7:371-382, 2000
201. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH: Summary of Canadian guidelines for the initial management of community-acquired pneumonia. An evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. *Can J Infect Dis* 11:237-248, 2000
202. Saginur R, Croteau D, Bergeron MG, the ESPRIT Group (Chow AW, participant): Comparative efficacy of teicoplanin and cefazolin for cardiac operation prophylaxis in 3027 patients. *J Thorac Cardiovasc Surg* 120:1120-1130, 2000
203. Winston DJ, Lazarus HM, Beveridge RA, Hathorn JW, Gucalp R, Ramphal R, Chow AW, Ho WG, Horn R, Feld R, Louie TJ, Territo MC, Blumer JL, Tack KJ. Randomized double-blind multicentre trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. *Clin Infect Dis* 32:381-390, 2001
204. Kum WWS, Chow AW. Inhibition of staphylococcal enterotoxin A-induced superantigenic and lethal activities by monoclonal antibody to toxic shock syndrome toxin-1. *J Infect Dis* 183:1739-1748, 2001.
205. Cameron SB, Nawijn MC, Kum WWS, Savelkoul HFJ, Chow AW. Regulation of helper T cell responses to staphylococcal superantigens. *Eur Cytok Network* 12:210-222, 2001.
206. Kum WWS, Cameron SB, Hung RWY, Kalyan S, Chow AW. Temporal sequence and kinetics of pro-inflammatory and anti-inflammatory cytokine secretion induced by toxic shock syndrome toxin-1 in human peripheral blood mononuclear cells. *Infect Immun* 69:7544-7549, 2001.
207. Kum WWS, Hung RWY, Cameron SB, Chow AW. Temporal sequence and functional implications of V-specific T cell receptor down-regulation and costimulatory molecule expression following in vitro stimulation with the staphylococcal superantigen toxic shock syndrome toxin-1. *J Infect* 185:555-560, 2002.
208. Wong RSY, Chow AW. Identification of enteric pathogens by heat shock protein 60 kDa (HSP60) gene sequences. *FEMS Microbiol Lett* 206:107-113, 2002
209. Livesley NJ, Chow AW. Infected pressure ulcers in the elderly. *Clin Infect Dis* 35:1390-1396, 2002.
210. Kwok AYC, Wilson Jt, Coulthart M, Ng LK, Mutharia L, Chow AW. Phylogenetic study and identification of human pathogenic *Mycobacterium* species based on *hsp60* gene sequences. *Can J Microbiol* 46:222-240, 2000

- pathogenic *Vibrio* species based on partial hsp60 gene sequences. *Can J Microbiol* 48:903-910, 2002.
211. Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, Buchman T, Dellinger EP, Jernigan J, Gorbach S, Chow A, Bartlett J. Guidelines for the selection of anti-infective agents for intraabdominal infections. *Clin Infect Dis* 37:997-1005, 2003.
 212. Kwok AYC, Chow AW. Phylogenetic study of *Staphylococcus* and *Micrococcus* species by DNA sequence analysis of a partial hsp60 gene encoding the 60 kDa heat shock protein. *Internat J System Evol Microbiol*, 53:1-6, 2003.
 213. Chan KCW, Chow AW. Management of septic shock- current concepts. *Hong Kong J Paediatr* 8:3-14. 2003.
 214. Cameron SB, Stolte EH, Chow AW, Savelkoul HFJ: T helper cell polarization as a measure of the maturation of the immune response. *Mediators of Inflammation* 12:285-292, 2003
 215. Kalyan S, Chow AW: Human peripheral T cells potentiate the early pro-inflammatory cytokine response to staphylococcal toxic shock syndrome toxin-1. *J Infect Dis* 189:1892-1896, 2004.
 216. Hung RWY, Chow AW: Dissecting the end game: clinical relevance, molecular mechanisms, and laboratory assessment of apoptosis. *Clin Invest Med* 27:324-344, 2004.
 217. Hull MW, Chow AW: An approach to oral infections and their management. *Curr Infect Dis Rep* 7:17-27, 2005.

(b) Book Chapters

1. **Chow AW**, Guze LB: Treatment of Bacteroidaceae bacteremia: clinical experience with 112 patients. In: *Anaerobic Bacteria: Role in Disease*. Edited by A Balow, RM DeHaan, VR Dowell, LB Guze, Springfield, Charles C. Thomas and Co., pp 553- 569, 1974 (B09)
2. **Chow AW**: Vibriosis. In: *Infectious Diseases: Diagnosis and Management*. Edited by TT Yoshikawa, AW Chow and LB Guze. Houghton Mifflin Publishers, Boston, pp 393- 397, 1980 (B16)
3. **Chow AW**: Nosocomial infections. In: *Infectious Diseases: Diagnosis and Management*. Edited by TT Yoshikawa, AW Chow and LB Guze. Houghton Mifflin Publishers, pp 262- 273, 1980 (B21)
4. **Chow AW**: Odontogenic and orofacial infections. In: *Infectious Diseases: Diagnosis and Management*. Edited by TT Yoshikawa, AW Chow and LB Guze. Houghton Mifflin Publishers, Boston, pp 69- 75, 1980 (B24)
5. **Chow AW**: Wound and soft tissue infections. In: *Infectious Diseases: Diagnosis and Management*. Edited by TT Yoshikawa, AW Chow and LB Guze. Houghton Mifflin Publishers, Boston, pp 223- 231, 1980 (B25)
6. **Chow AW**: Female genital infections. In: *Infectious Diseases: Diagnosis and Management*. Edited by TT Yoshikawa, AW Chow and LB Guze. Houghton Mifflin Publishers, Boston, pp 155- 164, 1980 (B26)
7. **Chow AW**: Anaerobic infections. In: *Infectious Diseases: Diagnosis and Management*. Edited by TT Yoshikawa, AW Chow and LB Guze. Houghton Mifflin Publishers, Boston, pp 419-427, 1980 (B27)
8. **Chow AW**: Anaerobic infections. In: *Pediatric Therapy, 6th Edition*. Edited by HC Shirkey. CV Mosby Co., St. Louis, pp 421- 431, 1980 (B28)
9. **Chow AW**: Bacteremias, endocarditis e infecciones intracraneales. In: *Bacterias Anaerobias, Importancia Clinica y Microbiologica*. Edited by JAG Rodriguez, Ediciones Universidad de Salamanca, pp 171 204, 1980 (B29)
10. **Chow AW**: Haemophilus infections. In: *Infectious Diseases: Diagnosis and Management*. Edited by TT Yoshikawa, AW Chow and LB Guze. Houghton Mifflin Publishers, Boston, pp 372 -378, 1980 (B18)
11. **Chow AW**: Campylobacteriosis. In: *Infectious Diseases: Diagnosis and Management*. Edited by TT Yoshikawa, AW Chow and LB Guze. Houghton Mifflin Publishers, Boston, pp 398- 404, 1980 (B15)
12. **Chow AW**: Antimicrobial susceptibility testing. In: *Infectious Diseases: Diagnosis and Management*. Edited by TT Yoshikawa, AW Chow and LB Guze. Houghton Mifflin Publishers, Boston, pp 659- 667, 1980 (B17)
13. **Chow AW**: Listeriosis. In: *Infectious Diseases: Diagnosis and Management*. Edited by TT Yoshikawa, AW Chow and LB Guze. Houghton Mifflin Publishers, Boston, pp 330- 335, 1980 (B20)
14. **Chow AW**: Intraabdominal sepsis. In: *Infectious Diseases: Diagnosis and Management*. Edited by TT Yoshikawa, AW Chow and LB Guze. Houghton Mifflin Publishers, Boston, pp 444- 454, 1980 (B20)

AW Chow and LB Guze. Houghton Mifflin Publishers, Boston, pp 141- 154, 1980 (B22)

15. **Chow AW:** Actinomycosis. In: Infectious Diseases: Diagnosis and Management. Edited by TT Yoshikawa, AW Chow and LB Guze. Houghton Mifflin Publishers, Boston, pp 428- 434, 1980 (B19)
16. **Chow AW:** Upper respiratory infections. In: Infectious Diseases: Diagnosis and Management. Edited by TT Yoshikawa, AW Chow and LB Guze. Houghton Mifflin Publishers, Boston, pp 76- 83, 1980 (B23)
17. **Chow AW,** Burdge DR: Pressure sores. In: Infections in the Elderly. Gleckman NM, Gantz D (eds). Little, Brown and Co., Boston, pp 319- 341, 1983 (B45)
18. Yeo EC, **Chow AW:** Streptococcal pharyngitis. In: Current Therapy, Edition 6, HG Conn, WB Saunders, Philadelphia, pp 131-132, 1983 (B46)
19. **Chow AW:** Erythromycin. In: Antimicrobial Therapy. Ristuccia AM, Cunha BA (eds). Raven Press, New York, pp 209- 218, 1984 (B49)
20. Phillips P, **Chow AW:** Nosocomial infections. In: Essentials of Infectious Diseases. Mandell LA, Ralph E (eds). Blackwell Scientific Publications, Edinburgh, p. 387 -397, 1985 (B52)
21. Jewesson PJ, **Chow AW:** Pharmacokinetics and antimicrobial agents during pregnancy (Chapter), in Infections in Reproductive Health. Vol. 2, Uncommon Infections and Special Topics, Keith LG, Berger GS, Edelman DA (eds). MTP Press, London, p. 311- 327, 1985 (B50)
22. **Chow AW:** Infections of the oral cavity, neck and head. In: Principles and Practice of Infectious Diseases, 2nd ed. Mandell LA, Douglas RG, Bennett JE (eds). John Wiley and Sons, Inc., New York, pp 375- 385, 1985 (B51)
23. Megrant DW, **Chow AW:** Bacterial aspiration and anaerobic pleuropulmonary infections. In: Respiratory Infections. Sande MA, Root RK, Hudson LD (eds). Churchill Livingstone, New York, pp 269- 292, 1986 (B55)
24. Garber GE, **Chow AW:** Vulvovaginitis, cervicitis and pelvic inflammatory disease. In: Current Therapy in Infectious Disease, Kass EH, Platt R (eds), 2nd ed, BC Decker, Philadelphia, pp 238- 248, 1986 (B56)
25. Shafran SD, **Chow AW:** Epidemic pleurodynia. In: Current Therapy of Respiratory Medicine, Cherniack RM (ed), BC Decker, Philadelphia, pp 232 -233, 1986 (B58)
26. **Chow AW:** Odontogenic infections. In: Infections of the Head and Neck, Schlossberg D (ed), Springer Verlag, New York, pp 148- 160, 1987 (B60)
27. **Chow AW:** Infections caused by Bacteroides and other mixed nonsporulating anaerobes. In: Stein's Textbook of Internal Medicine, 2nd ed. Stein JH (ed), Little, Brown, Boston, pp 1705- 1713, 1987 (B59)
28. Shafran SD, **Chow AW:** Les traitements anti infectieux pendant la grossesse (Chapter, Antimicrobial therapy during pregnancy) in Pathologies et Grossesse. Wechsler B, Marec JJ, Pechere JC (ed), MEDSI/McGraw Hill, Toronto, pp 425- 438, 1988 (B63)
29. Whiting JL, **Chow AW:** Toxic shock syndrome In: Conn's Current Therapy. Rakel RE (ed), W.B. Saunders, Philadelphia, pp 935 -938, 1988 (B62)
30. Roscoe D, **Chow AW:** Mucosal immunity and normal flora in infectious syndromes of the head and neck. In: Infectious Syndromes of the Head and Neck, Infectious Disease Clinics of North America Series, **Chow AW** (ed), W.B. Saunders, Philadelphia, pp 1- 19, 1988 (B64)
31. Kureishi A, **Chow AW:** The tender tooth. In: Infectious Syndromes of the Head and Neck. In: Infectious Disease Clinics of North America Series, **Chow AW** (ed), W.B. Saunders, Philadelphia, pp 163- 182, 1988 (B65)
32. Garber GE, **Chow AW:** Female genital tract infections. In: Anaerobic Infections in Humans. George L, Finegold SM (eds), Academic Press, NY, pp 429- 453, 1989 (B71)
33. Whiting JL, **Chow AW:** Toxic shock syndrome. In: Conn's Current Therapy. Rakel RE (ed), W.B. Saunders, Philadelphia, pp 958- 961, 1989 (B69)
34. **Chow AW,** Wolters EC, Paty D: Bacterial and other nonviral infections of the central nervous system. In: Textbook of Internal Medicine. Kelly W (ed). J.B. Lippincott, NY, pp 2402-2408, 1989 (B68)
35. Shafran SD, **Chow AW:** Epidemic pleurodynia. In: Current Therapy of Respiratory Disease, 3rd ed, Cherniack RM (ed), BC Decker, Philadelphia, PP 285 -286, 1989 (B66)
36. **Chow AW:** Infections caused by Bacteroides and other mixed nonsporulating anaerobes. In: Stein's Textbook of Internal Medicine, 2nd ed. Stein JH (ed), Little, Brown, Boston, pp 1705- 1713, 1987 (B59)

- Internal Medicine, 3rd ed. Stein JH (ed), Little, Brown, Boston, pp 1505- 1515, 1990 (B79)
37. Burdge DR, **Chow AW**: The pressure ulcer. In: Infections in the Nursing Home. Verghese A, Berk SL (eds), S Karger AG, Basel, pp 143- 161, 1990 (B75)
 38. Garber GE, **Chow AW**: Vulvovaginitis, cervicitis and pelvic inflammatory disease. In: Current Therapy in Infectious Disease, Kass EH, Platt R (eds), 3rd ed, BC Decker, Philadelphia, pp 197- 208, 1990 (B74)
 39. Whiting JL, **Chow AW**: Toxic shock syndrome In: Conn's Current Therapy. Rakel RE (ed), W.B. Saunders, Philadelphia, pp 972- 975, 1990 (B73)
 40. **Chow AW**: Infections of the oral cavity, neck and head. In: Principles and Practice of Infectious Diseases, 3rd ed, Mandell LA, Douglas RG, Bennett JE (ed). John Wiley and Sons, New York, pp 516- 529, 1990 (B67)
 41. **Chow AW**, Paty D: Bacterial and other nonviral infections of the central nervous system. In: Textbook of Internal Medicine, 2nd ed. Kelly W (ed). J.B. Lippincott, NY, pp 2205- 2211, 1991 (B82)
 42. Shafran SD, **Chow AW**: Antimicrobial use during pregnancy and lactation. In: Difficult Medical Management. Taylor RB (ed), W.B. Saunders, Philadelphia, pp 55- 69, 1991 (B80)
 43. Garber GE, **Chow AW**: Vulvovaginitis, cervicitis, and pelvic inflammatory disease. In: Current Therapy in Internal Medicine, 3rd ed. JP Kassirer (ed), BC Decker, Philadelphia, pp 224- 234, 1991 (B85)
 44. **Chow AW**, Paty D: Approach to the patient with suspected bacterial and nonviral infections of the central nervous system. In: Textbook of Internal Medicine, 2nd ed. Kelly W (ed). J.B. Lippincott, NY, pp 2328- 2334, 1991 (B83)
 45. Vortel G, **Chow AW**: Sinus infections. In: Infectious Diseases. Gorbach SL, Bartlett JG, Blacklow NR (eds), W.B. Saunders, Philadelphia, pp 431-437, 1992 (B88)
 46. **Chow AW**: Head, neck and upper respiratory tract infections. In: Principles of Critical Care. Hall JB, Schmidt GA, Wood LDH (eds), McGraw Hill, New York, pp 1309-1324, 1992 (B89)
 47. **Chow AW**: Infections of the parameningeal structures. In: Infectious Diseases. Gorbach SL, Bartlett JG, Blacklow NR (eds), W.B. Saunders, Philadelphia, pp 437-441, 1992 (B87)
 48. **Chow AW**: Toxic shock syndrome. In: The 5 Minute Clinical Consult. Griffith HW, Dambro M (eds), Lea & Febiger, Philadelphia, pp 1010-1011, 1993 (B92)
 49. **Chow AW**: Toxic shock syndrome. In: The 5 Minute Clinical Consult. Griffith HW, Dambro M (eds), Lea & Febiger, Philadelphia, pp 1050-1051, 1994 (B99)
 50. Forrest DM, **Chow AW**: Erythromycin and newer macrolides. In: Antimicrobial Therapy in the Elderly Patient. Yoshikawa TT, Norman DC (eds), Marcel Dekker, New York, pp 333-352, 1994 (B98)
 51. **Chow AW**: Infections caused by Bacteroides and other mixed nonsporulating anaerobes. In: Stein's Textbook of Internal Medicine, 4th ed. Stein JH (ed), Mosby Year Book, St. Louis, PP 2158-2169, 1994 (B100)
 52. Grant GA, **Chow AW**: Toxic shock syndrome. In: Conn's Current Therapy. Rakel RE (ed), W.B. Saunders, Philadelphia, 1994 (B105)
 53. Mahmood WA, **Chow AW**: Phlephlbitis and liver abscess. In: Infectious Diseases, 5th ed. Hoeprich PD, Jordan MC, Ronald AR (eds), J.B. Lippincott, Philadelphia, pp 882-884, 1994 (B103).
 54. **Chow AW**: Appendicitis and diverticulitis. In: Infectious Diseases, 5th ed. Hoeprich PD, Jordan MC, Ronald AR (eds), J.B. Lippincott, Philadelphia, pp 878-881, 1994 (B102)
 55. **Chow AW**: Peritonitis. In: Infectious Diseases, 5th ed. Hoeprich PD, Jordan MC, Ronald AR (eds), J.B. Lippincott, Philadelphia, pp 872-878, 1994 (B101)
 56. Mahmood WA, **Chow AW**: Subphrenic and other intraabdominal abscesses. In: Infectious Diseases, 5th ed. Hoeprich PD, Jordan MC, Ronald AR (eds), J.B. Lippincott, Philadelphia, pp 885-890, 1994 (B104)
 57. **Chow AW**: Infections of the oral cavity, neck and head. In: Principles and Practice of Infectious Diseases, 4th ed. Mandell GL, Bennett JE, Dolin R (eds), Churchill Livingstone, New York, pp 593-606, 1995 (B106)
 58. **Chow AW**: Toxic shock syndrome. In: The 5 Minute Clinical Consult. Griffith HW, Dambro M (eds), Lea & Febiger, Philadelphia, pp 1062-1063, 1995 (B107)
 59. **Chow AW**: Septic shock. In: Therapeutic Choices. Gray J (ed), Canadian Pharmaceutical Association, Ottawa, pp 626-35, 1995 (B108)

60. **Chow AW:** Toxic shock syndrome. In: The 5 Minute Clinical Consult. Griffith HW, Dambro M (eds), Williams & Wilkins, Philadelphia, pp 1068-9, 1996 (B112)
61. Mahmood WA, **Chow AW:** Infection of the sinuses, larynx, and pharynx. In: Current Practice of Medicine, Bone R, Neu H (eds), Current Medicine, Philadelphia, VIII:6.1-6.11, 1996 (B109)
62. **Chow AW:** Toxic shock syndrome. In: The 5 Minute Clinical Consult. Griffith HW, Dambro M (eds), Williams & Wilkins, Philadelphia, pp 1078-1079, 1997 (B121)
63. **Chow AW,** Paty D: Bacterial and other nonviral infections of the central nervous system. In: Textbook of Internal Medicine, 3rd ed. Kelly W (ed). J.B. Lippincott, NY, pp 2410-7, 1997 (B113)
64. **Chow AW,** Paty D: Approach to the patient with suspected bacterial and nonviral infections of the central nervous system. In: Textbook of Internal Medicine, 3rd ed. Kelly W (ed). J.B. Lippincott, NY, pp 2369-77, 1997 (B114)
65. **Chow AW:** Odontogenic infections. In: Infectious Diseases and Antimicrobial Therapy of the Ears, Nose and Throat. Johnson JT, Yu V (eds). W.B. Saunders, Philadelphia, pp 489-499, 1997 (B116)
66. **Chow AW:** Orofacial nonodontogenic infections. In: Infectious Diseases and Antimicrobial Therapy of the Ears, Nose and Throat. Johnson JT, Yu V (eds). W.B. Saunders, Philadelphia, pp 481-488, 1997 (B117)
67. **Chow AW:** Infections caused by Bacteroides and other mixed nonsporulating anaerobes. In: Stein's Textbook of Internal Medicine, 5th ed. Stein JH (ed), Mosby Year Book, St. Louis, pp 1613-1621, 1998 (B120)
68. **Chow AW:** Septic shock. In: Therapeutic Choices, 2nd ed. Gray J (ed), Canadian Pharmaceutical Association, Ottawa, pp 683-693, 1998 (B119)
69. **Chow AW:** Toxic shock syndrome. In: Griffith's 5 Minute Clinical Consult. Dambro MR (ed), Williams & Wilkins, Philadelphia, pp 1078-79, 1998 (B124)
70. **Chow AW:** Life-threatening infections of the head, neck and upper respiratory tract. In: Principles of Critical Care, 2nd ed. Hall JB, Schmidt GA, Wood LDH (eds), McGraw-Hill, New York, pp 887-902, 1998 (B118)
71. **Chow AW:** Infections of the sinuses and parameningeal structures. In: Infectious Diseases, 2nd ed. Gorbach SL, Bartlett JG, Blacklow NR (eds), W.B. Saunders, Philadelphia, pp 517-530. 1998 (B115)
72. **Chow AW:** Epidemiology, pathogenesis and clinical manifestations of odontogenic infections. In: UpToDate, vol. 7, Rose BD (ed), UpToDate, Inc., Wellesley, MA. 1999 (Electronic textbook in Internal Medicine) (B123)
73. **Chow AW:** Toxic shock syndrome, In: Griffith's 5 Minute Clinical Consult. Dambro MR (ed), Williams & Wilkins, Philadelphia, pp 1088-1089, 1999 (B125)
74. **Chow AW:** Complications, diagnosis, and treatment of odontogenic infections. In: UpToDate, vol. 7, Rose BD (ed), UpToDate, Inc., Wellesley, MA. 1999 (Electronic textbook in Internal Medicine) (B124)
75. **Chow AW:** Infection of the upper and lower respiratory tract. In: Current Practice of Medicine, 2nd ed. Fitzgerald FT, Turck M (eds), Current Practice of Medicine 2:517-538, 1999 (B122)
76. **Chow AW:** Infections of the oral cavity, neck and head. In: Principles and Practice of Infectious Diseases, 5th ed. Mandell GL, Bennett JE, Dolin R (eds), Churchill Livingstone, Philadelphia, pp 689-702, 2000 (B126)
77. **Chow AW:** Toxic shock syndrome. In: Griffith's 5 Minute Clinical Consult. Dambro MR (ed), Lippincott, Williams & Wilkins, Philadelphia, pp 1094-1095, 2000 (B127)
78. **Chow AW,** Paty D: Bacterial infections of the nervous system. In: Kelley's Textbook of Internal Medicine, 4th ed. Humes HD (ed). Lippincott Williams & Wilkins, Philadelphia, pp 2936-2946, 2000 (B128)
79. **Chow AW,** Paty D: Approach to the patient with suspected infection of the central nervous system. In: Kelley's Textbook of Internal Medicine, 4th ed. Humes HD (ed). Lippincott Williams & Wilkins, Philadelphia, pp 2894-2903, 2000 (B129)
80. **Chow AW:** Septic shock. In: Therapeutic Choices, 3rd ed. Gray J (ed), Canadian Pharmacists Association, Ottawa. pp 737-747, 2000 (B130)
81. **Chow AW:** Orofacial and odontogenic infections. In: Infectious Diseases in Aging – A Clinical Handbook. Yoshikawa TT, Norman DC (eds). Humana Press Inc., Totowa, NJ, pp 147-162, 2000 (B131)
82. **Chow AW:** Community-acquired pneumonia. In: Best Practice of Medicine, Infectious Diseases (electronic textbook in Internal Medicine). Turck M (ed), Praxis Press Inc, NY. pp 1-24, May 2000 [url: <http://praxis.md/>] (B132)

83. **Chow AW:** Sinusitis. In: Best Practice of Medicine, Infectious Diseases (electronic textbook in Internal Medicine). Turck M (ed), Praxis Press Inc, NY, pp 1-33, April 2000 [url: <http://praxis.md/>] (B133)
84. **Chow AW:** Acute epiglottitis. In: Best Practice of Medicine, Infectious Diseases (electronic textbook in Internal Medicine). Turck M (ed), Praxis Press Inc, NY, pp 1-12, April 2000 [url: <http://praxis.md/>] (B134)
85. **Chow AW:** Acute bronchitis. In: Best Practice of Medicine, Infectious Diseases (electronic textbook in Internal Medicine). Turck M (ed), Praxis Press Inc, NY, pp 1-17, May 2000 [url: <http://praxis.md/>] (B135)
86. **Chow AW:** Viral upper respiratory infection (VURI). In: Best Practice of Medicine, Infectious Diseases (electronic textbook in Internal Medicine). Turck M (ed), Praxis Press Inc, NY, pp 1-26, April 2000 [url: <http://praxis.md/>] (B136)
87. **Chow AW:** Pharyngitis and tonsillitis. In: Best Practice of Medicine, Infectious Diseases (electronic textbook in Internal Medicine). Turck M (ed), Praxis Press Inc, NY, pp 1-23, April 2000 [url: <http://praxis.md/>] (B137)
88. **Chow AW:** Acute sinusitis. Current status of etiologies, diagnosis and treatment, Vol 21. In: Remington JS, Swartz MN (eds), Curr Clin Topics Infect Dis, Blackwell Scientific, Malden, Mass., pp 31-63, 2001.
89. **Chow AW:** Toxic shock syndrome. In: Griffith's 5 Minute Clinical Consult. Dambro MR (ed), Lippincott, Williams & Wilkins, Philadelphia, pp 1100-1101, 2001
90. **Chow AW:** Acute epiglottitis. (Chapter) in: Best Practice of Medicine. Gotto Jr AM (Editor-in-Chief); (electronic textbook in Internal Medicine). Turck M (Infectious Diseases Section Editor). Thomson MicroMedex Inc, Greenwood Village, CO. pp 1-10, October 12, 2001 [url: <http://bpm.micromedex.com>].
91. **Chow AW:** Sinusitis. (Chapter) in: Best Practice of Medicine. Gotto Jr AM (Editor-in-Chief); (electronic textbook in Internal Medicine). Turck M (Infectious Diseases Section Editor). Thomson MicroMedex Inc, Greenwood Village, CO. pp 1-29, October 17, 2001 [url: <http://bpm.micromedex.com>].
92. **Chow AW:** Toxic shock syndrome. In: Griffith's 5 Minute Clinical Consult. Dambro MR (ed), Lippincott, Williams & Wilkins, Philadelphia, pp 1104-1105, 2002
93. Livesley N, **Chow AW:** Infected pressure ulcers. In: Infection Management for Geriatrics in Long-Term Care Facilities. Yoshikawa TT, Ouslander JG (eds), Marcell Dekker, New York, NY, pp 257-281, 2002.
94. **Chow AW:** Topics in Infectious Diseases (chapter). In: IVIG - Utilization Management Handbook, 1st ed, Pei D (ed), Provincial Blood Coordinating Office, Vancouver, BC, pp 90-100, 2002
95. **Chow AW:** Peripharyngeal fascial "space" infections - I. In: UpToDate, vol. 10.1, Rose BD (ed), UpToDate, Inc., Wellesley, MA. 2002 (Electronic textbook in Internal Medicine), 2002.
96. **Chow AW:** Peripharyngeal fascial "space" infections - II. In: UpToDate, vol. 10.1, Rose BD (ed), UpToDate, Inc., Wellesley, MA. 2002 (Electronic textbook in Internal Medicine), 2002.
97. **Chow AW:** Community-acquired pneumonia. (Chapter) in: Best Practice of Medicine. Gotto Jr AM (Editor-in-Chief); (electronic textbook in Internal Medicine). Turck M (Infectious Diseases Section Editor), Thomson MicroMedex Inc, Greenwood Village, CO. pp 1-36, October 15, 2002 [url: <http://bpm.micromedex.com>].
98. **Chow AW:** Viral upper respiratory infections. (Chapter) in: Best Practice of Medicine. Gotto Jr AM (Editor-in-Chief); (electronic textbook in Internal Medicine). Turck M (Infectious Diseases Section Editor). Thomson MicroMedex Inc, Greenwood Village, CO. pp 1-28, Mar 8, 2002 [url: <http://bpm.micromedex.com>].
99. **Chow AW:** Acute bronchitis. (Chapter) in: Best Practice of Medicine. Gotto Jr AM (Editor-in-Chief); (electronic textbook in Internal Medicine). Turck M (Infectious Diseases Section Editor), Thomson MicroMedex Inc, Greenwood Village, CO. pp 1-23, October 16, 2002 [url: <http://bpm.micromedex.com>].
100. **Chow AW:** Pharyngitis and tonsillitis. (Chapter) in: Best Practice of Medicine. Gotto Jr AM (Editor-in-Chief); (electronic textbook in Internal Medicine). Turck M (Infectious Diseases Section Editor), Thomson MicroMedex Inc, Greenwood Village, CO. pp 1-20, August 12, 2002 [url: <http://bpm.micromedex.com>].
101. Sharkawy AA, **Chow AW:** Cervicofacial actinomycosis. In: UpToDate, vol. 10.3, UpToDate, Inc., Wellesley, MA. 2002 (electronic textbook in Internal Medicine). pp 1-6, Aug 2002.
102. **Chow AW:** Sinusitis. In Gotto A (ed.): DISEASEDEX(tm) -- General Medicine, January 27, 2003. MICROMEDEX, Greenwood Village, Colorado. <http://www.mdx.com/products/diseasedexgeneral/>
103. **Chow AW:** Head and neck infections. In: Therapy of Infectious Diseases, Baddour LM, Gorbach SL (eds), WB

Saunders, New York, pp 25-39, 2003

104. **Chow AW:** Gastrointestinal and intraabdominal infections. In: The Quinolones - An Unfolding Story. Low DE, Ronald AR (eds), Biosciences, Birkhauser, Verlag AG, Basel, Switzerland, pp 135-163, 2003
105. **Chow AW:** Toxic shock syndrome. In: Griffith's 5 Minute Clinical Consult. Dambro MR (ed), Lippincott, Williams & Wilkins, Philadelphia, pp 1112, 2003
106. **Chow AW:** Peripharyngeal fascial "space" infections - I. In: UpToDate, vol. 11.3, Rose BD (ed), UpToDate, Inc., Wellesley, MA. April 29, 2003 (Electronic textbook in Internal Medicine), 2003. <http://www.uptodate.com/>
107. **Chow AW:** Peripharyngeal fascial "space" infections - II. In: UpToDate, vol. 11.3, Rose BD (ed), UpToDate, Inc., Wellesley, MA. April 29, 2003 (Electronic textbook in Internal Medicine), 2003. <http://www.uptodate.com/>
108. Chan K, **Chow AW:** Septic shock. In: Therapeutic Choices, 4th ed. Gray J (ed), Canadian Pharmacists Association, Ottawa, pp 986-1000, 2003
109. Baker AS, **Chow AW:** Infections of head and neck spaces and salivary glands (Chapter 43). In: Infectious Diseases, 3rd ed. Gorbach SL, Bartlett JG, Blacklow NR (eds), Lippincott Williams & Wilkins, Philadelphia, PA, pp 420-428, 2004.
110. **Chow AW:** Infections of the sinuses and parameningeal structures (Chapter 44). In: Infectious Diseases, 3rd ed. Gorbach SL, Bartlett JG, Blacklow NR (eds), Lippincott Williams & Wilkins, Philadelphia, PA, pp 428-443, 2004.
111. **Chow AW:** Community-acquired pneumonia. (Chapter) in: Best Practice of Medicine. Gotto Jr AM (Editor-in-Chief); (electronic textbook in Internal Medicine). Turck M (Infectious Diseases Section Editor), Thomson MicroMedex Inc, Greenwood Village, CO. pp. 1-40, January 21, 2004 [url: <http://bpm.micromedex.com>].
112. **Chow AW:** Toxic shock syndrome. In: Griffith's 5 Minute Clinical Consult. Dambro MR (ed), Lippincott, Williams & Wilkins, Philadelphia, PA, pp 1114-1115, 2004.
113. **Chow AW:** Epidemiology, pathogenesis and clinical manifestations of odontogenic infections. In: UpToDate, vol. 12, UpToDate, Inc., Wellesley, MA. June 2004 (Electronic textbook in Internal Medicine)
114. **Chow AW:** Complications, diagnosis, and treatment of odontogenic infections. In: UpToDate, vol. 12, UpToDate, Inc., Wellesley, MA. June 2004 (Electronic textbook in Internal Medicine)
115. **Chow AW:** Infections of the oral cavity, neck and head. (Chapter 57) In: Principles and Practice of Infectious Diseases, 6th ed. Mandell GL, Bennett JE, Dolin R (eds), Elsevier Churchill Livingstone, Philadelphia, pp 787-802, 2005.
116. **Chow AW:** Life-threatening infections of the head, neck and upper respiratory tract. (Chapter 54) In: Principles of Critical Care, 3rd ed. Hall JB, Schmidt GA, Wood LDH (eds), McGraw-Hill, New York, pp 881-895, 2005
117. **Chow AW:** Toxic shock syndrome. In: Griffith's 5 Minute Clinical Consult.. Dambro MR (ed), Lippincott, Williams & Wilkins, Philadelphia, PA, pp 1124-1125, 2005
118. **Chow AW:** Anaerobic Infections (Chapter). In: ACP Medicine. Dale CC (Editor-in-Chief), WebMD Scientific American Medicine, New York, NY, April 2005 (<http://www.acpmedicine.com/abstracts/sam/med0705.htm>)
119. Savelkoul, HFJ, Cameron SB, **Chow AW:** Maturation of the immune response. In: Encyclopedic Reference of Immunotoxicology. Vohr HW (ed), Springer, New York, pp 426-430, 2005.
120. Wu J, **Chow AW:** Clindamycin (Chapter 17). In: Antibiotic Therapy for Geriatric Patients. Yoshikawa TT, Rajagopalan S (eds), Taylor & Francis Group, New York, NY, 2006, pp 235-247
121. **Chow AW:** Anaerobic Infections (Chapter 141) in ACP Medicine, 2006 Edition. Dale CC and Federman DD (eds). WebMD Inc., New York, NY, pp 1604-1620, 2006
122. Reynolds SC, **Chow AW:** Infected pressure ulcers (Chapter). In: Infection Management for Geriatric Patients in Long-term Care Facilities, 2nd ed. Yoshikawa TT and Outslander JG (eds), Marcel Dekker, New York, NY, 2006 (in press)

(c) Conference Proceedings

1. **Chow AW**, Malkasian KL, Marshall JR, Guze LB: Parenteral doxycycline therapy for acute severe pelvic inflammatory disease. In Doxycycline (Vibramycin R) - Recent Investigations and Clinical Experience. New York, Pfizer Laboratories Division, Pfizer Inc., pp 43-46, 1974 (B07)
2. **Chow AW**, Patten V, Guze LB: In vitro activity of doxycycline against anaerobic bacteria, In Doxycycline (Vibramycin R) - Recent Investigations and Clinical Experience. New York, Pfizer Laboratories Division, Pfizer Inc., pp 9-11, 1974 (B08)
3. Ch'ien LT, Whitley RJ, Alford CA Jr, Galasso GJ, and the Collaborative Study Group (**Chow AW**, participant): Adenine arabinoside for therapy of herpes zoster in immunosuppressed patients preliminary results of a collaborative study. J Infect Dis 133 (suppl):A184- A191, 1976 (A32)
4. **Chow AW**, Bednorz D, Guze LB: Susceptibility of obligate anaerobes to metronidazole - an extended study of 1,054 clinical isolates. In Metronidazole: Proceedings of the International Metronidazole Conference, Montreal, May 26-28, 1976, Excerpta Medica, Princeton, pp 286-292, 1977 (B11)
5. **Chow AW**, Barry RE, Patten V, Benfield JR, Bray GA: Effect of metronidazole on the intestinal microflora in patients with jejunioileal bypass. In Metronidazole: Proceedings of the International Metronidazole Conference, Montreal, May 26-28, 1976, Excerpta Medica, Princeton, pp 368-374, 1977 (B12)
6. **Chow AW**, Bartlett KH: Comparative in vitro activity of ceftazidime (GR 20263) and other beta lactamase stable cephalosporins against Pseudomonas. Effect of inoculum size and divalent cation supplementation. J Antimicrob Chemother 8 (suppl B):345- 348, 1981 (A77)
7. **Chow AW**, Bartlett KH: Comparative in vitro activity of ceftazidime (GR 20263) and other beta lactam stable cephalosporins against anaerobic bacteria. J Antimicrob Chemother 8 (suppl B):91- 95, 1981 (B30)
8. Marshall JR, **Chow AW**, Sorrell TC: Effectiveness of mezlocillin in female genital tract infections. J Antimicrob Chemother 9 (suppl A):149- 158, 1982 (B33)
9. **Chow AW**: Antimicrobial therapy of gynaecologic infections an overview. J Antimicrob Chemother 9 (suppl A):146- 158, 1982 (B34)
10. **Chow AW**, Bartlett KH, Gribble MJ: In vitro activity of cefuroxime and ceftazidime against anaerobic bacteria. Curr Chemother & Immunother Vol. 1. Proc of the 12th Internat Congr of Chemother, P Periti & GG Grassi, eds, Amer Soc for Microbiol, Wash, D.C., pp 489- 491, 1982 (B35)
11. Gribble MJ, McDonald CV, Bowie WR, Sacks S, Naiman S, Grossman L, Buskard N, Smith J, **Chow AW**: Controlled randomized trial of piperacillin versus gentamicin/tobramycin plus carbenicillin/ticarcillin in therapy of serious infections. Curr Chemother & Immunother Vol 1. Proc of the 12th Internat Congr of Chemother, P Periti & GG Grassi, eds, Amer Soc for Microbiol, Wash, D.C., pp 697- 699, 1982 (B36)
12. **Chow AW**, Finegold SM: In vitro activity of ceftizoxime against anaerobic bacteria and comparison with other cephalosporins. J Antimicrob Chemother 10 (suppl C):45- 50, 1982 (A86)
13. Whitley RJ and the NIAID Collaborative Antiviral Study Group (**Chow AW**, participant): Herpes simplex virus infections of the central nervous system. Proceedings of the 13th International Congress of Chemotherapy, Vienna, Part 18, pp 31-42, 1983 (B38)
14. Mandell LA, Feld R, Louie T, Robson HG, **Chow A**, Bow E, Belch A, Goldsand G, Pater J: A prospective randomized trial of ticarcillin and moxalactam versus ticarcillin and tobramycin in the treatment of febrile neutropenic patients. Proceedings of the 13th International Congress of Chemotherapy, Vienna, Part 84, pp 19-24, 1983 (B39)
15. **Chow AW**, Finlay KR: Ocular penetration of N-formimidoyl thienamycin (MK787) in rabbits with staphylococcal endophthalmitis. Proceedings of the 13th International Congress of Chemotherapy, Vienna, 1983 (B40)
16. Finlay KR, **Chow AW**: Efficacy of N-formimidoyl thienamycin (MK787/MK791) in experimental staphylococcal endophthalmitis. Proceedings of the 13th International Congress of Chemotherapy, Vienna, 1983 (B41)
17. Feld R, Louie T, Mandell L, Robson H, **Chow A**, Bow E, Belch A, Goldsand G, Pater J: The use of combination beta-lactam therapy in febrile neutropenic hosts. Proceedings of the 13th International Congress of Chemotherapy, Vienna, Part 44, pp 25-28, 1983 (B42)
18. **Chow AW**, Bartlett KH: Phenotypic characterization of *Staphylococcus aureus* isolates associated with toxic shock syndrome. Proc. 5th International Symposium on Staphylococci. Jeljaszewicz J (ed), Zbl Bakt Suppl 14, Gustav

Fischer Verlag, Stuttgart, 1985, p 95-100 (A111)

19. **Chow AW**, Bartlett KH, Goldring AM: In vitro susceptibility of *Clostridium difficile* to new b-lactam antibiotics. Proc 14th International Congress of Chemotherapy, Kyoto, Japan 28:842-844, 1985 (B53)
20. See RH, **Chow AW**: The microbiology of toxic shock syndrome an overview. Rev Infect Dis 11:s55 s60, 1989 (B70)
21. Rosten PM, Bartlett KH, **Chow AW**: Purification and purity assessment of toxic shock syndrome toxin 1. Rev Infect Dis 11:s110 s116, 1989 (A134)
22. **Chow AW**, Bartlett KH: Sequential assessment of vaginal microflora in healthy women randomly assigned to tampon or napkin use. Rev Infect Dis 11:s68 s74, 1989 (A135)
23. **Chow AW**, Wong J: Cervicovaginal opsonic activity, immunoglobulins, complement, and soluble fibronectin in healthy women randomly assigned to tampon or napkin use. Rev Infect Dis 11:s270 274, 1989 (A136)
24. **Chow AW**: Empirical treatment of patients with febrile neutropenia - teicoplanin vs vancomycin. Proceedings of symposium on Gram-positive Infections in the Immunocompromised - Teicoplanin, an Approach for the Nineties, London, August 1992. The Medicine Group, London, pp 9-12, 1993 (B95)
25. **Chow AW**, Jewesson PJ, Kureishi A, Phillips GL: Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients. Eur J Haematol Suppl 54:18-24, 1993 (A162)
26. Mandell LA, Marrie TJ, Niederman S, The Canadian Hospital Acquired Pneumonia Consensus Conference Group (**Chow AW**, participant): Initial antimicrobial treatment of hospital acquired pneumonia in adults - a conference report. Can J Infect Dis 4:317-321, 1993 (B97)
27. See RH, Kum WWS, Chang AH, Goh SH, **Chow AW**: Activation of human monocytes for IL-1b and TNFa secretion by staphylococcal toxic shock syndrome toxin-1 requires direct cell contact with T lymphocytes. In: The Staphylococci, Proceedings of the VIIIth International Symposium on Staphylococci and Staphylococcal Infections, Stockholm 1992. Mollby R, Flock J-I, Nord CF Christensson B (eds), Gustav Fischer Verlag, Stuttgart, Zbl. Bakt. Suppl. 26:443-445, 1994 (A166)
28. Lee VTP, Goh SW, Byrne SK, Vortel J, **Chow AW**: Analysis of the coagulase gene by polymerase chain reaction as an epidemiologic typing method of Staphylococcus aureus. In: The Staphylococci, Proceedings of the VIIIth International Symposium on Staphylococci and Staphylococcal Infections, Stockholm 1992. Mollby R, Flock J-I, Nord CF Christensson B (eds), Gustav Fischer Verlag, Stuttgart, Zbl. Bakt. Suppl. 26:107-109, 1994 (A167)
29. **Chow AW**: Pharmacoeconomic considerations of gram-positive infections. Proceedings in: Resistance in Gram-positive bacteria - implications for the economics of treatment. Medicine Publishing Foundation Symposium Series 36, The Medicine Group, Oxon, PP 42-46, 1995 (B110)
30. **Chow AW**, Rubinchik E: Recombinant expression and immunogenicity of MHC class II binding epitopes of staphylococcal toxic shock syndrome toxin-1. In: Proceedings of the European Conference on Toxic Shock Syndrome, London, England, September 10-12, 1997. Arbuthnott JP (ed), Royal Society of Medicine Press, London, UK, pp 85-88, 1998 (A190)
31. **Chow AW**: Future and emerging treatments for microbial infections. In: Proceedings of the Vancouver Orbital Symposium, March 15-17, 2002, Vancouver, BC; Rootman J (ed), Marcel Dekker, New York, pp 45-64, 2005

(d) Abstracts

1. **Chow AW**, Forrester J, Hryniuk W: Cytosine arabinoside therapy for herpes virus infections. Abstract No. 38, 10th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ill. p 16, October 1970
2. Hryniuk W, Forester J, Shojani M, Bercovitch L, Chow A: Disseminated herpes zoster infections controlled with low doses of cytosine arabinoside. Abstract No. 5, American Society of Hematology, 14th Annual Meeting, 1971, San Francisco, p 30, December 1971
3. **Chow AW**, Fiala M, Hryniuk W, Guze LB: Cytosine arabinoside (Ara C) therapy for herpes simplex encephalitis. Abstract No. 56, 11th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlantic City, N.J., p 28, October 1971
4. **Chow AW**, Guze LB: Bacteroides bacteremia. Abstract No. 25, 11th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlantic City, N.J., p 19, October 1971

Agents and Chemotherapy, Atlantic City, N.J., p 13, October 1971

5. **Chow AW**, Guze LB: Bacteroides bacteremia. Interplanetary Society, Annual Meeting, Oxford, England, March 1972
6. Fiala M, **Chow AW**, Miyaski K, Guze LB: Susceptibility of herpes viruses to cytosine arabinoside (Ara C). Abstract No. V242, American Society for Microbiology, 72nd Annual Meeting, Philadelphia, PA, p 225, April 1972
7. **Chow AW**, Guze LB: Bacteroidaceae bacteremia: analysis of 112 patients. Clin Res 21:595, 1973
8. **Chow AW**, Craigie B, Montgomerie JZ, Guze LB: Susceptibility of anaerobic bacteria to minocycline. Abstract No. 115, 13th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., September 1973
9. Yamauchi T, **Chow AW**, Leake RD, Anthony BF, Rosenblatt RM: Isolation of Bacteroidaceae from neonatal blood cultures. Ped Res 7:381, 1973
10. **Chow AW**, Leake RD, Yamauchi T, Anthony BF, Rosenblatt R, Guze LB: Neonatal Bacteroidaceae bacteremia: incidence and clinical experience. Abstract No. 113, 113th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., September 1973
11. **Chow AW**, Montgomerie JZ, Guze LB: Evaluation of parenteral clindamycin for anaerobic sepsis. Clin Res 21:595, 1973
12. **Chow AW**, Malkasian K, Guze LB, Marshall JR: Bacteriology of acute pelvic inflammatory disease. Abstract No. 386, 14th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1974
13. **Chow AW**, Ota J, Guze LB: Gentamicin plus clindamycin as initial therapy for severe sepsis - a prospective study. Abstract No. 288, 14th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1974
14. **Chow AW**, Goldin RH, Edwards Jr JE, Louie JE, Guze LB: Sternoarticular septic arthritis in heroine users. Dokumentation Drogenge fahrdung und Alkoholmi Bbranch 3:246 -247, 1974
15. **Chow AW**, Ota J, Guze LB: Gentamicin clindamycin therapy for suspected sepsis a prospective study. Clin Res 22:438A, 1974
16. Okada DM, **Chow AW**, Barrett CL, Guze LB, Marshall JR: Cephalothin prophylaxis in cesarean section. Abstract No. 25, 15th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., September 1975
17. **Chow AW**, Okada DM, Barrett CL, Marshall JR, Guze LB: Factors associated with infection following cesarean section. Abstract No. 224, 15th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., September 1975
18. Barry RE, **Chow AW**, Billesdon J, Benfield JR: Role of intestinal flora in colonic pseudoobstruction. Abstract No. 433, 15th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., September 1975
19. **Chow AW**, Barry RE, Billesdon J: Intestinal flora and chloroglycine breath test in colonic pseudoobstruction following jejunoileal bypass. Abstract No. 434, 15th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., September 1975
20. **Chow AW**, Marshall JR, Guze LB: The microbiology of septic abortion. Abstract No. 222, 15th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., September 1975
21. Okada DM, **Chow AW**: Newborn scalp abscess from intrapartum fetal monitoring. Abstract No. 145, 16th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, October 1976
22. **Chow AW**, Marshall JR: Microbiology and treatment of septic abortion. Abstract No. 291, 16th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, October 1976
23. **Chow AW**: Genital infection with Type II herpes simplex virus. Obstet Gynec Surgery 31:192- 194, 1976
24. **Chow AW**, Patten V: Suboptimal survival of Neisseria gonorrhoeae in a nonbuffered anaerobic transport system. Abstract No. C201, 77th Annual Meeting of American Society for Microbiology, New Orleans, Louisiana, May, 1977
25. **Chow AW**, Patten V, Bednorz N: Susceptibility of Campylobacter fetus to 22 antimicrobial agents. Abstract No. 500, 17th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, October 1977

566, 17th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, October 1977

26. **Chow AW**, Barry RE, Dwyer SM, Schwartz AA, Bray GA: Role of intestinal flora in colonic pseudoobstruction complicating jejunioileal bypass. National Meeting, American Federation for Clinical Research, Clin Res 25:373A, 1977
27. Sorrell TC, Patten V, **Chow AW**: Gentamicin-resistance in bacteremic isolates of *Staphylococcus aureus*. Abstract No. RT 33, 78th Annual Meeting of American Society for Microbiology, Las Vegas, Nevada, May, 1978
28. Patten V, Schwartz AA, Kaufman CS, **Chow AW**: The predominating intestinal flora of the Zucker Rat as an experimental model for jejunioileal bypass. Abstract No. RT 28, 78th Annual Meeting of American Society for Microbiology, Las Vegas, Nevada, May, 1978
29. Leake RD, Rosenblatt RM, Yoshimori W, Anthony BF, **Chow AW**: Nosocomial NICU *Klebsiella* infections. Ped Res 12:424, 1978
30. Sorrell TC, **Chow AW**, Guze LB: Gentamicin-resistant *Staphylococcus aureus* bacteremia - clinical and epidemiologic facets. Clin Res 26:406A, 1978
31. Bayer AS, **Chow AW**, Concepcion NF, Guze LB: Susceptibility of 40 Lactobacilli to six antimicrobials with gram positive anaerobic spectra. Abstract No. 44, 18th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October 1978
32. Sorrell TC, **Chow AW**, Patten V, Guze LB: In vitro activity of mezlocillin against anaerobic organisms. Abstract No. 362, 18th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October 1978
33. **Chow AW**, Yoshikawa TT, Guze LB: Role of intestinal colonization as major reservoir in nosocomial outbreak with multiply resistant *Proteus mirabilis*. Annual meeting, Canadian Infectious Disease Society and Royal College of Physicians and Surgeons, Montreal, Feb, 1979
34. Bayer AS, **Chow AW**, Morrison JO, Guze LB: In vitro bactericidal synergy of penicillins and aminoglycosides against antibiotic tolerant lactobacilli. Abstract No. 586, 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Mass., October 1979
35. Bayer AS, **Chow AW**, Ishida K, Guze LB: Experimental infective endocarditis due to antibiotic tolerant *Lactobacillus plantarum* correlation of in vitro susceptibility studies with in vivo efficacy. Abstract No. 1057, 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Mass., October 1979
36. **Chow AW**, Carlson C, Sorrell TC: Host defences in acute pelvic inflammatory disease. I. Bacterial clearance in the murine uterus and oviduct. 1st International Symposium on PID, Atlanta, Georgia, April 1980
37. Sorrell TC, Yoshimori R, Marshall JR, **Chow AW**: Puerperal endomyometritis - prospective randomized comparison of mezlocillin and ampicillin. Abstract No. 226, 20th Interscience Conference on Anti microbial Agents and chemotherapy, New Orleans, September 1980
38. **Chow AW**, Carlson C, Sorrell TC: Role of uterotubal junction in bacterial ingress of the murine oviduct. Abstract No. 223, 20th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 1980
39. **Chow AW**, Carlson C, Sorrell TC: Bacterial clearance in the murine uterus and oviduct. Clin Res 28:365A, 1980
40. Harris GS, **Chow AW**: Management of infective endophthalmitis by pars plana vitrectomy. Annual Meeting of the Canadian Ophthalmology Society, Montreal, June, 1981
41. **Chow AW**, Bartlett KH: Comparative susceptibility of obligate anaerobes and *Pseudomonas* species to ceftazidime and related compounds. 1st international Ceftazidime Symposium, London, England, April 1981
42. Gribble M, McDonald C, Bowie W, Sacks S, Naiman S, Grossman L, Buskard N, Smith J, **Chow AW**: Empiric therapy of febrile neutropenia prospective randomized comparison of piperacillin versus gentamicin/tobramycin plus carbenicillin/ticarcillin. Annual meeting, Canadian Infectious Disease Society and Royal College of Physicians and Surgeons, Toronto, September 1981
43. Gribble MJ, **Chow AW**: Hemolysis and biotypic characterization of *Staph. aureus* associated with toxic shock syndrome. Clin Res 29:386A, 1981
44. Gribble MJ, McDonald CV, Bowie WR, Sacks S, Naiman S, Grossman L, Smith J, **Chow AW**: Controlled randomized trial of piperacillin versus gentamicin/tobramycin plus carbenicillin/ticarcillin in therapy of serious

infections. Abstract No. 66, 12th International Congress of Chemotherapy, Florence, Italy, July, 1981

45. **Chow AW**, Carlson CL: Association of hemolytic activity with piliation and mannose sensitive hemagglutination in urinary isolates of E. coli. Clin Res 29:382A, 1981
46. **Chow AW**, Bartlett KH, Gribble MJ: In vitro activity of cefuroxime and ceftazidime against anaerobic bacteria. Abstract No. 1171, 12th International Congress of Chemotherapy, Florence, Italy, July, 1981
47. **Chow AW**, Gribble MJ, Bartlett KH: Hemolytic activity of Staphylococcus aureus associated with toxic shock syndrome. Annual Meeting, Canadian Society for Clinical Investigation and the Canadian Infectious Disease Society, Toronto, September 1981
48. Gribble M, McDonald C, Bowie W, Sacks S, Naiman S, Grossman L, Buskard N, Smith J, **Chow AW**: Prospective randomized trial of piperacillin versus gentamicin/tobramycin plus carbenicillin/ ticarcillin in serious infections. Abstract No. 405, 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ill., November 1981
49. Marshall JR, **Chow AW**, Sorrell TC: Effectiveness of mezlocillin in female genital tract infections. 1st International Symposium on Mezlocillin, Advances in Antimicrobial Therapy, Dusseldorf, West Germany, September 1981
50. **Chow AW**: Antimicrobial therapy of gynaecologic infections an overview. 1st International Symposium on Mezlocillin, Advances in Antimicrobial Therapy, Dusseldorf, West Germany, September 1981
51. **Chow AW**: Comparative antibacterial spectrum of moxalactam, cefotaxime and cefoperazone. Clinical Symposium on the New Generation of Beta lactam Antibiotics, Las Vegas, Nevada, Jan, 1982
52. Dornan KJ, Thompson DM, Conn AR, Wittmann BK, Stiver HG, **Chow AW**: Toxic shock syndrome in the postoperative patient. Curr Surg, 1982
53. **Chow AW**, Finlay KR, Carlson C: Intrathecal and intraocular penetration of N formimidoyl thienamycin (MK 787) in normal rabbits. Abstract No. 810, 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami, Florida, October 1982
54. **Chow AW**, Carlson C: Host defences in acute pelvic inflammatory disease. II. Role of type I pili on invasiveness and clearance of E. coli in the murine oviduct. Clin Invest Med 5:31B, 1982
55. **Chow AW**, Wittmann BK, Bergdoll MS: Postpartum toxic shock syndrome (TSS) and intrapartum transmission to the neonate. Abstract No. 369, 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami, Florida, October 1982
56. **Chow AW**, Bartlett KH: Role of vaginal Enterobacteriaceae in toxic shock syndrome. Clin Invest Med 5:31B, 1982
57. **Chow AW**, Bartlett KH: Lethality and abscess formation in mice by Staph. aureus from toxic shock syndrome (TSS) patients and healthy controls. Annual Meeting, Canadian Society of Microbiology, Winnipeg, Manitoba, June, 1983
58. **Chow AW**, Bartlett KH, Macfarlane AM, Percival Smith R: Relationship of toxic shock marker protein, phage type and hemolytic pattern in vaginal Staphylococcus aureus. Annual Meeting, Canadian Society of Microbiology, Winnipeg, Manitoba, June, 1983
59. Feld R, Louie T, Mandell L, Robson H, **Chow AW**, Bow E, Belch A, Goldsand G, Pater J, and the National Cancer Institute of Canada Clinical Trials Group: A multicentre comparative trial of moxalactam and ticarcillin (MT) vs tobramycin and ticarcillin (TT) in febrile, neutropenic cancer patients. Am Soc Clin Oncol Annual Meeting, San Diego, May, 1983
60. **Chow AW**, Finlay KR: Ocular penetration of N formimidoyl thienamycin (MK787) in rabbits with staphylococcal endophthalmitis. 13th International Congress of Chemotherapy, Vienna, Austria, August -September 1983
61. **Chow AW**, Bartlett KH, Altmeier WA: Staphylococcus aureus associated with toxic shock syndrome recession of phage type 29 and emergence of nontypable (NT) strains. Clin Res 31:49A, 1983
62. **Chow AW**, Bartlett KH, Macfarlane AM, Percival Smith R: Association of Enterobacteriaceae and Staphylococcus aureus in toxic shock syndrome. Clin Res 31:495A, 1983
63. **Chow AW**, Percival Smith RKL, Bartlett KH, Macfarlane AM: Vaginal colonization with toxigenic Staphylococcus aureus in healthy women. Clin Invest Med 6 (suppl 2):61, 1983
64. Finlay KR, **Chow AW**: Efficacy of N formimidoyl thienamycin (MK787/MK791) in experimental staphylococcal endophthalmitis. 13th International Congress of Chemotherapy, Vienna, Austria, August -September 1983

endophthalmitis. 13th International Congress of Chemotherapy, Vienna, Austria, August -September 1983

65. Louis TJ, mandell LA, Feld R, Robson HG, **Chow AW**, Bow E, Belch A, Goldsand G, Pater J: A prospective randomized trial of ticarcillin and moxalactam versus ticarcillin and tobramycin in the treatment of febrile neutropenic patients. Abstract, 23rd ICAAC, Las Vegas, October 1983
66. **Chow AW**, Wong CK, Macfarlane AM, Bartlett KH: Nonmenstrual toxic shock syndrome - problems of diagnosis and definition. Clin Invest Med 6 (suppl 2):61, 1983
67. **Chow AW**, Bartlett KH, Percival Smith R: Vaginal colonization of Escherichia coli and its relation to contraceptive methods and urinary infection. Annual Meeting, Canadian Infectious Disease Society and Royal College of Physicians and Surgeons, Calgary, Alberta, September 1983
68. **Chow AW**, Percival Smith RK, Bartlett KH, Macfarlane AMG, Morrison BJ: Co isolation of toxic shock marker protein positive S. aureus and E. coli in healthy women. 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, October 1983
69. Finlay KR, **Chow AW**: Ocular toxicity and pharmacokinetics of intravitreal N formimidoyl thienamycin (MK787/MK791). 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, October 1983
70. Megran DW, Bartlett KH, **Chow AW**: Prevalence of toxic shock (TSS) marker protein in S. aureus bacteremia. 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, October 1983
71. Bow EJ, Pater J, Willan A, Louie TJ, Robson H, Chow A, Belch A, Mandell L, Goldsand G, Feld R: The impact of trimethoprim sulfamethoxazole for infection prophylaxis on outcome of empiric antibiotic therapy in febrile granulocytopenic patients with cancer. , ASCO Annual Meeting, Toronto, Ontario, May 6- 8, 1984
72. **Chow AW**, Bartlett KH: Phenotypic characterization of toxic shock syndrome associated Staphylococcus aureus isolates. 5th International Symposium on Staphylococci and Staphylococcal Infections, Warsaw, Poland, June, 1984
73. **Chow AW**, McInnes A, Bartlett KH, McBride BC: Clumping factor and toxic shock associated S. aureus. Canadian Society of Microbiologists, June, 1984
74. **Chow AW**, Cheng N, Bartlett KH: Variable endotoxic potential of vaginal gram negative bacteria. Canadian Society of Microbiologists, June, 1984
75. **Chow AW**, Bartlett KH: Purification and characterization of the staphylococcal toxic shock toxin (TST). Clin Invest Med 7(suppl 2):63, 1984
76. Chow A, Bartlett KH, Altemeier WA: Value of phage typing and association of new phages in staphylococcal toxic shock syndrome. Clinical Research 32:557A, 1984
77. **Chow AW**, McInnes A, Bartlett KH, McBride BC: Clumping factor and toxic shock associated S. aureus. Clin Res 32:557A, 1984
78. **Chow AW**, Cheng N: Growth permissiveness of vaginal washings from toxic shock syndrome (TSS) and control women for toxigenic (+) and nontoxigenic (-) S. aureus (SA). , 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., October 1984
79. Rosten PM, **Chow AW**: An enzyme linked immunosorbent assay for the detection of toxic shock syndrome toxin 1 in body fluids. Conjoint Meeting in Infectious Diseases, Vancouver, November 1984
80. Haldane DJM, Bauman DS, **Chow AW**, Doyle P, Garber G, Ngui Yen J, Smith JA: Cryptococcal latex agglutination false negative. Conjoint Meeting in Infectious Diseases, Vancouver, November 1984
81. **Chow AW**, Cheng N, Bartlett KH: Variable endotoxic activity of vaginal aerobic and anaerobic gram negative bacteria. Clin Invest Med 7(suppl 2):68, 1984
82. Shafran SD, Wong J, **Chow AW**: In vitro activity of SCH 34343 and cefbuperazone against anaerobic bacteria, 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., October 1984
83. **Chow AW**, Bartlett KH, Cheng N, Goldring AM: Role of vaginal E. coli and endotoxin in toxic shock syndrome (TSS). , 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., October 1984
84. **Chow AW**, Bartlett KH, Goldring AM: Comparative in vitro susceptibility of Clostridium difficile to newer b lactam antibiotics. Abstract 666, 14th International Congress of Chemotherapy, Kyoto, Japan, June 1985

- antibiotics. Abstract S 86 6, 14th International Congress of Chemotherapy, Kyoto, Japan, June, 1985
85. Rosten P, Bartlett KH, **Chow AW**: Enzyme linked immunosorbent assay for detection of toxic shock syndrome toxin 1 (TSST 1). American Society of Microbiology, Las Vegas, March, 1985
 86. Williams CM, Okada DM, Marshall JR, **Chow AW**: Predictive value and role of Ureaplasma and other aerobes and anaerobes from intraoperative cultures in postsection endometritis. Abstract R 590, Royal College of Physicians, Vancouver, September 1985
 87. **Chow AW**, Cheng N: Comparative in vitro activity of new quinolones against anaerobic bacteria. Abstract 577, ICAAC, Minneapolis, September 1985
 88. Williams CM, Okada DM, Marshall JR, Schulzer M, **Chow AW**: Isolation of high virulence microorganisms from amniotic fluid during cesarean section. Abstract 38, ICAAC, Minneapolis, September 1985
 89. Rosten PM, **Chow AW**: Serologic responses to toxic shock syndrome toxin 1 (TSST 1) in menstrual and nonmenstrual TSS. Abstract 85, ICAAC, Minneapolis, September 1985
 90. Haug L, **Chow AW**: Mechanisms of interaction between Staphylococcus aureus and Escherichia coli. Abstract, UBC Health Sciences Research Day, Vancouver, November 1985
 91. **Chow AW**, Wong J: Opsonic and complement activity in vaginal washings from menstruating women convalescent from toxic shock syndrome (TSS) and healthy controls. Abstract C 576, Can Soc Clin Invest, Vancouver, September 1985
 92. **Chow AW**, Wong J: Demonstration of opsonic activity, immunoglobulins, complement and fibronectin in vaginal washings from toxic shock women and healthy controls. Clin Res 34:101A, 1986
 93. Louie T, Mandell L, Feld R, **Chow AW**, Robson H, Bow E, Miedzinski L, Nicolle L, Rachlis A, Phaneuf D, Pater J: Multicenter comparison of aztreonam plus cloxacillin (AC), aztreonam plus tobramycin (AT), or moxalactam plus tobramycin (MT) as empiric therapy of febrile neutropenic episodes. ICAAC, New Orleans, September 1986
 94. Whiting JL, Cheng N, **Chow AW**: Synergistic combinations of ciprofloxacin and other agents against anaerobic bacteria. ICAAC, New Orleans, September 1986
 95. Rosten PM, Bartlett KH, **Chow AW**: Differential antibody responses to toxic shock syndrome (TSS) toxin 1 in male and female TSS patients and healthy controls. Can Soc Clin Invest, Toronto, September 1986
 96. **Chow AW**, Reiner NE, Rosten PM, Bartlett KH: Purification of toxic shock syndrome toxin 1. International Symposium on Toxic Shock Syndrome, Atlanta, November 1987
 97. Rosten PM, Bartlett KH, **Chow AW**: Purification and assessment of purity of TSST 1. Can Soc Microbiol, Saskatoon, 1987
 98. **Chow AW**, Wong J: Cervicovaginal opsonic activity, immunoglobulin, complement and soluble fibronectin in healthy women randomly assigned to tampon or napkin use. International Symposium on Toxic Shock Syndrome, Atlanta, November 1987
 99. Adilman S, **Chow AW**: Using F(ab')₂ fragments in a rapid screening colony immunoblot assay for toxic shock syndrome toxin 1 production by Staphylococcus aureus. UBC Health Sciences Research Day, Vancouver, October, 1987
 100. **Chow AW**, Cheng N, Sadhu K, Costerton JW: Gardnerella vaginalis lacks classical cell wall lipopolysaccharide and has gram positive cell wall ultrastructure. Clin Res 35:470A, 1987
 101. Stiver HG, Brunham R, **Chow AW**, Cheng N: Double-blind comparison of single dose ceftriaxone vs cefazolin for infection prophylaxis in vaginal hysterectomy. ICAAC, New York, 1987
 102. Rosten PM, Bartlett KH, **Chow AW**: Seroconversion by Western blot to toxic shock syndrome toxin 1 (TSST 1) and other staphylococcal exoproteins in menstrual and nonmenstrual TSS. CSCI, Winnipeg, 1987
 103. **Chow AW**, Wong J: Synergistic combinations of ciprofloxacin against multiply drug resistant nonfermenting gram negative bacilli. ICAAC, New York, 1987
 104. **Chow AW**, Cheng N: In vitro activity of deptomycin (LY46032) and paldimycin (U 70138F) against anaerobic gram positive bacteria. ICAAC, New York, 1987
 105. Whiting JL, Rosten PM, **Chow AW**: Seroconversion to toxic shock syndrome toxin 1 (TSST 1) and staphylococcal enterotoxins A, B, C, (SEA, SEB, SEC) among TSS and control patients. International Symposium on Toxic Shock

Syndrome, Atlanta, November 1987

106. **Chow AW**, Goldring AM, Bartlett KH: Sequential and quantitative vaginal microflora in healthy women randomly assigned to tampon or napkin use. International Symposium on Toxic Shock Syndrome, Atlanta, November 1987
107. Bartlett KH, Buscard NA, Elliott M, Goldring AM, **Chow AW**: Comparison of rapid diagnostic test (RDT) [Murex] with conventional RIA and ELISA for hepatitis type B virus (HbsAg). Can Soc Microbiol, Saskatoon, 1987
108. Kain KC, **Chow AW**: The distinctive clinical spectrum of nonmenstrual toxic shock syndrome. Royal College/CSCI, Ottawa, September 1988. Clin Invest Med 11:C66, 1988
109. Adilman SM, Rosten PM, **Chow AW**: Rapid screening for toxic shock syndrome toxin 1 (TSST 1) by a colony immunoblot assay using F(ab')₂ fragments. Western AFCR, Carmel, CA, February 1988. Clin Res 36:144A, 1988
110. **Chow AW**, Wong J: Cervicovaginal opsonic activity, immunoglobulin, complement, and soluble fibronectin in healthy women randomly assigned to tampon or napkin use. Western AFCR, Carmel, CA, February 1988. Clin Res 36:145A, 1988
111. **Chow AW**, Goldring AM, Bartlett KH: Sequential and quantitative vaginal microflora in healthy women randomly assigned to tampon versus napkin use. Western AFCR, Carmel, CA, February 1988. Clin Res 36:144A, 1988
112. Sett S, Hudon PJ, Jamieson WRE, **Chow AW**: Prosthetic valve endocarditis experience with porcine bioprostheses. Annual Meeting, American Heart Association, 1989
113. Kureishi A, Jewesson PJ, Cole CD, Reece DE, Phillips GL, Smith JA, **Chow AW**: The nephrotoxic potential of teicoplanin vs vancomycin in the empiric treatment of febrile neutropenic patients. ICAAC, Houston, 1989
114. Musser JM, Selander RK, **Chow AW**: A single clone of Staphylococcus aureus is associated with most cases of toxic shock syndrome (TSS). ICAAC, Houston, 1989
115. Sett S, Hudon MP, Jamieson WRE, **Chow AW**: Prosthetic valve endocarditis experience with porcine bioprostheses. Royal College/CSCI, Edmonton, September 1989. Clin Invest Med 12:B56, 1989
116. Scudamore CH, Gibney RG, **Chow AW**, Reiner NE, Forward AD, Shackleton CR: Management of echinococcal cyst disease by ultrasound location, and operative aspiration and sterilization. Royal College/CSCI, Edmonton, September 1989. Clin Invest Med 12:B56, 1989
117. Birnbaum DW, Schulzer M, Mathias RG, Kelly M, **Chow AW**: Receipt and adoption of universal precautions (UP) and body substance isolation (BSI) guidelines in Canadian hospitals. ASM, Anaheim, CA, May 1990
118. See RH, Krystal G, **Chow AW**: Binding of toxic shock syndrome toxin 1 and staphylococcal enterotoxin A to separate epitopes on the HLA DR receptor. Western AFCR, Carmel, February 1990. Clin Res 38:115A, 1990 (selected for Western AFCR Student Research Award in Infectious Disease, 1990)
119. See RH, Krystal G, **Chow AW**: Binding of toxic shock syndrome toxin 1 and staphylococcal enterotoxin A to separate epitopes on the HLA DR receptor. National AFCR, Washington DC, May 1990. Clin Res 38:305A, 1990
120. **Chow AW**, Olsen M, Lam K, Costerton JW: A vaginal tampon model of staphylococcal toxic shock syndrome (TSS) in New Zealand White rabbits. Royal College/CSCI, Toronto, September 1990. Clin Invest Med 13:B59, 1990
121. See RH, Krystal G, **Chow AW**: Binding of toxic shock syndrome toxin 1 and staphylococcal enterotoxin A to overlapping or separate epitopes on the HLA DR receptor. Royal College/CSCI, Toronto, September 1990. Clin Invest Med 13:B59, 1990 (selected for CSCI Trainee Award, CSCI, 1990)
122. Kureishi A, Jewesson PJ, Phillips GL, Reece D, Smith JA, **Chow AW**: Teicoplanin vs vancomycin as empiric therapy in febrile neutropenic patients. 30th ICAAC, Atlanta, Ga, October 1990
123. Birnbaum DW, Kelly M, Mathias RG, Schulzer M, **Chow AW**: Receipt and adoption of universal precautions (UP) and body substance isolation (BSI) guidelines in Canadian hospitals. 3rd International Conference on Nosocomial Infections, Atlanta, Ga, July 1990
124. Lee VTP, See RH, **Chow AW**: Detection and quantitation of staphylococcal enterotoxin B by enzyme linked immunosorbent assay. UBC Resident Research Day, Vancouver, May 1991
125. See RH, Krystal G, **Chow AW**: Phosphorylation and dephosphorylation of cellular proteins in human monocytes induced by toxic shock syndrome toxin 1 (TSST 1) and other staphylococcal exotoxins. Northwestern ASM, Portland, June 1991

126. Vortel JJ, Bell A, **Chow AW**, Farley JD: Methicillin resistant *Staphylococcus aureus* (MRSA) in a British Columbia hospital (BCH) investigation of an outbreak. UBC Dept Med Residents Research Day, Vancouver, May 29, 1991 (awarded best presentation by a fellow)
127. **Chow AW**, Percival Smith R: Vaginal mechanical contraceptive devices and urinary tract infections. National AFCR, Seattle, May 1991. Clin Res 39:241A, 1991
128. See RH, Krystal G, **Chow AW**: Activation of human monocytes by toxic shock syndrome toxin 1 (TSST 1) is accompanied by dephosphorylation of monocyte cellular proteins. 31st ICCAC, Chicago, Oct 1, 1991
129. **Chow AW**, Percival Smith R, Jones W, Noble M, Schechter M: Vaginal mechanical contraceptive devices and urinary tract infection. International Symposium on STD Research. Banff, Oct 7- 9, 1991
130. Chang A, Musser JM, **Chow AW**: A single clone of *S. aureus* which produces both TSST 1 and SEA causes the majority of menstrual toxic shock syndrome. Western AFCR, Carmel, Feb 1991. Clin Res 39:36A, 1991
131. Kum WWS, Laupland KB, **Chow AW**: Recognition of unique epitopes of staphylococcal toxic shock syndrome toxin-1 by polyclonal and monoclonal antibodies. ASM, New Orleans, May 1992
132. Goh SH, Byrne SK, Zhang JL, Lee VT, **Chow AW**: Molecular typing of *S. aureus* by PCR analysis of the 3' end of the staphylocoagulase gene. ASM, New Orleans, May 1992
133. Birnbaum DW, Schulzer M, Mathias RG, Kelly M, **Chow AW**: New infection control strategies are not effective. International Society of Technology Assessment in Health Care 8th Annual Meeting, Vancouver, June 14-20, 1992
134. Lee VTP, **Chow AW**: The role of staphylococcal enterotoxin B (SEB) in toxic shock syndrome (TSS). Western AFCR, Carmel, Feb 5- 8, 1992. Clin Res 40:101A, 1992
135. See RH, Kum WWS, Chang AH, Goh SH, **Chow AW**: Activation of human monocytes for IL-1b and TNFa secretion by staphylococcal toxic shock syndrome toxin-1 requires direct cell contact with T lymphocytes. VIIIth International Symposium on Staphylococci and Staphylococcal Infections. Stockholm, June 29 - July 3, 1992
136. Lee VTP, Goh SH, Byrne SK, Vortel J, **Chow AW**: Analysis of the coagulase gene by polymerase chain reaction as an epidemiologic typing method of *Staphylococcus aureus*. VIIIth International Symposium on Staphylococci and Staphylococcal Infections. Stockholm, June 29 - July 3, 1992
137. Chang AH, See RH, **Chow AW**: Binding of TSST 1 for receptors on human T lymphocytes and requirement of T cell monocyte contact in the induction of resting T cell proliferation. Western AFCR, Carmel, Feb 5 8, 1992. Clin Res 40:102A, 1992
138. De Boer M, Novick R, **Chow AW**: Role of co-expression of staphylococcal toxic shock toxin-1 (TSST-1) and enterotoxin A (SEA) in menstrual TSS - studies with isogenic mutants in TSST-1 and SEA production. UBC Health Sciences Student Research Forum, Nov 1992
139. See RH, Krystal G, **Chow AW**: TSST 1 and staphylococcal enterotoxins induce distinct patterns of protein phosphorylation in human monocytes. Western AFCR, Carmel, Feb 5 -8, 1992. Clin Res 40:53A, 1992
140. See RH, Chang AH, Goh SH, Kum WS, **Chow AW**: Induction of TNF and IL 1 by staphylococcal toxic shock syndrome toxin 1 (TSST 1) requires the presence of both monocytes and T cells. Western AFCR, Carmel, Feb 5 8, 1992. Clin Res 40:53A, 1992
141. Wong GC, Goh SH, **Chow AW**: Detection of staphylococcal enterotoxin C in toxic shock and non-toxic shock associated *Staphylococcus aureus* isolates. UBC Health Sciences Student Research Forum, Nov 1992 (C140)
142. Kertesz D, Byrne S, Chow A: Characterization of *Neisseria meningitidis* by polymerase chain reaction and restriction endonuclease digestion of the class I outer membrane protein. ASM, New Orleans, May 1993
143. Li N, Kum WWS, **Chow AW**: Formalin-inactivation of staphylococcal toxic shock syndrome toxin-1. Royal College/CSCI, Annual Meeting, Vancouver, Sept 12, 1993. Clin Invest Med Suppl 16:B77, 1993
144. Jewesson P, Chow A, Wai A, Frighetto L, Nickoloff D, Smith J, Schwartz L, Sleigh K, Danforth D, Pezim M, Stiver G: Double-blind comparison of cefoxitin (CFX), ceftizoxime (CTZ) and metronidazole-gentamicin (M-G) as prophylaxis for colorectal procedures. 33rd ICAAC, New Orleans, Oct 18-20, 1993
145. Jewesson P, Stiver G, Wai A, Frighetto L, Nickoloff D, Smith J, Schwartz L, Sleigh K, Danforth D, Scudamore C, **Chow AW**: Double-blind comparison of cefazolin (CFZ) and ceftizoxime (CTZ) for prophylaxis against infections following elective biliary tract surgery. 33rd ICAAC, New Orleans, Oct 18-20, 1993

146. De Boer ML, **Chow AW**: Molecular analysis of the staphylococcal enterotoxin B and toxic shock syndrome toxin-1 genetic elements. IDSA Annual Meeting, New Orleans, Oct 16-17, 1993
147. Lee VTP, **Chow AW**: Regulation of interleukin-1 β (IL-1 β) mRNA expression in human monocytes when stimulated with purified toxic shock syndrome toxin-1 (TSST-1). IDSA Annual Meeting, New Orleans, Oct 16-17, 1993
148. Wherry J, Wenzel R, Abraham E, Allred R, Balk R, Bone R, Levy H, Nasraway S, Perl T, Silverman H, Wunderink R, and the TNF MAb Study Group (**Chow AW**, participant): A controlled randomized double blind clinical trial of monoclonal antibody to human tumor necrosis factor (TNF MAb) in patients with sepsis syndrome. ACCP Annual Meeting, 1993
149. Lee VTP, Goh SH, **Chow AW**: T cell signals in the IL-1 β transcriptional activation by human blood monocytes stimulated with staphylococcal toxic shock syndrome toxin-1 (TSST-1). Royal College/CSCI, Vancouver, Sept 12, 1993. Clin Invest Med Suppl 16:B78, 1993
150. Kertesz DA, Byrne SK, **Chow AW**: Characterization of Neisseria meningitidis by polymerase chain reaction and restriction endonuclease digestion of the porA gene. Royal College/CSCI Annual Meeting, Vancouver, Sept 12, 1993. Clin Invest Med Suppl 16:B78, 1993
151. Kum WWS, Laupland KB, **Chow AW**: Purified staphylococcal lipase induces tumor necrosis factor-a (TNF-a), interleukin-1 β (IL-1 β), and interleukin-6 (IL-6) from human blood monocytes. Royal College/CSCI Annual Meeting, Vancouver, Sept 12, 1993. Clin Invest Med Suppl 16:B78, 1993
152. Laverdiere M, Gallimore B, Restieri C, Poonia K, **Chow AW**: In vitro synergism of ceftriaxone-aminoglycoside combinations against Pseudomonas aeruginosa. Royal College/CSCI Annual Meeting, Vancouver, Sept 13, 1993. Clin Invest Med Suppl 16:B83, 1993
153. Scudamore CH, Hemming AW, Fenwick J, Chow A, Shackleton CR, Erb S: The effects of veno-veno bypass and portal occlusion on gut mucosal perfusion during liver transplantation. Royal College/CSCI Annual Meeting, Vancouver. Clin Invest Med Suppl 16:B140, 1993
154. De Boer M, Novick R, **Chow AW**: Tampon-associated vaginal infection model of toxic shock syndrome using isogenic S. aureus mutants derived by tst inactivation and allele replacement. Western WSCI, Carmel CA, Feb 19, 1993. Clin Res 41:44A, 1993
155. Wherry J, Wenzel R, Wunderink R, Silverman H, Perl T, Nasraway S, Levy H, Bone R, Balk R, Allred R, and the TNF MAb Study Group (**Chow AW**, participant): Monoclonal antibody to human tumor necrosis factor (TNF MAb): multi-center efficacy and safety study in patients with sepsis syndrome. 33rd ICAAC, New Orleans, Oct 18-20, 1993
156. Kum WWS, Laupland KB, **Chow AW**: Demonstration of lethal and superantigenic domains of staphylococcal toxic shock syndrome toxin-1 by monoclonal antibodies. Western WSCI, Carmel CA, Feb 19, 1993. Clin Res 41:44A, 1993
157. **Chow AW**, Laupland KB, Kum WWS: Localizing the major antigenic and lethal domains of staphylococcal toxic shock syndrome toxin-1 by epitope mapping using polyclonal and monoclonal antibodies. National AFCR, Washington DC, May 3, 1993. Clin Res 41:280A, 1993
158. De Boer ML, **Chow AW**: The staphylococcal enterotoxin B gene is amplified as part of a tandem duplication in diverse clones of Staphylococcus aureus. Annual CSM/CBDN Meeting, Vancouver, June 13-17, 1994
159. Bathe OF, Rudston-Brown B, **Chow AW**, Phang PT: Gut production of tumor necrosis factor in a porcine model of septic shock. Annual CSM/CBDN Meeting, Vancouver, June 13-17, 1994
160. Goh SH, Wood J, Hemmingsen S, **Chow AW**: Molecular cloning and characterization of chaperonin 60/10 (HSP60/10) genes from staphylococcus aureus and s. epidermidis. Annual CSM/CBDN Meeting, Vancouver, June 13-17, 1994
161. Merks HW, Sleigh K, Poonia K, Tweeddale MG, **Chow AW**: Plasma IL-6 levels decline rapidly in patients with sepsis syndrome following treatment with anti-TNF monoclonal antibody, but the response is blunted in patients with shock compared to those without shock. Annual CSM/CBDN Meeting, Vancouver, June 13-17, 1994
162. Li N, Kum WWS, **Chow AW**: Protective effect of a formaldehyde-inactivated staphylococcal toxic shock syndrome toxin-1 in immunized rabbits. Annual CSM/CBDN Meeting, Vancouver, June 13-17, 1994
163. **Chow AW**, Tweeddale MG, Sleigh K, Poonia K, Merks H: Effect of monoclonal antibody to human tumor necrosis factor (TNF MAb) on TNF- α , TNF- β , IL-1 α , IL-1 β , IL-6, IL-8, IL-10, IL-12, IL-18, IL-1 α , IL-1 β , IL-1 γ , IL-1 δ , IL-1 ϵ , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ , IL-1 ω , IL-1 ν , IL-1 μ , IL-1 λ , IL-1 κ , IL-1 \jmath , IL-1 \i , IL-1 \h , IL-1 \g , IL-1 \f , IL-1 \e , IL-1 \d , IL-1 \c , IL-1 \b , IL-1 \a , IL-1 ζ , IL-1 η , IL-1 θ , IL-1 ι , IL-1 κ , IL-1 λ , IL-1 μ , IL-1 ν , IL-1 ξ , IL-1 ω , IL-1 ρ , IL-1 σ , IL-1 τ , IL-1 υ , IL-1 ϕ , IL-1 χ , IL-1 ψ

- factor (TNF MAb) on TNF α , IL-1 β and IL-6 levels in patients with sepsis syndrome. Abst No. N-IN-0037, National ASCI, Baltimore, May 2, 1994
164. Kum WWS, Wood JAO, **Chow AW**: Toxic shock syndrome toxin-1 residues 47-60 are responsible for binding to human monocytes, eliciting T-cell mitogenicity, and stimulating cytokine secretion from human peripheral blood mononuclear cells. Annual CSM/CBDN Meeting, Vancouver, June 13-17, 1994
 165. Kum WWS, **Chow AW**: Staphylococcal toxic shock syndrome toxin-1 and enterotoxin A superantigens share overlapping domains for monocyte binding, T-cell mitogenesis and cytokine secretion. Annual CBDN Meeting, Quebec City, June 16, 1995
 166. Rubinchik E, Kum WWS, Wilson D, Ruschkowski S, Finlay B, **Chow AW**: Display of superantigen epitope of toxic shock syndrome toxin-1 (TSST-1) on the surface of the filamentous fusion phage fuse-2. Annual CBDN Meeting, Quebec City, June 16, 1995
 167. Reynolds R, Goh SW, Potter S, Hemmingsen SM, **Chow AW**: Heat shock protein 60 (HSP60) gene sequences as universal targets for microbic species identification - the staphylococci as a model system. Annual CBDN Meeting, Quebec City, June 16, 1995
 168. DeBoer ML, Kum, WWS, Chow, AW: Co-production of staphylococcal enterotoxin A with toxic shock syndrome toxin-1 by *Staphylococcus aureus* does not increase morbidity or mortality in a rabbit model of toxic shock syndrome. Annual CBDN Meeting, Quebec City, June 16, 1995
 169. Bathe OF, Rudston-Brown B, **Chow AWC**, Phang PT: Gut production of cytokines in a porcine model of septic shock. American Thoracic Society Annual Meeting, Seattle, May 22, 1995
 170. Bathe OF, **Chow AWC**, Phang PT: Gut and liver production of cytokines in a porcine model of mesenteric ischemia-reperfusion. UBC Dept. of Surgery Resident Research Day, Vancouver, April 21, 1995 (Dr. Bathe won the Basic Science Prize for the best paper presented by a surgical resident)
 171. Kum WWS, **Chow AW**: Staphylococcal toxic shock syndrome toxin-1 and enterotoxin A superantigens share overlapping domains for monocyte binding, T-cell mitogenesis and cytokine secretion. Abst No. 0383, 19th ICC, Montreal, July 19, 1995. *Can J Inf Dis* 6:248C, 1995
 172. DeBoer ML, Kum WWS, **Chow AW**: Staphylococcal toxic shock syndrome toxin-1 and enterotoxin A induce T cell proliferation and TNF α production synergistically in human blood mononuclear cells. Abst No. 0382, 19th ICC, Montreal, July 19, 1995. *Can J Inf Dis* 6:248C, 1995
 173. **Chow AW**, Sleigh K, Merks H, Salit IE, Bergeron MG, Auger P, Schlech W, Shafran S, Robson HG, Saginur R, and the Canadian ESPRIT Study Group: Genotyping of nasal and wound *S. aureus* by coagulase gene RFLP from patients undergoing open heart surgery. Abst No. 0213, 19th ICC, Montreal, July 18, 1995. *Can J Inf Dis* 6:221C, 1995
 174. Saginur R, et al: *S. aureus* nasal carriage (SANC) and post-operative wound infections. International Meeting on Staphylococci, Leon, France, June 1996
 175. Rubinchik E, **Chow AW**: Characterization of toxic shock syndrome toxin-1 (TSST-1) epitope expressed as a fusion protein with glutathione-s-transferase. UA/UC Annual Meeting, Kananaskas, May 6, 1996
 176. Kum WWS, **Chow AW**: A mutation at glycine residue 31 of toxic shock syndrome toxin-1 defines a functional site critical for major histocompatibility complex class II binding and superantigenic activity. UA/UC Annual Meeting, Kananaskas, May 6, 1996
 177. **Chow AW**, Goh SW, Potter S, Hemmingsen SM: Heat shock protein gene sequences as universal targets for species identification of coagulase negative staphylococci. Western AFCR, Carmel, February 16, 1996. *J Invest Med* 44: 126A, 1996
 178. **Chow AW**: Old pathogens - new guises and different vices. Canadian Association for Clinical Microbiology and Infectious Diseases Annual Meeting Symposium, Hamilton, Nov 10-14, 1996
 179. Reynolds R, **Chow AW**: Speciation of the coagulase negative staphylococci using a 600 base pair region of the heat shock protein 60 gene. CSCI/Royal College Annual Meeting, Halifax, Sept 28, 1996. *Clin Invest Med* 19:S56, 1996
 180. Kum WWS, **Chow AW**: Monoclonal antibodies (MAb5 and MAb4) protect against the lethal effect of toxic shock syndrome toxin-1 in the D-galactosamine sensitized mouse model. Western AFCR, Carmel, February 16, 1996. *J*

Invest Med 44:110A, 1996

181. Reynolds R, Chow A: Heat shock protein 60 as a method for the identification of the coagulase negative staphylococci. Abst No. 196, IDSA, New Orleans, September 20, 1996
182. Kum WWS, **Chow AW**: Toxic shock syndrome toxin-1 (TSST-1) synthetic peptides inhibit TSST-1 induced superantigenic activities *in vitro* and *in vivo*. Annual CBDN meeting, Kananaskas, May 8, 1997
183. Rubinchik E, Kum WWS, Wilson D, Ruschkowski S, Wong R, Finlay B, Hancock REW, **Chow AW**: Recombinant staphylococcal toxic shock syndrome toxin-1 epitope expression and immunobiologic characterization. CBDN Annual Meeting, Montebello, Quebec, May 31, 1997
184. Rubinchik E, Kum WWS, Wong RSY, Hancock REW, **Chow AW**: Humoral response to the TSST-1 superantigenic epitope expressed on the surface of *E. coli*. Annual CBDN meeting, Kananaskas, May 8, 1997
185. McNeill S, West M, McNicol P, **Chow AW**: Synergistic activity of a novel cationic peptide antibiotic combined with vancomycin or teicoplanin against vancomycin-resistant enterococci (VRE). Abstract LB-18, ICAAC, Toronto, Sept 30, 1997
186. Pang LTY, **Chow AW**: Relative role of toxic shock syndrome toxin-1 and staphylococcal enterotoxin A superantigens in the D-galactosamine-sensitized murine model of lethal shock. Abstract 364, Royal College/CSCI Annual Meeting, Vancouver, Sept 26, 1997. Clin Invest Med 20:S56, 1997
187. Rubinchik E, **Chow AW**: Immunogenicity and protective activity of MHC class II binding epitopes of toxic shock syndrome toxin-1 expressed as recombinant or synthetic peptides. Abstract 368, Royal College/CSCI Annual Meeting, Vancouver, Sept 26, 1997. Clin Invest Med 20:S56, 1997
188. **Chow AW**, Rubinchik E: Recombinant expression and immunogenicity of MHC class II binding epitopes of staphylococcal toxic shock syndrome toxin-1. Abstract A10, European Symposium on Toxic Shock Syndrome, London, England, Sept 10-12, 1997
189. Rubinchik E, **Chow AW**: Comparative antigenicity and immunogenicity of recombinant toxic shock syndrome toxin-1 (TSST-1) superantigen peptides. Western AFCR, Carmel, Feb 1997. J Invest Med 45:104A, 1997
190. Drews SJ, Sanghera JS, Pelech SL, **Chow AW**: Toxic shock syndrome toxin-1 superantigen induced activation of myelin basic protein kinases in THP-1 cell. Abstract 426, Royal College/CSCI Annual Meeting, Vancouver, Sept 26, 1997. Clin Invest Med 20:S74, 1997
191. Hung R, **Chow AW**: Toxic shock syndrome toxin-1 (TSST-1) induced apoptosis of T cells *in vitro*. Abstract 369, Royal College/CSCI Annual Meeting, Vancouver, Sept 26, 1997. Clin Invest Med 20:S56, 1997
192. Kum WWS, **Chow AW**: Toxic shock syndrome toxin-1 (TSST-1) synthetic peptides inhibit TSST-1 induced superantigenic activities *in vitro* and *in vivo*. Annual CBDN meeting, Kananaskas, May 8, 1997
193. Lee SS, **Chow AW**: Species identification of *Staphylococcus haemolyticus* using species-specific HSP60 DNA probes. UBC Experimental Medicine Student Research Day, Vancouver, Oct 31, 1997 (best overall presentation award)
194. Kum WWS, **Chow AW**: Staphylococcal toxic shock syndrome toxin-1 and enterotoxin A share overlapping domains which are critical for superantigenic and lethal activities. Biomedicine '98. Washington DC, May 2, 1998. J Invest Med 46:217A, 1998
195. Lee SS, Bryce E, **Chow AW**: Species identification of *S. Haemolyticus* and *S. Epidermidis* using HSP60 DNA probes. ASM Annual Meeting, Atlanta, Georgia, May 17-21, 1998
196. Lee SS, Bryce E, Byrne S, Davies JE, **Chow AW**: Heterogenous vancomycin resistance in *Staphylococcus haemolyticus*. ICAAC, San Diego, Sept 24-27, 1998
197. Cameron S, **Chow AW**: Th1 versus Th2 polarization in a murine model of toxic shock, UBC Experimental Medicine Study Research Day, Vancouver, Oct. 23, 1998 (best overall presentation award)
198. **Chow AW**, McNeill, McNicol P, West MHP: *In vitro* activity of clinafloxacin, and synergy with a novel cationic peptide antibiotic, against vancomycin-resistant enterococci (VRE). ICAAC, San Diego, Sept. 24-27, 1998
199. **Chow AW**, McNeill, McNicol P, West MHP: Synergistic activity of a novel cationic peptide antibiotic combined with either ampicillin or gentamicin against vancomycin-resistant enterococci (VRE). ICAAC, San Diego, Sept 24-27, 1998

200. Lee SS, Bryce E, **Chow AW**: Novel vancomycin "hetero-resistance" in *Staphylococcus haemolyticus*. 66th Conjoint Meeting on Infectious Diseases, Toronto, Nov 6-11, 1998. *Can J Infect Dis* 9 (suppl D): 45D, 1998
201. Hung RW, **Chow AW**: Toxic shock syndrome toxin-1 induced apoptosis – possible mechanisms. Western AFCR, Carmel, Feb 1998. *J Invest Med*, 46:161A, 1998
202. Drews SJ, Sahl B, Sanghera JS, Pelech SL, **Chow AW**: Toxic shock syndrome toxin-1 activation of mitogen activated protein kinases in THP-1 cells. Western AFCR, Carmel, Feb 1998
203. Kwok AYC, Su S, Reynolds RP, **Chow AW**: Phylogenetic analysis and taxonomic relationships among coagulase-negative staphylococci based on HSP60 gene sequences. ASM Annual Meeting, Atlanta, Georgia, May 17-21, 1998
204. Lee SS, Bryce E, **Chow AW**: Identification of *Staphylococcus haemolyticus* and *Staphylococcus epidermidis* using HSP60 DNA probes. CBDN Annual General Meeting, Banff, AB, Apr 30-Nat 3m 1998
205. Kwok AYC, Su S, Reynolds RP, **Chow AW**: Phylogenetic analysis and taxonomic relationships among coagulase-negative staphylococci based on HSP60 gene sequences. ASM Annual Meeting, Atlanta, Georgia, May 17-21, 1998
206. Hung RW, **Chow AW**: Toxic shock syndrome toxin-1 induced apoptosis in thymocytes in vivo. Western AFCR, Carmel, January 1999; *J Invest Med* 47(2):74A, 1999
207. Pang LTY, Kum WWS, Kwok AYC, **Chow AW**: Identification of cross-reactive superantigenic epitopes in staphylococcal enterotoxin B and toxic shock syndrome toxin-1. Western AFCR, Carmel, January 1999
208. Wong RSY, **Chow AW**. The application of HSP60 gene sequences for detecting bacterial causes of invasive diarrhea. Abst C-476:202-202, ASM Ann Meeting, Chicago, May 1999
209. Hung RW, **Chow AW**: Anti-apoptotic regulation by toxic shock syndrome toxin-1 - role of Fas receptor. UBC Experimental Medicine Student Research Day, Vancouver, Oct 29, 1999
210. Cameron SB, Kum WSS, **Chow AW**: The in vivo response to repeated injections of toxic shock syndrome toxin-1 (TSST-1) in a murine model system: induction of OL-10 response. UBC Experimental Medicine Student Research Day, Vancouver, Oct 29, 1999 (best overall presentation award)
211. Hung R, **Chow AW**: Toxic shock syndrome toxin-1 induction of apoptosis in naïve and mature immune cell populations. CSCI/MRC Joint Program, Montreal, September 23, 1999 (CSCI trainee award)
212. R, **Chow AW**: Toxic Shock syndrome toxin-1 induction of apoptosis in native and mature immune cell populations. Hung Western CSCI Regional Meeting: Young Investigators' Forum. Vancouver, June 26, 1999
213. Kwok AYC, Wilson JT, Coulthart M, Ng L, Johnson W, **Chow AW**: Species identification and phylogenetic analysis of marine *Vibrios* based on heat shock protein 60 kDa (HSP60) gene sequences, ASM Ann Meeting, Chicago, May 1999, Abst R-9:617-617
214. Cameron S, Kum W. **Chow AW**: The in vivo response to subcutaneously injected toxic shock syndrome toxin-1 (TSST-1) in a mouse model system: role of T helper cell polarization in pathogenesis. Western CSCI Regional Meeting: Young Investigators' Forum. Vancouver, June 26, 1999 (best overall presentation award)
215. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**: Identification of *Vibrio* isolates by partial heat shock protein 60 Kda (HSP60) gene sequences. CBDN Annual General Meeting, Banff, AB, May 8-12, 1999
216. Wong RSY, **Chow AW**. The application of HSP60 gene sequences for detecting bacterial causes of invasive diarrhea. Abst C-476:202-202, ASM Ann Meeting, Chicago, May 31, 1999
217. Shlaes DM, Janota K, Severin A, Bradford PA, **Chow AW**: Peptidoglycan structure in vancomycin resistant *S. haemolyticus*. ICAAC Ann. Meeting, San Francisco, September 1999
218. Cameron SB, Kum WS, **Chow AW**: The in vivo response to toxic shock syndrome toxin-1 (TSST-1) in a murine model system - role of IFN- and IL-10 in pathogenesis. Western AFCR, Carmel, February 2000
219. Hung RW, **Chow AW**: Anti-apoptotic regulation by toxic shock syndrome toxin-1 - role of Fas receptor, Western AFCR, Carmel, February 2000
220. Iyo AH, **Chow AW**: A PCR-based genotypic method for the rapid detection of respiratory pathogens in community acquired pneumonia. CBDN Annual General Meeting, Canmore, AB, May 7, 2000

221. Kwok AYC, Chuang YC, **Chow AW**: Detection of *Campylobacter jejuni* and *Campylobacter coli* in fecal samples following oral feeding in NZW rabbits. CBDN Annual General Meeting, Canmore, AB, May 7, 2000
222. Leung LH, **Chow AW**: Vancomycin heteroresistance (VH) in *Staphylococcus haemolyticus* and *S. epidermidis*. Abst D-326, 40th ICAAC, Toronto, Sept 17-20, 2000 (ASM Student Travel Award)
223. Cameron S, Kum W, **Chow AW**: The use of repeated doses of toxic shock syndrome toxin-1 (TSST-1) in a murine model system to induce T regulatory cells (Tr1). CSCI-MRC Program, Edmonton, AB, Sept 21, 2000
224. Hung RW, **Chow AW**: A single-amino-acid substitution mutant of toxic shock syndrome toxin-1 induces apoptosis independent of Fas receptor and CD8+ cytotoxic T lymphocytes. CSCI-MRC Program, Edmonton, AB, Sept 21, 2000
225. Hung RW, Kum WW, **Chow AW**: A mutant of toxic shock syndrome toxin-1 exerts apoptotic activity by a Fas receptor and perforin independent pathway. Western AFCR, Camel, CA, Feb 2001
226. Iyo AH, Marrie TJ, Low D, Beecroft M, **Chow AW**: Detection of respiratory pathogens associated with community acquired pneumonia from a single oropharyngeal swab and PCR-amplified HSP60 gene sequences. CBDN Annual Meeting, Canmore AB, May 2001
227. Leung EH, **Chow AW**: Vancomycin heteroresistance in coagulase negative staphylococci (CNS) and *Staphylococcus aureus*. CBDN Annual Meeting, Canmore AB, May 2001
228. Iyo A, **Chow A**: Detection of Respiratory Pathogens Associated with Community Acquired Pneumonia from a Single Oropharyngeal Swab Using PCR-amplified HSP60 Gene Sequences. IDSA Symposium on Rapid Diagnosis, Orlando FL, April 2001
229. Hung RW, Kum WWS, **Chow AW**: Identification of regulatory domains for apoptosis in the toxic shock syndrome toxin-1 molecule. CSCI-CIHR Program, Ottawa ON, Sept 20, 2001. Clin Invest Med 24:220, 2001
230. Leung EH, **Chow AW**: Stable and reversible vancomycin resistance (VR) in bacteremic isolates of *Staphylococcus haemolyticus*. UBC Experimental Medicine Student Research Day, Vancouver, Nov 2, 2001
231. Hung RW, Kum WWS, **Chow AW**: Regulation of apoptosis by the toxic shock syndrome toxin-1 (TSST-1) and mutant toxin G31R. UBC Experimental Medicine Student Research Day, Vancouver, Nov 2, 2001 (best poster presentation award)
232. Kalyan S, **Chow AW**: Activation of gamma/delta T cells by staphylococcal toxic shock syndrome toxin-1: role in dysregulation of the innate immune response? UBC Experimental Medicine Student Research Day, Vancouver, Nov 2, 2001
233. Hung RW, Kum WWS, **Chow AW**: Mechanisms for induction apoptosis by the toxic shock syndrome toxin-1 (TSST-1) mutant G31R. Western AFCR, Carmel, CA, Feb 2001; J Invest Med 50:48A, 2002
234. Leung EH, **Chow AW**: Inducibility of vancomycin heteroresistance (VH) among blood isolates of coagulase-negative staphylococci. Canadian Infectious Disease Society Annual Meeting, Banff AB, Mar 2002
235. Hung RW, Kum WWS, **Chow AW**: Regulation of apoptosis by toxic shock syndrome toxin-1 (TSST-1) and the mutant G31R. Exp Biol Annual Meeting, New Orleans, Apr 2002
236. Kum WWS, **Chow AW**: Staphylococcal superantigen toxic shock syndrome toxin-1 induces proliferation of human PBMC through a CD80-/CD154-dependent, CD86-/interleukin (IL)-2-independent mechanism. Exp Biol Annual Meeting, New Orleans, Apr 2002
237. Harris DE, Cameron SB, **Chow AW**: Hepatic toxicity induced by the staphylococcal superantigen TSST-1 versus endotoxin in D-galactosamine sensitized mice. CBDN Annual Meeting, Saskatoon, SK, June 2002
238. Hawkins LM, Nomellini J, Smit, **Chow AW**: Serodiagnosis of infectious diseases based on species-specific hsp60 B-cell epitopes. CBDN Annual Meeting, Saskatoon, SK, June 2002
239. Leung EH, **Chow AW**: Reversible and stable vancomycin resistance selected from blood isolates of coagulase negative staphylococci. CBDN Annual Meeting, Saskatoon, SK, June 2002
240. Thambirajah AA, Sleigh K, Stiver HG, **Chow AW**: Differential heat shock protein response to exercise in chronic fatigue syndrome patients compared to matched healthy controls: a preliminary report. CBDN Annual Meeting, Saskatoon, SK, June 2002
241. Yong PJ, **Chow AW**: Training clinician-scientists: a survey of MD/PhD students in Canadian Medical Schools. CSCI-
CIHR Program, Ottawa ON, Sept 20, 2001

CIHR Program, Ottawa ON, Sept 26, 2002

242. Hung RH, **Chow AW**: The G31R mutant of toxic shock syndrome toxin-1: intrinsic and extrinsic pathways for apoptosis. CSCI-CIHR Program, Ottawa ON, Sept 26, 2002
243. Kalyan S, **Chow AW**: Peripheral gamma-delta T cells potentiate the early inflammatory response to toxic shock syndrome TSST-1. Western AFCR, Carmel, CA, Feb 1, 2003; Abst 389, J Invest Med 51 (suppl 1):S159, 2003
244. Andrews G, Sleigh K, Forster B, Stiver G, **Chow A**, Maedler B, MacKay A, Isserow S: Chronic fatigue syndrome: pre- and post-exertional quantitative single voxel ¹H MR spectroscopy of the basal ganglia. American Neuropsychiatric Association annual meeting, Honolulu, HI, Feb 5-8, 2003
245. Kalyan S, **Chow AW**: Enhanced secretion of IFN γ in human PBMC by toxic shock syndrome toxin-1 following priming of $\gamma\delta$ T cells is attributed to both an increased proportion of IFN γ -producing $\gamma\delta$ T cells, and their capacity to increase $\alpha\beta$ T cell responsiveness. UBC Experimental Medicine Research Day, Vancouver, BC, Oct 2003 (best oral student presentation award)
246. Hung RW, **Chow AW**: Mitochondrial involvement during apoptosis triggered by the G31R mutant of toxic shock syndrome toxin-1. UBC Experimental Medicine Research Day, Vancouver, BC, Oct 2003
247. Kalyan S, **Chow AW**: Immunoregulation by gd T cells in TSST-1 pathogenesis. National CIHR Student Symposium, Winnipeg, MA, May 2003
248. Rosenke K, **Chow AW**: Detection of Bacterial Contamination in Platelet Concentrates by Nucleic Acid Amplification of the Universal MicrobialHSP60 Gene Target. CBDN Annual Meeting, Calgary, AB, Apr 23-27, 2003
249. Ivison S, Hawkins L, Nomellin J, Smit J, **Chow AW**: Serodiagnosis of infectious diseases based on species-specific B cell epitopes. CBDN Annual Meeting, Calgary, AB, Apr 23-27, 2003
250. Hung RW, **Chow AW**: Mitochondrial involvement during apoptosis triggered by the G31R mutant of Toxic Shock Syndrome Toxin-1. CSCI-CIHR Young Investigator Forum, Ottawa, Sep 2003; Clin Invest Med 26(4):180-1, 2003
251. Kalyan S, **Chow AW**: Activated $\gamma\delta$ T cells heighten IFN γ expression in $\alpha\beta$ T cells in response to toxic shock syndrome toxin-1. Western AFCR, Carmel, CA, Feb 2004; J Invest Med 52(suppl 1):S151, 2004
252. Kalyan S, **Chow AW**: Toxic Shock Syndrome Toxin-1 Regulates the Intracellular Expression of High Mobility Group-1 Protein in T cells as well as Monocytes. 12th International Congress of Immunology, Montreal, QC, May 2004
253. Kum WW, Chuang J, Cameron SB, **Chow AW**: *In vitro* generation of CD4⁺ regulatory T cells following repeated exposure to Staphylococcal superantigen toxic shock syndrome toxin-1. 12th International Congress of Immunology, Montreal, QC, May 2004
254. Lester R, Ivison S, **Chow AW**: Staphylococcal heat shock protein 60 kDa (hsp60) fragments induce proinflammatory cytokine responses in innate immune cells. UBC Department of Medicine Research Day, May 2004 (best poster research award)
255. Li HW, Kum WWS, **Chow AW**: Repeated subcutaneous injection of toxic shock syndrome toxin-1 induced regulatory T cells in C57B6 mice. Western AFCR, Carmel, CA, Feb 2005.
256. Lam G, **Chow AW**: B cell modulation by toxic shock syndrome toxin-1 induced CD25+ vs. CD25- regulatory T cells generated in Balb/c mice. Western AFCR, Carmel, CA, Feb 2005
257. Chuang M, Ivison S, Hawkins L, Nomellin J, Smit, **Chow AW**: Disparate human immune responses to *Campylobacter jejuni* heat shock protein 60 kDa (HSP60) following immunization vs. infection. CBDN AGM, Banff, AB, Feb 2005
258. Godin P, **Chow AW**: Internalization of *Staphylococcus aureus* inside HaCat skin keratinocytes. CBDN AGM, Banff, AB, Feb 2005
259. Rosenke K, Purssell A, Ivison S, Nomellini J, Smit J, McAlinden G, Masri B, Dunca CP, **Chow AW**: Serologic responses to staphylococcal Hsp60 peptides in infected and non-infected total hip and knee revision arthroplasty. CBDN AGM, Banff, AB, Feb 2005
260. Ivison S, **Chow AW**: Expression, purification and stimulation of human peripheral blood mononuclear cells (PBMC) with *Staphylococcus aureus* heat shock protein 60 (Hsp60). CBDN AGM, Banff, AB, Feb 2005

261. Kalyan S, **Chow AW**: Both activated T cells and monocytes are required for the translocation and secretion of nuclear high mobility group-1 protein in toxic shock syndrome toxin-1 induced inflammation. Can Soc Immunol Annual Meeting, Whistler, BC, Apr 2005 (Student Travel Award).
262. Lam G, **Chow AW**: B-cell modulation by toxic shock syndrome toxin-1 induced CD25+ vs. CD25- CD4+ regulatory T-cells generated in Balb/c mice. Annual Canadian Student Health Research Forum, Focus on Infection, Immunity & Health, Winnipeg, MB, June 2005
263. Godin P, **Chow AW**: The intracellular life-style of Staphylococcus aureus inside human keratinocytes. Infectious Disease Society of America Annual Meeting, San Francisco, Oct 2005
264. Haowei Li, **Chow AW**: Distinct regulatory T cells induced by repeated injection of toxic shock syndrome toxin-1 – a comparative study with staphylococcal enterotoxin A. Federation of Clinical Immunology Societies Annual Meeting, San Francisco, June 2006
265. Lam GY, **Chow AW**: TSST-1 induced CD4+ T regulatory cells downregulate B cell expansion, immunoglobulin synthesis and isotype switching. Federation of Clinical Immunology Societies Annual Meeting, San Francisco, June 2006

2. NON-REFEREED PUBLICATIONS

(a) Editorials, Letters, Reviews and Edited Conferences

1. **Chow A**: Psychological trauma in children subsequent to hospitalization and operative procedures. Univ Man Med J 37:138- 139, 1966 (B03)
2. **Chow A**: Medical journalism in proper perspective. Univ Man Med J 38:42- 43, 1966 (B02)
3. **Chow A**: Self education in medicine. J Can Assoc Med Students & Interns 25:18 -19, 1966 (B01)
4. **Chow AW**: A history of Chinese medicine. Univ Man Med J 38:109- 113, 1967 (B04)
5. **Chow AW**: Gonococcus in cervix and cul-de-sac - reply. Amer J Obstet Gynecol 125:278-279, 1976 (B10)
6. Infectious Diseases Specialty Conference: Yoshikawa TT, Goodman SJ: Brain abscess. Eds. JA Turner, JZ Montgomerie, **AW Chow**, TT Yoshikawa and LB Guze. West J Med 121:207- 219, 1974.
7. Infectious Diseases Specialty Conference: Anthony BF, Keys TF, Louie JS, Yoshimori RN: Gonococcal infections laboratory, clinical and epidemiological aspects. Eds. JA Turner, JZ Montgomerie, **AW Chow**, TT Yoshikawa and LB Guze. West J Med 120:456 -462, 1974.
8. Infectious Diseases Specialty Conference: Imagawa DT, Fiala M, St. Geme JW Jr, Yamauchi T: Viral infections of the fetus. Eds. JA Turner, JZ Montgomerie, **AW Chow**, TT Yoshikawa and LB Guze. West J Med 120:369 –375, 1974.
9. Infectious Diseases Specialty Conference: Montgomerie JZ, Yoshikawa TT, Lewis AJ, Fiala M, Locks MD, Turner J. Pericarditis. Eds. JA Turner, JZ Montgomerie, **AW Chow**, TT Yoshikawa and LB Guze. West J Med 122:295- 309, 1975
10. Infectious Diseases Specialty Conference: Yoshikawa TT, Fiala M, Barrett PVD, Walsh JH: Viral hepatitis. Eds. JA Turner, JZ Montgomerie, **AW Chow**, TT Yoshikawa and LB Guze. West J Med 123:202-210, 1975
11. Infectious Diseases Specialty Conference: Oill PA, Yoshikawa T, Yamauchi T: Infectious disease emergencies. Part I: Patients presenting with altered state of consciousness. Eds. JA Turner, JZ Montgomerie, **AW Chow**, TT Yoshikawa and LB Guze. West J Med 125:36 -46, 1976.
12. Infectious Diseases Specialty Conference: Oill PA, Roser SM, Galpin JE, Zement I, Selecky PA, Schofferman J: Infectious disease emergencies. Part III: Patients presenting with respiratory distress syndromes. Eds. JA Turner, JZ Montgomerie, **AW Chow**, TT Yoshikawa and LB Guze. West J Med 125:452- 478, 1976.
13. Infectious Diseases Specialty Conference: Oill PA, Bayer AS, Criley JM, Blaufuss A, Fisher LS: Infectious disease emergencies. Part II: Patients presenting with cardiac decompensation and cardiovascular insufficiency (shock). Eds. JA Turner, JZ Montgomerie, **AW Chow**, TT Yoshikawa and LB Guze. West J Med 125:119- 136, 1976.
14. Infectious Diseases Specialty Conference: Oill PA, Montgomerie JZ, Cryan WS, Edwards JE Jr: Infectious disease emergencies. Part V: Patients presenting with localized infections. Eds. JA Turner, JZ Montgomerie, **AW Chow**,

TT Yoshikawa and LB Guze. West J Med 126:196 -208, 1977.

15. Infectious Diseases Specialty Conference: Oill PA, Targan S, Panitch N: Infectious disease emergencies. Part IV: Patients presenting with gastrointestinal disorders. Eds. JA Turner, JZ Montgomerie, **AW Chow**, TT Yoshikawa and LB Guze. West J Med 126:32- 45, 1977.
16. Infectious Diseases Specialty Conference: Henderson DK, Tillman DB, Webb HH, Raimondi PJ, Schwartz AA: Infectious disease emergencies the clostridial syndromes. Eds. DK Henderson, **AW Chow**, LB Guze. West J Med 129:101- 120, 1978.
17. **Chow AW**: The subspecialty of infectious disease (ID) and the multi faceted role of the ID physician. BC Med J 22:125, 1980
18. **Chow AW**: A "physiologic" penicillin preparation (letter). Can Med Assoc J 122:755, 1980
19. Gribble MJ, **Chow AW**: Gynaecologic infections a management approach. Drug Therapy 11:67 -76, 1981 (B31)
20. **Chow AW**: Pelvic inflammatory disease. Medicine North America 8:913- 918, 1981
21. Gribble MJ, **Chow AW**: Erythromycin. Med Clin N Amer 66:79-89, 1982
22. **Chow AW**: Toxic shock syndrome. Medicine North America 6:535 542, 1983
23. Jewesson PJ, **Chow AW**: Dealing with the misuse of antibiotics in the hospital. Can Med Assoc J 128:1061-1062, 1983
24. **Chow AW**: The febrile child - clinical management of fever and other types of pyrexia (book review). Infection Control 5:195-196, 1984
25. **Chow AW**, Jewesson PJ: Safety of antimicrobial drugs in pregnancy, The Medical Letter 27:93-95, 1985
26. Megran DW, **Chow AW**: Adverting complications of tooth and gum infections. Diagnosis, pp 100- 111, March, 1986
27. Jewesson PJ, **Chow AW**: Use and safety of miconazole during pregnancy (letter). West J Med 147:599-600, 1987
28. Vortel G, **Chow AW**: Sinusitis. Med N Amer 9:1057 -1063, 1990
29. See RH, **Chow AW**: Immunoblots for detection of toxic shock syndrome toxin 1 produced by *Staphylococcus aureus*. J Clin Microbiol 28:1490, 1990
30. **Chow AW**: A practical guide to investigation of the HIV-infected patient. Can J Diag Apr:1, 1991
31. Kertesz D, **Chow AW**: Clinical evaluation for sinusitis. Abstracts for Infectious Disease, 1993
32. **Chow AW**: Toxic shock syndrome. Med North Amer, pp 140-204, 1995
33. IDSA Clinical Affairs Committee (**Chow AW**, member): IDSA Position Statement:: Hospital pharmacists and infectious diseases specialists. Clin Infect Dis 25:802, 1997
34. **Chow AW**: The Staphylococci in Human Disease (book review). New Engl J Med 338:136-137, 1998

(b) Books and Monographs

- 1 **Chow AW**, Mesker SM, Grier M, Bartos H (eds): Infection Control Manual, Harbor General Hospital, County of Los Angeles, 1979.
- 2 Yoshikawa TT, **Chow AW**, Guze LB (eds): Infectious Diseases - Diagnosis and Management. Houghton Mifflin, Boston, 1980
- 3 **Chow AW** (ed): Infectious Syndromes of the Head and Neck. Infectious Disease Clinics of North America Series, Vol 2, No. 1, W.B. Saunders, Philadelphia, Mar 1988

(c) NCBI GenBank Submissions (microbial hsp60 gene sequences)

1. Goh S, Wood J, Hemmingsen S, **Chow AW**: Analysis of cloned HSP60 and HSP10 genes from *Staphylococcus epidermidis* and *Staphylococcus aureus*. GenBank Database, accession No. U13618, August, 1994.
2. Bay SJ, Dovichi NJ, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Staphylococcus lugdunensis*, partial genomic sequence. GenBank, Accession No. U92810, March 1997.

3. Bay SJ, Dovichi NJ, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Staphylococcus haemolyticus*, partial genomic sequence. GenBank, Accession No. U92809, March 1997.
4. Bay SJ, Dovichi NJ, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Staphylococcus aureus*, partial genomic sequence. GenBank, Accession No. AF029244, October 1997.
5. Bay SJ, Dovichi NJ, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Staphylococcus epidermidis*, partial genomic sequence. GenBank, Accession No. AF029245, October 1997.
6. Bay SJ, Dovichi NJ, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Staphylococcus saprophyticus*, partial genomic sequence. GenBank, Accession No. AF029246, October 1997.
7. Kwok AYC, Kloos WE, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Macrococcus bovicus* ATCC51825T, partial genomic sequence. GenBank, Accession No. AF242275, March 6, 2000
8. Kwok AYC, Kloos WE, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Macrococcus carouzelicus* ATCC51828T, partial genomic sequence. GenBank, Accession No. AF242276, March 6, 2000
9. Kwok AYC, Kloos WE, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Macrococcus equiperdus* ATCC51831T, partial genomic sequence. GenBank, Accession No. AF242277, March 6, 2000
10. Kwok AYC, Kloos WE, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Staphylococcus auricularis* ATCC33753T, partial genomic sequence. GenBank, Accession No. AF242278, March 6, 2000
11. Kwok AYC, Kloos WE, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Staphylococcus carnosus* strain H, partial genomic sequence. GenBank, Accession No. AF242279, March 6, 2000
12. Kwok AYC, Kloos WE, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Staphylococcus chromogenes* ATCC43764T, partial genomic sequence. GenBank, Accession No. AF242280, March 6, 2000
13. Kwok AYC, Kloos WE, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Staphylococcus equorum* ATCC43958T, partial genomic sequence. GenBank, Accession No. AF242281, March 6, 2000
14. Kwok AYC, Kloos WE, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Staphylococcus felis* ATCC49168T, partial genomic sequence. GenBank, Accession No. AF242282, March 6, 2000
15. Kwok AYC, Kloos WE, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Staphylococcus hominis* subsp novobiosepticus strain "R22T", partial genomic sequence. GenBank, Accession No. AF242283, March 6, 2000
16. Kwok AYC, Kloos WE, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Staphylococcus lutrae* ATCC700373, partial genomic sequence. GenBank, Accession No. AF242284, March 6, 2000
17. Kwok AYC, Kloos WE, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Staphylococcus muscae* strain "CCS767", partial genomic sequence. GenBank, Accession No. AF242285, March 6, 2000
18. Kwok AYC, Kloos WE, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Staphylococcus pasteurii* BM9359T, partial genomic sequence. GenBank, Accession No. AF242286, March 6, 2000
19. Kwok AYC, Kloos WE, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Staphylococcus piscifermentans* ATCC51136, partial genomic sequence. GenBank, Accession No. AF242287, March 6, 2000
20. Kwok AYC, Kloos WE, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Staphylococcus pulvereri* ATCC51698T, partial genomic sequence. GenBank, Accession No. AF242288, March

6, 2000

21. Kwok AYC, Kloos WE, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Staphylococcus saccharolyticus* ATCC14953T, partial genomic sequence. GenBank, Accession No. AF242289, March 6, 2000
22. Kwok AYC, Kloos WE, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Staphylococcus succinus* ATCC700337T, partial genomic sequence. GenBank, Accession No. AF242290, March 6, 2000
23. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio alginolyticus* ATCC17749, partial genomic sequence. GenBank Accession No. AF230930, Nov 17, 2000
24. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio alginolyticus* strain 86148, partial genomic sequence. GenBank Accession No. AF230931, Nov 17, 2000
25. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Listonella anguillarum*, partial genomic sequence. GenBank Accession No. AF230932, Nov 17, 2000
26. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio anguillarum*, partial genomic sequence. GenBank Accession No. AF230933, Nov 17, 2000
27. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio carchariae*, partial genomic sequence. GenBank Accession No. AF230934, Nov 17, 2000
28. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio cholerae* ATCC14033, partial genomic sequence. GenBank Accession No. AF230935, Nov 17, 2000
29. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio cholerae* ATCC25872, partial genomic sequence. GenBank Accession No. AF230936, Nov 17, 2000
30. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio cholerae* strain Inaba, partial genomic sequence. GenBank Accession No. AF230937, Nov 17, 2000
31. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio cholerae* strain Ogawa, partial genomic sequence. GenBank Accession No. AF230938, Nov 17, 2000
32. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio cholerae* strain 0139, partial genomic sequence. GenBank Accession No. AF230939, Nov 17, 2000
33. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio cholerae* strain non-O1, partial genomic sequence. GenBank Accession No. AF230940, Nov 17, 2000
34. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio cincinnatiensis*, partial genomic sequence. GenBank Accession No. AF230941, Nov 17, 2000
35. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio damsela*, partial genomic sequence. GenBank Accession No. AF230942, Nov 17, 2000
36. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio hollisae*, partial genomic sequence. GenBank Accession No. AF230943, Nov 17, 2000

37. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio fluvialis* ATCC33809, partial genomic sequence. GenBank Accession No. AF230944, June 30, 2001
38. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio fluvialis* strain 89751, partial genomic sequence. GenBank Accession No. AF230945, June 30, 2001
39. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio furnissii*, partial genomic sequence. GenBank Accession No. AF230946, June 30, 2001
40. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio metschnikovii*, partial genomic sequence. GenBank Accession No. AF230947, June 30, 2001
41. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio mimicus* ATCC33653, partial genomic sequence. GenBank Accession No. AF230948, June 30, 2001
42. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio mimicus* strain 85450, partial genomic sequence. GenBank Accession No. AF230949, June 30, 2001
43. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio ordalii*, partial genomic sequence. GenBank Accession No. AF230950, June 30, 2001
44. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio parahaemolyticus* ATCC17802, partial genomic sequence. GenBank Accession No. AF230951, June 30, 2001
45. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio parahaemolyticus* ATCC27519, partial genomic sequence. GenBank Accession No. AF230952, June 30, 2001
46. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio parahaemolyticus* strain 971065, partial genomic sequence. GenBank Accession No. AF230953, June 30, 2001
47. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio salmonicida*, partial genomic sequence. GenBank Accession No. AF230954, June 30, 2001
48. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio vulnificus* ATCC27562, partial genomic sequence. GenBank Accession No. AF230955, June 30, 2001
49. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio vulnificus* ATCC921751, partial genomic sequence. GenBank Accession No. AF230956, June 30, 2001
50. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio sp* strain 971598, partial genomic sequence. GenBank Accession No. AF230957, June 30, 2001
51. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Vibrio sp*. Strain 971599, partial genomic sequence. GenBank Accession No. AF230958, June 30, 2001
52. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Aeromonas hydrophila*, partial genomic sequence. GenBank Accession No. AF230959, June 30, 2001
53. Kwok AYC, Wilson JT, Coulthart M, Ng LK, Johnson W, Mutharia L, **Chow AW**. Heat shock protein 60 kDa (HSP60 or GroEL) gene sequence from *Plesiomonas shigelloides*, partial genomic sequence. GenBank

3. WORK IN FINAL STAGES OF PREPARATION

1. Lester R, Ivison S, Kalyan S, **Chow AW**: Microbial and host heat shock protein 60 in infection and immunity.
2. Lee SS, Iyo A, **Chow AW**: Identification of clinical isolates of *Staphylococcus epidermidis* and *Staphylococcus haemolyticus* using hsp60 gene probes: comparison with MicroScan and ATI methods. *Diagn Microbiol Infect Dis*
3. Thambirajah AA, Sleigh K, Stiver HG, **Chow AW**: Differential heat shock protein response to strenuous exercise in chronic fatigue syndrome patients and matched healthy volunteers. *J Chronic Fatigue*
4. Kalyan S, **Chow AW**: Staphylococcal toxic shock syndrome toxin-1 induces the translocation and secretion of high mobility group box-1 protein. *Eur J Immunol*
5. Cameron S, Harris D, Stolte E, Kum W, Mui A, **Chow AW**: *In vivo* generation of regulatory T cells following repeated exposure to staphylococcal Toxic Shock Syndrome Toxin-1. *J Infect Dis*
6. Hung RWY, Kum WWS, **Chow AW**: Dose-dependent apoptotic signaling induced by staphylococcal Toxic Shock Syndrome Toxin-1 in human peripheral blood mononuclear cells. *J Infect Dis*
7. Kum WWA, Hung RWY, Cameron SB, **Chow AW**: Dose-dependent proliferative response of staphylococcal Toxic Shock Syndrome Toxin-1 is mediated by CD80 and CD154 signalling but independent of IL-2, γ c receptor, or CD86 co-stimulation. *Infect Immun.*
8. Kalyan S, **Chow AW**: Differential regulation of apoptosis by $V\gamma 9V\delta 2$ T cells following stimulation with staphylococcal Toxic Shock Syndrome Toxin-1. *Can J Microbiol*
9. Kalyan S, **Chow AW**: Enhancement of CD40 and HMGB-1 expression on APC by peripheral human $V\gamma 9V\delta 2$ T cells and monocytes following stimulation with staphylococcal Toxic Shock Syndrome Toxin-1
10. Kalyan S, **Chow AW**: The immunoregulatory role of $\gamma\delta$ T cells – tipping the balance. *Clin Invest Med*

4. SUMMARY OF PUBLICATIONS (February 12, 2006)

	Total		Past 5 Years	
	Published/ In press	Submitted	Published/ In press	Submitted
Referred Papers	217	3	23	3
Book Chapters	122		47	
Conference Proceedings	31		1	
Books and Monographs	3		0	
Abstracts	265	2	48	2
Editorials, Reviews, Letters	34		0	
Invited Presentations	82		39	
Patents	2	2	1	2
Disclosures	62		50	